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The West Nile Virus (WNV), a member of the Flaviviridae family, is a reemerging 
pathogen causing outbreaks in multiple continents. In recent years, clinical symptoms 
resulting from WNV have worsened in severity, with an increased frequency in 
neuroinvasive diseases among the elderly. Since, there are presently no successful 
antiviral therapies and vaccines for human use against WNV, continual efforts to 
develop new chemotherapeutics against this virus are highly desired. The viral NS2B-
NS3 protease is a promising target for viral inhibition due to its importance in viral 
replication and its unique substrate preference. The overall goal of this thesis was to 
identify potent small molecule inhibitors against full-length NS2B-NS3 protease. For 
the design of WNV NS2B-NS3 protease inhibitors, initially, a library of 110 
compounds was screened against viral protease assay by high throughput screening 
(HTS). The ‘‘hit’’ compounds were further sorted out by cytotoxicity test and the 
non-toxic compounds were chosen for library synthesis and biological evaluation 
based on structural activity relationship (SAR) study. 
In chapter 2, a WNV NS2B-NS3 protease inhibitor with a 9,10-dihydro-3H,4aH-
1,3,9,10a-tetraaza-phenanthren-4-one scaffold was selected as a non-peptidic “hit” 
compound. Optimization of this initial “hit” by solution-phase synthesis of a focussed 
library of compounds with this scaffold for screening led to the identification of a 
novel, uncompetitive inhibitor (2-1a40, IC50 = 5.41±0.45 µM) of the WNV NS2B-
NS3 protease. Molecular docking of this chiral compound onto the WNV protease 
indicates that the S-enantiomer of 2-1a40 appears to interfere with the productive 
interactions of the NS2B cofactor with the NS3 protease domain and is a preferred 
isomer for the inhibition of the WNV NS3 protease.  
viii 
In chapter 3, we have optimized another “hit” through a facile synthesis of a focused 
library of compounds with a 2-{6-[2-(5-phenyl-4H-[1,2,4]triazol-3-
ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold. Screening of 
these compounds led to the identification of a novel, uncompetitive inhibitor (3-1a24, 
IC50 = 3.35±0.15 µM) of the WNV NS2B-NS3 protease. Molecular docking of 3-
1a24 onto the WNV protease indicated that the compound interferes with the 
productive interactions of the NS2B cofactor with the NS3 protease domain and is an 
allosteric inhibitor of the WNV NS2B-NS3 protease.  
Finally, in chapter 4 we have synthesized a focused library of compounds based on 
the 4-benzoyl-3-hydroxy-1-(5-mercapto-1,3,4-thiadiazol-2-yl)-5-phenyl-1H-pyrrol-
2(5H)-one scaffold and their SAR study resulted in the identification of a novel 
racemate inhibitor (4-1a16, IC50 = 6.1±1.9 µM) of the WNV NS2B-NS3 protease. In 
addition, chiral separation led to a highly potent uncompetitive inhibitor (-)-4-1a16 of 
WNV protease (IC50 = 2.2±0.7 µM) and in silico docking study suggested that the 
inhibitor (R)-4-1a16 interferes with the productive interactions of NS2B cofactor with 
the NS3 protease as an allosteric inhibitor. In addition, docking studies indicated that 
the R-enantiomer is the preferred isomer for the inhibition of the WNV NS2B-NS3 
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Chapter 1: Introduction 
 
1.1 Introduction  
The reemergence of the West Nile Virus (WNV), a neurotropic Flavivirus, is a 
mosquito-borne pathogen that is causing outbreaks in multiple continents1. The more 
commonly known species of WNV are such as dengue virus (DENV), yellow fever 
virus (YFV), hepatitis C virus (HCV) and tick-borne encephalitis viruses (TBEV), etc. 
This virus is a major cause of infectious disease in human and other animals. Till date, 
vaccines are available for YFV, JEV, and TBEV; however there have been no 
successful antiviral therapies and vaccines for human use against WNV.2,3 The WNV 
was first isolated and identified as a distinct pathogen from a feverish woman in 
Uganda’s West Nile district and subsequently was associated with sporadic cases of 
disease as well as major outbreaks in Africa, Europe, the Middle East, west and 
central Asia.4,5 Since 1999, when the first WNV outbreak occurred in the city of New 
York , the Center for Disease Control (CDC) has reported that more than thirty 
thousand people were infected, resulting in 1263 fatalities cases in the United State of 
America alone.6 The clinical manifestation of WNV in human was found to vary 
significantly from being asymptomatic to developing a mild febrile syndrome termed 
“West Nile fever” or a neuroinvasive disease termed “West Nile meningitis or 
encephalitis”. Approximately 80% of WNV infected patients are asymptomatic, 20% 
develop West Nile fever and less than 1% develop severe neurological 
manifestations.7 The symptoms of West Nile fever in human include an abrupt onset 
of fever, headache, fatigue, variable malaise, anorexia, nausea, myalgia, 
lymphadenopathy and a non-pruritic generalized maculapapular rash. Additional non-
neurological manifestations that may develop in West Nile fever patients include 
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hepatitis, pancreatitis, myocarditis, rhabdomyolysis, orchitis and ocular 
manifestations. Neurological manifestations of WNV infection include meningitis, 
encephalitis, acute flacid paralysis (AFP)/poliomyelitis, Parkinsonism, pharyngitis, 
conjunctivitis, coma, and seizure/status epilepticus.8 Despite the growing public 
health concern associated with WNV infection, thus current treatment is supportive 
care only. In vitro and animal model studies have provided important clues to the 
possible novel therapies against WNV. However, the development of effective 
therapeutics that diminishes disease may be difficult, as patients with the most severe 
disease often have underlying immune deficits and present to clinical attention 
relatively late in the course of the disease. Among the challenges will be the 
development of therapeutics that efficiently cross into the central nervous system 
(CNS), clear virus from infected neurons, and have a beneficial effect on patient 
outcome.9 In this chapter, we provide a comprehensive review of WNV, describe its 
transmission, life cycle, molecular virology, viral proteins, drug target, existing 
inhibitors and identification of “hit” compound by HTS. The focus, however, will be 
on the WNV non-structural (NS) NS2B-NS3 protease and its inhibitors, which 
represents the basis of this thesis. 
 
1.2 Viral transmission  
Infection is transmitted primarily by mosquitoes, although the role of tick and other 
hematophagous insects as vectors cannot be excluded. The majority of the clinical 
cases are found in human or horse to maintain with an infection cycle (Figure 1.1) 
involving birds and mosquito.10 However, the ecology of transmission between 
primary vectors and vertebrate hosts is complicated. The mosquito must feed on an 
3 
infected amplifying host bird, to serve as an effective vector. Birds with high viremia, 
i.e. containing WNV concentrations of sufficiently high levels in their blood are 
effective hosts for WNV amplification and transmission.11a In addition, bird migration 
provides a potential basis for viral transport over large distances and has been  
 
Figure 1.1 WNV transmission cycle11b 
proposed as an explanation for the seasonal recurrence of WNV infections in 
temperate zones where winter precludes mosquito activity. The Culex mosquito is 
caught up most commonly worldwide and postulated to have major contribution to 
spread out in the New York City outbreak.6 However, Aedes, Anopheles, Minomyia, 
and Mansonia mosquitoes may also serve as transmission vector. 
 
1.3 Molecular virology of WNV 
1.3.1 West Nile virion morphology and composition  
West Nile virion is a small virus particle of approximately 500 Å in diameters and is 
composed of an icosahedral nucleocapsid (NC) that is ~25 nm in diameter. The 
4 
consists a single-strand positive-sense RNA genome of 11000-12000 nucleotides long 
and is capped by virus capside (C) protein which is also surrounded by lipid bilayer 
and 180 copies of two glycoproteins.12 The envelop (E) protein and membrane (M) or 
its precursor (prM) protein are embedded on the NC.13 In addition, advance cryo-
electron microscopy (cryoEM) data suggested many important structural feature of 
West Nile virion at the level of atomic resolution (Figure 1.2).14 The E protein is the 
major viral surface protein and the major antigenic determinant. It mediates binding 
and fusion during virus entry into host cells. The E protein is arranged in a head-to-  
 
Figure 1.2 A 17 Å structure of West Nile Virus determined by cryo-EM. (A) A 
surface shaded view of the virus with one asymmetric unit of the icosahedron shown 
by the triangle. The 5-fold and 3-fold icosahedral symmetry axes are labeled. (B) A 
central cross section showing the concentric layers of density.14 
 
tail homo dimer conformation that lies parallel to the lipid bilayer on the virus 
surface. It also known from cryo-EM  that flavivirus employs a fusion mechanism in 
which the distal β barrels domain II of the glycoprotein E are inserted into the cellular 
membrane.15 On the other hand, the M protein is produced from the proteolytic 
processing of a prM precursor protein. The prM precursor protects the E protein from 
fusing with intracellular membranes as the virion transits through the secretory 
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pathway. The immature prM-E virus particles are larger in size (~60 nm) compared to 
the mature M-E virions (~50 nm). The larger particle size is due to the prM-E 
heterodimer protruding from the virus surface resulting in a spiky appearance 
compared to the smooth outer surface observed in the M-E mature virion.16  
1.3.2 The WNV life cycle  
Cellular and molecular biology studies have elucidated the basic mechanism of action 
of WNV in host cells. This virus can replicate in various types of cell cultures from a 
wide variety of avian, mammalian, amphibian, and insect species.17 In the life cycle of 
WNV, the E protein first attaches to the surface of a host cell (Figure 1.3) at an 
unknown host receptor and subsequently enters the cell by receptor-mediated 
endocytosis. At lower pH region of endosome triggers an irreversible trimerisation of 
the E protein results in fusion of the viral and cell membrane.18 The fusion covered by 
the pr portion of prM protein and protected from premature fusion with cell 
membranes.19,20 The lysosome enters after fusion of E protein and the virus has a self 
signal that it is inside a cell. The NC is released into the cytoplasm and single strand 
positive sense RNA dissociates from its C protein, once the genome is released into 
the cytoplasm, the RNA is translated into a single polyprotein.21,22 The amino terminal 
end of the polyprotein includes the three structural components of the virus, while the 
rest forms the seven different NS proteins are processed co- and post-translationally 
by viral and host proteases. The genome replication occurs on intracellular 
membranes and initially immature particles are formed in the lumen of the 
endoplasmic reticulum (ER). The particle contains prM-E proteins, lipid membrane 
and NC cannot induce host-cell fusion to make them non-infectious. Subsequent, 
cleavage of the prM-E heterodimer occurs in the trans-Golgi network (TGN) by furin, 
the E protein changes conformation lying parallel on the virus surface.23a However,  
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Figure 1.3 The life cycle of West Nile Virus (Diagram from the microbial world).23b 
Replication of WNV occurs in the cytoplasm. The interesting feature of its replication 
is the synthesis of a single polyprotein and its subsequent digestion.  
 
the remains associated to the E protein, preventing membrane fusion during virion 
release at the host cell surface.24 When the virion enters the extracellular milieu, the pr 
protein dissociates from the E protein and allowing for membrane fusion to occur in 
the next replication cycle .24 The particle only contains the glycoproteins and 
membrane in ER is known as subviral particle also cleaved by furin. However, the 
lack of C protein and genomic RNA make them non-infectious.25 Mature virus and 
sub-viral particles are subsequently released from the host cell by exocytosis. 
1.3.3 WNV poly protein processing  
The WNV contain a ~10.8-kb single-stranded positive-sense RNA genome which has 
3' and 5' untranslated region (UTR) and an open reading frame (ORF) translates into a 
large polyprotein of about 350 kD that is processed to individual flavivirus proteins 
which are arranged in the genome with the order of UTR-5'-C-prM-E-NS1-NS2A-
7 
NS2B-NS3-NS4A-NS4B-NS5-3'-UTR (Figure 1.4).26 The 5' UTR is about 120 
nucleotides in length and 3' UTR comprises about 500 nucleotides. As can be seen, 
the ORF encodes a total of 10 viral proteins: three structural proteins (C, M and E) are 
forming the new virion and seven NS proteins are expressed in the infected cells 
which are requires for viral replication. All of the flavivirus NS proteins emerge to be 
directly or indirectly involved in viral RNA synthesis. Still, the functions of the WNV 
NS proteins have not been completely characterized. However, little is known about 
the interactions between the various viral NS proteins and the host cell proteins that 
may also be required for the formation of active viral RNA replication complexes.21,27 
Processing of the polyprotein is believed to occur in the viral induced membranous 
structures which are continuous with the rough ER known as convoluted 
membranes/paracrystalline (CM/PC) arrays.28 A host signal peptidase located within 
the lumen of the ER cleaves the junctions C-prM, prM-E, E-NS1, and NS4A-
NS4B29,30 while cleavage at the NS1-NS2A junction takes place in the lumen of the 
ER by an unknown protease.31 The cleavage of prM to generate mature M is carried 
out by the host proteases furin, in the Golgi during export of virions through the 
secretory pathway.32 The virus encoded NS2B-NS3 protease cleaves the remaining 
junctions of NS2A-NS2B, NS2B-NS3, NS3-NS4A and NS4B-NS5 and also cleaves 
sites at the C-terminus of the C protein and the C-terminus of NS4A.26,33,34 Cleavage 
at all of these sites has been shown to be essential for replication of Flaviviruses, 
highlighting the vital role of NS2B-NS3protease.33,35,36 Many of the NS proteins are 
believed to associate with the viral RNA to form a complex which carries out 
replication of the genomic RNA within membranous structures referred to as vesicle 
packets (VPs). The replication complex is composed of NS5 function as RNA 










Figure 1.4 Schematic representations of flavivirus genome organization and 
polyprotein processing. Top, the flaviviral genome with the structural and NS proteins 
coding region, the 5' UTR with 5' cap structure and the 3' UTR with the potential 3' 
secondary structure are shown. Below, the mature flavivaral proteins generated after 
processing of polyprotein are demonstrated. The dotted line boxes are represent the 
structural proteins C, prM and E, with solid line boxes represents the NS proteins and 
corresponding cleavage site with various protease are indicated.37a 
 
helicase, RNA triphosphatase and nucleotide triphosphatase, function of NS1 protein 
as unknown yet, suspected to play a structural role in helping to anchor the replication 
complex to membrane of the VPs and NS2A, NS4A and NS4B proteins putatively 
involved in protein-protein interactions and membrane association.28,37b,38 In addition, 
the 5’m7GpppAmp cap structure is synthesized by the RNA triphosphatase activity of 
NS339 and methylated by the methyltransferase activity of NS5.40 
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The capsid protein  
The WNV capsid protein is encoded at the 5' end of the genome which is about 11 
kD, highly rich in basic amino acid residues and a large number of positively charged 
residues, which are distributed throughout the protein.41,42 The hydrophobic 
carboxylic terminal of the protein serves as a signal sequence for the translocation of 
prM across the membrane of the endoplasmic reticulum (ER). Cleavage of the 
carboxylic terminus of the capsid protein is catalyzed by the viral NS2B-NS3 protease 
complex on the cytoplasmic side of the ER membrane, while the C-prM junction on 
the lumenal side is cleaved by host signal peptidase.43 Analysis of the purified capsid 
protein from E.coli revealed its largely α-helical structure in the dimmeric form.44 
However, its dimmer formation mechanism is not elucidated yet, but interaction with 
RNA can induced isolated ca proteipsidn to assemble into NC like particle.45    
The prM/M protein  
The mature membrane protein is about 26 kD and while it was about 34 kD before 
cleaved from its precursor prM. The N-terminal region of prM has 1-3 N-linked 
glycosylation sites, as well as six conserved, disulfide-linked cysteine residues. The 
C-terminal region of prM contains two transmembrane domains which help to secure 
prM and M in the ER membranes, and may assist in the heterodimerization of prM 
and E. Besides providing structural support for E in the immature virion, prM also 
protects E from undergoing conformational changes during the transit of immature 
virions through acidic compartments of the trans-Golgi network.20 Furin-mediated 
cleavage of virion-associated prM to release the pr fragment occurs in the Golgi and 
leads to the rearrangement of E trimers into the homodimers seen in mature virion 
structures.46  
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The envelop (E) protein 
The E protein is about 53 kD and the major portion on the surface of flavivirus 
virions. This protein is primarily responsible for facilitating entry into the cell during 
infection, by binding to an unknown receptor protein and mediating the fusion of viral 
and host membranes.18 The native form of E is composed of three domains. Domain I 
is located at the N-terminus and contains the most conserved sequence, which has 
been hypothesized to be part of the flavivirus receptor-binding site.47 Domain II 
contains a putative fusion peptide, which mediates insertion into the host membrane 
during virus entry, and domain III, which is located at the carboxylic terminus of the 
E protein contains a hydrophobic domain which serves as a signal sequence for the 
translocation of NS1 into the lumen of the ER during polyprotein translation.46,48,49   
The NS1 protein 
Nonstructural glycoprotein protein 1 (NS1) is about 46 kD and has been shown to 
exist as a dimmer.50 This is the only flaviviral NS protein known to be glycosylated 
which contains two or three N-linked glycosylation sites and 12 conserved cysteines 
that form disulfide bonds.46,51,52 The pattern of disulfide pairing has been recently 
solved. The N-terminal end of NS1 is cleaved from the E protein by host signal 
peptidase, while the NS1/NS2a junction is cleaved by an unknown host protease.49,53 
Although the majority of NS1 is retained in infected cells, it is also detected at the cell 
surface where it is slowly secreted.22 NS1 has an important nuclear role in RNA 
replication, with a large deletion in the NS1 gene was shown to be deficient in RNA 
replication. Even, mutation of the N-linked glycosylation sites in NS1 can lead to 
dramatic defects in RNA replication and virus production. However, its exact function 
in viral RNA replication is not known yet.54,55  
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The NS2A protein 
NS2A is a small hydrophobic protein of about 24kD and contains a serine protease-
dependent cleavage site, which results in the release of a C-terminal truncated NS2A 
product of about 22 kD (NS2Aα).36 Previously, many research group have been 
shown that a mutation in the carboxylic terminal cleavage site of NS2A resulted in a 
failure to yield infectious virus in spite of normal viral RNA replication presenting the 
importance of this protein and suggesting that this protein may be involved in virus 
assembly.56 The NS2A/NS2B junction is cleaved by the viral serine protease.31  
The NS2B protein  
The NS2B is membrane associated another small hydrophobic protein of about 14kD 
and encodes three membrane domains, two of them located at the N-terminal and 
third one located at the carboxylic terminal. This protein has been shown to exist in 
complex with and functions as the cofactor for the viral serine protease NS3.57,58 The 
conserved hydrophilic domain of NS2B is essential for its cofactor activity, whereas 
the hydrophobic regions of NS2B are required for co-translational insertion of the 
NS2B-NS3 precursor into ER membranes and for the interaction between NS3 and 
NS2B.59,60 The NS2B/NS3 junction is cleaved by viral serine protease. Mutation of 
conserved residues in NS2B can have dramatic effects on auto proteolytic cleavage 
and trans cleavage activities. 
The NS3 protein 
NS3 is a (~70 kD) multifunctional protein with both protease and helicase functions. 
However, NS3 is not an active protease until its N-terminal region comprises the 
protease domain to forms a stable complex with NS2B. The N-terminal third of NS3 
encodes a serine protease that is a member of the trypsin super-family which forms 
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the catalytic domain of the NS2B-NS3 protease complex.35,61 This protease auto 
catalytically cleaves itself from the polyprotein and also cleaves at multiple other sites 
in the polyprotein like NS2A/NS2B, NS2B/NS3, NS3/NS4A and NS4B/NS5; 
carboxylic termini of mature capsid protein and NS4A.62 The C-terminal region of 
NS3 protease encodes domains with homology to the super family II of RNA 
helicases and NTPases.39,63 Additionally, the NS3 protein has been shown to act as an 
RNA 5' triphosphatase, dephosphorylating the 5' end of the genome prior to cap 
addition.64 Collectively, these functions establish NS3 as a protein that is essential to 
the replication cycle of flaviviruses. 
The NS4A and NS4B proteins 
NS4A and NS4B are small hydrophobic proteins with a size of 16 and 27 kD, 
respectively. The C-terminus of NS4A is generated by a combination of host signal 
peptidase and viral serine protease cleavage33. Genetic studies indicated that NS4A 
interacts with NS1 and that interaction is important for RNA replication65. 
Furthermore, NS4A has been shown to colocalize with double-stranded RNA and VPs 
within the replication complex, suggesting a role for NS4A in RNA replication66. On 
the other hand, the NS4B have been detected in reticular structures and its 
hydrophobic characters help to associate with membrane. It has been reported that, 
NS4B initially appears as a 30 kD protein which post-translationally modified to 28 
kD; however, its post-translational modification is not known. In addition, NS4B 
colocalization with the membrane-bound viral replication complexes, but the exact 




The NS5 protein 
The NS5 is largest and multifunctional proteins among the all other flavivirus proteins 
and very well conserved protein of about 103 kD that is cleaved from the polyprotein 
by viral serine protease.67 It contains a Gly-Asp-Asp peptide (GDD) motif, which is 
present in all RdRp, which was demonstrated for recombinant dengue type 1 virus 
NS5 expressed in E. coli.68 The N-terminal region of this protein shows homology to 
methyltransferase domains40 and mutagenesis studies of the C-terminal region of 
GDD motif of Kunjin virus completely abolished viral replication.69,70 Several groups 
have shown that NS5 is phosphorylated in vivo, and have detected the presence of 
some NS5 in the nucleus of infected cells.38,71,72 However, the significance of this 
localization is not currently understood. 
 
1.4 WNV drug target  
In order for a biomolecule to be selected as a drug target, two essential pieces of 
information are required. The first, evidence is that modulation of the target will 
produce therapeutic value. This knowledge may come from disease linkage studies 
that show an association between mutations in the biological target and certain disease 
state. The second is that the target is "druggable", that means it is capable to bind a 
molecule and this fact could be modulated its activity.  
As can be seen, the two components NS2B-NS3 viral serine protease activity plays an 
important role in flaviviral polyprotein processing and interference of its function has 
been shown to be stop in viral replication. In addition, site-directed mutagenesis 
studies also have shown that mutation of essential catalytic residues at NS3 protease 
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cleavage sites lead to a halt in viral infectivity, indicating its importance in the WNV 
life cycle.73 This mode of substrate recognition is conserved among other flaviviral 
proteases but not in the host cellular enzymes,62 indicating the possibility of designing 
inhibitors selective for flaviviral proteases without adversely affecting normal cellular 
functions. Thus, the biological importance of the NS2B-NS3 complex (NS2B-
NS3pro) in the activation of viral proteins coupled with unique substrate preference 
make it an attractive target for selective viral inhibition. Two possible strategies for 
inhibiting the Flavivirus NS2B-NS3protease are either blocking interactions with its 
substrate or blocking the essential association between NS3protease and its cofactor 
NS2B. Based on sequence and structure pattern analysis, WNV NS3 protease is a 
tripsine-like serine protease which form a catalytic triade with His51, Asp75 and 
Ser135 amino acid residues (Figure 1.5a) and this triade is located at the active site of 
the two component protease. This viral serine protease recognizes and cleaves to the 
C-terminal side of two highly conserved consecutive amino acid residues (R and K) at 
the P1 and P2 positions. This unusual specificity does not share by other host protease 
suggesting that inhibitor designed to recognize this site may also be highly specific. 
However, the charged nature of the interactions of such basic residues makes the 
design of nonpeptidic inhibitors extremely challenging.  Recently, the crystal structure 
coordinate (pdb id: 2fp7) of the WNV NS2B-NS3 protease have been published by 
Erbel et al.74 and further inspection of the X-ray crystal structure revealed the 
important information about the nature of the binding pockets. Active site mainly 
consist of four binding pocket, these are S1, S2, S3, and S4 (Figure 1.5a). The S1 
pocket is well defined hydrophobic due to the presence of two tyrosine side chains 




Figure 1.5 Crystal structure of WNV NS2B-NS3 protease (2fp7).74  (a) represents the 
substrate binding site with binding pockets S1, S2, S3 and S4; catalytic triad in green 
color. (b) Potential target sites for blocking cofactor association residues 78-87 with 
NS3 protease (blue). 
 
offer some opportunity to form hydrogen bond between substrate/inhibitor-protease 
via the protein back bone atom of NS3 (Tyr130, Pro131, Ser135 and Gly151). The S2 
pocket also well define but it is much narrow compared to S1. This pocket contains 
lot of amino acid residues those can act as a hydrogen bond acceptor and donor, these 
are NS2B (Gly83, Asn84 and Phe85) and NS3 (His51, Glu74, Asp75 and Asn152). In 
contrast to pocket S1 and S2, the pocket S3 is relatively wide and shallow. One side 
of this pocket lined with hydrophobic side chains NS3 (Val154 and Ile155) and other 
side of the pocket include NS2B (Phe85, Gln86 and Leu87) and NS3 (Gly153). 
Lastly, binding region of S4 pocket entirely covered by the residue Ile155. The 
residue predicted to be in the pocket at the active site by Fairlie et al.62 These 
informations help to design or modification of an inhibitor which will be interact with 
active site of two component viral protease by competing with substrate. 
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In alternative strategy, the blocking of association between NS2B and NS3 proteins 
which affects the productive interaction of NS2B-binding cavity with NS3 protease 
domain to increase NS3 protease catalytic activity75,73 and remains to be rigorously 
tested. In addition, it may avoid the problems facing development of substrate based 
competitive inhibitors for the active site. Likewise other flaviviral serine protease, 
human serine protease has largely conserved active site which could be accessible to 
the specificity and potency of the inhibitors. Therefore, inhibitor interference with the 
productive conformation of the NS2B cofactor is also a superior drug discovery 
strategy compared with targeting of the active site of the NS2B-NS3 protease27 Earlier 
studies have shown that the integration of residues 78-87 of NS2B (Figure 1.5b) into 
the protease-cofactor complex affected the formation of the catalytic active sites. 
Deletion or mutagenesis of these residues produced an inert enzyme. Therefore, the 
region on the NS3 protease, where key interactions with the NS2B cofactor (residue 
78-87) occur, is important for the NS2B-NS3 protease activity and particularly 
attention is paying to this region for developing allosteric inhibitors. Alternatively, the 
residue Trp62 from NS2B also has been shown to be essential for protease activity 
along with the surrounding residues NS2B59-62. This region binds into a deep 
hydrophobic trench in NS3, which could be targeted by small aromatic, drug-like 
compounds. However, because this region of the NS2B cofactor remains tightly 
associated in substrate-bound and substrate-free crystal structures, it is unidentified if 
an allosteric inhibitor would be capable of binding with high enough affinity to 
interrupt strong hydrophobic interactions of NS2B and NS3 protein.      
 The WNV NS5 protein contains a MTase domain involved in RNA capping and an 
RdRp domain essential for virus replication. The essential role of NS5 in flavivirus 
replication makes it an attractive antiviral target.76 Thus, the structure of the full-
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length molecule is required to provide a more accurate model for functional analysis 
and drug design. While recent studies have elucidated separate crystal structures for 
the MTase and RdRp domains of WNV NS577,78 and apparent instability of the full-
length recombinant protein during purification precluded crystallization of the entire 
molecule. A possible solution to this dilemma is co-purification and co-crystallization 
of NS5 in the presence of a monoclonal antibody (mAb) that binds to both MTase and 
RdRp domains and stabilizes the full-length protein. 
 
1.5 Strategies for the identification of novel inhibitors of WNV NS2B-NS3 
protease 
Each step of the WNV life cycle present a potential target for antiviral intervention. 
Three approaches are commonly taken to identify WNV NS2B-NS3 protease 
inhibitors; 1) Structure-based rational design 2) Biochemical enzyme based screening 
and 3) Genetic system-based screening.  
1.5.1 Structure-based rational design 
The traditional methods of drug discovery is rely on trial and error testing of chemical 
substances on cultured cells or animals, and matching the apparent effects to 
treatments, rational drug design begins with a hypothesis that modulation of a specific 
biological target may have therapeutic value. The atomic structures of many flavivirus 
proteins and domains have been solved. This structural information makes the rational 
design of inhibitors possible.  
From our above discussion, it is clear that WNV NS2B-NS3 protease and NS5 protein 
are the most promising targets in drug discovery and recently, their crystal structure 
has been published with or without ligand. The two X-ray structures of NS2B-NS3 
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protease with different inhibitors have similar conformations and are therefore 
appropriate for structure based drug design. The two component protease adopts a 
chymotrypsin-like fold with two six-stranded β-barrels and details of the nature and 
shape of the active side pockets are already described in the section of drug target. 
Among the reported peptides inhibitors of NS2B-NS3 protease, the preferred amino 
acids at the nonprime part of the protease active site are arginine at the P1 position 
and arginine or lysine at the P2 position79 underlining the role of electrostatic 
interactions with the negatively charged S1 and S2 pockets. Most of the reported 
active compounds are with charged moieties or the guanidino group being the most 
frequently used. Even, five non-peptidic compounds reported by Ganesh et al.80 have 
guanidine moieties. Ekonomiuk et al.81 group introduced thiourea moiety instead of 
guannidin and they found to shown moderate activity against viral protease. 
The N-terminal region of NS5 encodes an MTase, which is required to methylate the 
cap guanine N7 and the ribose 2'-OH of the first nucleotide during cap formation. A 
virtual screening, using NS5 MTase structure, revealed a compound that inhibited 
DENV 2'-O cap methylation with an IC50 value of 60 µM.82 The study used S-
adenosylmethionine (SAM), the methyl donor, as a starting molecule to search for 
analogs that could specifically dock into the SAM-binding pocket of the DENV-2 
MTase. Since the SAM molecule bound in the same pocket donates methyl groups to 
both N7 and 2'-O positions during cap methylations83, the identified compound is 
expected to inhibit N7 methylation of the viral RNA cap. A SAM analog in which the 
transferring methyl group is replaced by an amino group, inhibits both N7 and 2'-O 




1.5.2 Biochemical enzyme based screening 
For enzyme-based assays, the advantage is that the identified compounds possess 
known targets and major disadvantage is that cellular uptake and non-specific binding 
of the compound, two potential problems for many inhibitors, are not evaluated within 
the assay. Previous discussion suggests that the two component NS2B-NS3 serine 
protease and NS5 are important enzymes of the viral replication are ideal target for 
antiviral screening. Therefore, NS2B-NS3 protease assay is a fluorogenic peptide 
substrate-based assay (Figure 1.6) has been widely used in high throughput screening 
(HTS) technique.84,85 This method uses a small peptide substrate coupled to a highly 
fluorescent dye 7-amino-4-methylcoumarin (AMC), whose fluorescence is quenched 
while linked to  
 
Figure 1.6 Schematic representation of fluorogenic substrate (Pyr-RTKR-AMC) 
cleavage by WNV NS2B-NS3 protease. 
 
the un-cleaved peptide substrate. Upon protease-mediated cleavage, the fluorescent 
dye is released from the peptide, thus producing an increase in fluorescence intensity. 
The enzyme-based assays can potentially be developed for identify inhibitors of 
Flavivirus MTase. A scintillation proximity assay (SPA) could be developed for HTS, 
to search for MTase inhibitors. SPA is a radioactive homogeneous technology that 
relies upon the fact that the energy emitted from a radioisotope will only travel a 
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limited distance in an aqueous environment. When a radioisotope-labeled molecule 
binds to the microsphere beads, the radioisotope is brought into close proximity to the 
scintillant, and effective energy transfer from the particle occurs, resulting in light 
emission. When the radioisotope remains free in solution, it is too distant from the 
scintillant; the particle dissipates its energy into the aqueous medium and remains 
undetected. Because the flavivirus MTase specifically requires viral RNA for cap 
methylation, the RNA substrate should contain the 5 terminal stem-loop of genomic 
RNA. The 5 viral RNA should be biotin-labeled. Upon transfer of the 3H-labeled 
methyl group from SAM to RNA cap, the biotin-labeled RNA can be captured on the 
streptavidin SPA beads and measured with a scintillation counter. 
1.5.3 Genetic cell based assay 
The cell-based assays have two major advantages: more than one target and step are 
analyzed during replication and the uptake of compounds into cells is required, which 
represents a more authentic therapeutic environment. Inhibitors identified through 
cell-based assays have had a higher success rate in subsequent animal experiments. 
Since most flavivirus infections cause cytopathogenic effect (CPE), the traditional 
cell-based screening assay involves viral infection of cultured cells and monitoring of 
inhibition through measurement of CPE or quantification of viral RNA by reverse 
transcription polymerase chain reaction (RT-PCR).86,87 Unfortunately, these assays 
are labor-intensive and lack sensitivity. Thus, while informative, they are not ideal for 




1.6 Current inhibitors of WNV NS2B-NS3 protease   
The WNV infection is a major public health threat. As no effective therapy is 
currently available for clinical treatment of this infection, many research groups have 
focused on the development of antiviral therapies using recent advances in the 
structural and molecular biology of flavivirus. Efforts on inhibitor development 
against the WNV NS2B-NS3 protease have thus far focused mainly on natural or 
modified natural  peptidic ocompounds and only a few non-peptidic compounds have 
been reported. A number of compounds have been reported to inhibit WNV protease 
or viral replication in cell culture and few have shown in vivo efficacy.  
1.6.1 Peptide inhibitors 
The substrate-based peptide inhibitors of NS2B-NS3 protease were first described by 
Leung et al.88 with a Ki vlues at micromolar concentration for Dengue 2 (DEN2). 
These inhibitors were designed based on native substrate (Ac-EVKKQR-pNA) 
sequences P6-P1 and cleavable amide group replaced with an α-keto amide (Table 
1.1, cpd 1-1) transition state isosteric. Subsequent removal of α-keto amide group 
(Table 1-1, cpd 1-2) and simultaneously replacement of the  carboxylic terminus 
carboxylic acid with aldehyde group shows slightly better inhibition (Table 1.1, cpd 
1-3).89 Since, substrate-based peptide inhibitors with aldehyde as a warhead showed 
better inhibitory activity compare to the equivalent inhibitor α-keto amide, the 
inhibition of the NS2B-NS3 protease by aldehyde inhibitors have been investigated in 
details by a number of research groups. The truncation of the substrate based inhibitor 
to a tetra-peptide, tri-peptide or di-peptide were result in loosing inhibition potency by 
di-peptides against WNV NS2B-NS3 protease.  However, Knox’s group90 reported a 
series of inhibitors related to the benzoyl-norleucine-lysine-arginine-arginine 
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aldehyde (Bz-Nle-KRR-H) tetra-peptide (Table 1.1, cpds 1-4 to 1-9) containing a 
fixed basic amino acid residue (K) at third position enhanced inhibitory activity. Their 
biological activity found against the WNV NS2B-NS3 protease ranged from 1.9 to 
262 µM (Ki) suggesting a good lead compound for generating a broad spectrum of 
inhibitors. The modeling study of this class of peptides was supported to bind at the 
active site of WNV NS2B- NS3 protease complex. This shows a general trend that S1 
and S2 pockets of the protease are the key peptide recognition sites. The peptide 
inhibitor having side chain residue of capable for both σ-stacking and hydrogen 
bonding is favourable at the S1 pocket, while a positively charged  
Table 1.1 Summary of peptidic inhibitors of DENV and WNV NS2B-NS3 proteases  
Cpd Peptide DEN2 Ki (µM)  WNV Ki (µM) 
1-1 Ac-FAAGKR-αketo-SL-NH2 47  - 
1-2 Ac-FAAGKR-NH2 26  - 
1-3 Ac-FAAGRR-H 16  - 
1-4 Bz-Nle-KRR-H 5.8  4.1 
1-5 Bz-Nle-KKR-H 41  1.9 
1-6 Bz-Nle-KRA-H 193  4.6 
1-7 Bz-Nle-KAR-H >500  262 
1-8 Bz-Nle-KRF-H 16  110 
1-9 Bz-Nle-KFR-H 41  108 
1-10 Phenylacetyl-KKR-H -  9 
1-11 4-phenyl-phenacetyl-KKR-H -  6 
1-12 3-methoxy-phenacetyl-KKR-H -  11 
1-13 NH2- (hexa-D-R-NH2) -  0.478 
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1-14 NH2- (hepta-D-R-NH2) -  0.041 
1-15 NH2- (octa-D-R-NH2) -  0.17 
1-16 NH2- (nona-D-R-NH2) -  0.006 
1-17 NH2- (deca-D-R-NH2) -  0.002 
1-18 NH2- (undeca-D-R-NH2) -  0.001 
1-19 NH2- (dodeca-D-R-NH2) -  0.001 
1-20 4-phenylphenacetyl-KK-agtamine -  2.05 
 
residue is preferred in the S2 pocket. In addition, in silico studies suggested that 
aldehyde inhibitors bind to the substrate-binding cleft by forming a covalent bond 
with the catalytic Ser135. While the true level of inhibition by the actual aldehyde 
form of such inhibitors may be underestimated. Fairlie and coworkers62 have reasoned 
that aldehyde inhibitors containing arginine residue at P1 show only modest activity 
against flavivirus NS3 protease, as they are in equilibrium with their hydrate or hemi-
aminal cyclic form in aqueous form and only about 5% of the active free aldehyde 
remain to interact with the active site serine hydroxyl group. On the basis of diverse 
tetra-peptide aldehyde inhibitors a range of tri-peptide aldehyde have converted into 
aldehyde derivatives (Table 1.1, cpds 1-10 to 1-12) to prospectively inhibit the 
protease. The space at the N-terminus of these peptides (X) was examined to test 
whether substituent at this position could enhance interaction with enzyme. The 
smallest and most potent inhibitors was found from this series is a cationic tripeptides 
with non-peptidic caps at the N-terminus and aldehyde at the C-terminus. One of the 
compound (Table 1.1, cpd 1-11) from these series of peptide inhibitors shows high 
inhibition potency with Ki value of 6 nM and stable in serum.91 The incorporation of 
multiple D-Arginine residues into amide inhibitors (Table 1.1, cpds 1-13 to 1-19) has 
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been shown to enhance inhibitor potency against WNV NS2B-NS3 protease.92 The 
level of inhibition was found to be improved 500-fold by increasing the number of D-
Arg residues from 7 to 12. It is unlikely that the enzyme has specificity for binding to 
multiple arginine residues outside of the P2-P1 recognition site and another 
explanation is that multiple arginine residues have a cumulative effect on the 
association at S1 and S2. The D-arginine-based 9-12-mer peptides are potent 
inhibitors of WNV NS2B-NS3 protease with a range of Ki values from 1 to 6 nM. 
Most of the peptide inhibitors of the NS2B-NS3 protease involved covalent inhibitors 
that compete with the substrate for the catalytic site. Such peptide-based covalent 
inhibitors have their C-terminal carboxyl group chemically modified into aldehyde 
‘warheads’. This popular aldehyde functional group and peptide aldehydes have been 
shown to inhibit the WNV NS2B-NS3 protease at sub-micromolar potencies. 
However, warhead peptidomimetics have several undesirable characteristics, 
including lack of selectivity over other trypsin-like proteases due to their high 
reactivity and low chemical stability, curtailing their potential for drug development. 
Therefore, Lim et al.93  investigated peptidomimetics without aldehyde warheads if 
could inhibit the WNV NS2B-NS3 protease and they found agmatine peptidomimetic 
(Table 1.1, cpd 1-20) was shown to be a competitive inhibitor with a binding affinity 
of Ki value is 2.05 µM and specific to inhibit WNV NS2B-NS3 protease. The 
inhibitor does not bind covalently to the catalytic serine in the active site but instead 
employ hydrophobic and/or electrostatic interactions to compete with the natural 
substrate for the active site. Such inhibitors should be less reactive and hence more 
‘druggable’ compared to warhead inhibitors.  
 Although the in vitro results were fruitful, a major disadvantage of peptidic inhibitors 
is their short physiologic half life, as peptides are easily cleaved and inactivated in the 
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body. In addition, most of the peptide inhibitors are highly charged and interacting 
with WNV protease by electrostatic interaction; such charged peptides are highly 
prohibited to penetrate the cell membrane. Also, a high drug clearance rate in vivo 
will consequently lead to diminished therapeutic effects. Thus, there is a need to 
explore the inhibitory effects of non-peptidic compounds, which has been attempted 
by very few groups till date.  
1.6.2 Nonpeptidic inhibitors 
The degradation problem of peptide based inhibitors of proteases has been overcome 
in a number of ways, including the generation of macrocyclic inhibitors by covalent 
linkages. Such inhibitors retain the high potency and selectivity of peptide inhibitors 
while the macrocycle makes the peptide components more resistant to degradation. 
However, such a compound would most likely only be a tool for probing the effects of 
protease inhibition in vivo, rather than being a drug candidate. In comparison to the 
peptidic inhibitors, only a few nonpeptidic inhibitors are reported to show satisfactory 
inhibition against the WNV NS2B-NS3 protease. Besides peptide inhibitors, small 
molecules are one of the major tools for drug discovery. Small molecule drugs in the 
human body behave like a foreign molecule, which is found in an organism but does 
not normally produced. Attempts to deal with such types of small molecules have 
many advantages: a number of drugs are excreted from the human body intact and an 
ideal drug should leave the body after it completes its mission. However, most small 
molecules need to be modified structurally to facilitate excretion Modifications of 
small molecules are relatively more affordable than macromolecules. In addition, 
small molecules differ with respect to distribution, metabolism, serum half-life, 
typical dosing regimen, toxicity, species reactivity, antigenicity, clearance 
mechanisms, and drug-drug docking studies on compound 1-22 and 1-23 showed that 
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the amide oxygen of the indole ring in compound 1-22 and oxygen from phosphonic 
acid group form a strong hydrogen bond with Ser135 which is located at the active 
Figure 1.7 Non-peptidic inhibitors of WNV NS2B-NS3 protease and their inhibition 
potencies. 
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site and that might be reason of showing better inhibition than compound 1-21. The 
small molecule inhibitor of the WNV NS2B-NS3 protease with thiourea moiety has 
been identified by automatic fragment-based docking of about 12000 compounds.81 
High-throughput docking into the active site of the WNV protease and binding free 
energy evaluation were identified compound 1-24 (Figure 1.7) to shows moderate 
inhibitory activity. The thiourea moiety of symmetrical inhibitor (Figure 1.7, cpd 1-
24) was found to interact with S1 and S2 pocket through hydrogen bonding. Beside 
the rational designed inhibitors of WNV NS2B-NS3 protease, some inhibitors of this 
protease were identified by high throughput screening which provides a powerful 
complement to structural based rational design of small molecule inhibitors of 
protease. In the WNV NS2B-NS3 protease assay, Mueller et al.94 identified 8-
hydroxyquinoline (8-HQ) derivatives compound 1-25 and 1-26 (Figure 1.7) which 
showed s competitive inhibition with Ki values of 3.2 µM and 3.4 µM respectively. 
These two inhibitors identified from initial screening of 32337 molecules after 
applying the Lipinski’s rule of five.95 Further structural activity relation (SAR) study 
on scaffold 8-HQ assisted to find out more potent inhibitor (Figure 1.7, cpd 1-27) of 
WNV protease96. In addition, the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-
dihydroisoquinoline scaffolds were utilized in the design libraries of compounds for 
screening against WNV protease. Exploratory studies have led to the identification of 
a WNV protease inhibitor a 1-oxo-1,2-dihydroisoquinoline-based derivative which 
could potentially serve as a launching pad for a hit-to-lead optimization campaign97. 
One of the inhibitors (Figure 1.7, cpd 1-28) from the abovementioned scaffold 
showed moderate inhibition against WNV protease with IC50 value of 30 µM. A HTS 
study of more than 65000 compounds at the National Institutes of Health identified 
several sulfonyl pyrazolyl derivatives of novel, uncompetitive inhibitory activity. 
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Scaffold 5-amino-1-(phenylsulfonyl)-1H-pyrazol-3-yl (Figure 1.7, cpds 1-29 and 1-
30) appears to interfere with the productive interactions of the NS2B cofactor with 
NS3 protease domain. These compounds showed relatively high potencies (IC50 <200 
nM) against recombinant NS2B-NS3 protease in vitro and gave clues to block 
productive interactions.  However, this class of compound was relatively unstable in 
aqueous buffer solutions and degraded completely in hours, therefore they were 
unsuitable for inhibitory effects at physiological conditions.98 Further attempts to 
improve the stability of these compounds via addition of electronegative groups on 
the aromatic ring to shield the hydrolytically sensitive ester group and isosteric 
replacement of the ester moiety (Figure 1.7, cpd 1-31) led to slight increases in their 
half life in aqueous buffer but with compromises to their inhibitory potencies.99 Based 
on the structural requirements important for potency and stability of sulfonyl 
pyrazolyl derivatives, further modification on the corresponding 1-benzyl-3-methyl-
1H-pyrazol-5-yl derivatives (Figure 1.7, cpd 1-32) showed relatively better stability in 
aqueous buffer but with compromises to their inhibition activity with compare to 5-
amino-1-(phenylsulfonyl)-1H-pyrazol-3-yl. The small molecule interference with the 
productive interaction of the NS2B cofactor with NS3protease could be a superior 
drug discovery strategy when compared with targeting of the conserved active site of 
the flaviviral proteinase. In addition, to investigating the assumption, a focused 
structure-based approach was employed to identify the allosteric small molecule 
inhibitors of NS2B-NS3pro. Using high throughput in silico docking, a diverse set of 
275000 molecules from NCI compound library were virtually screened and found to 
show potentcial (Figure 1.7, cpds 1-33 and 1-34) activity against the protease. 
However, these compounds are too toxic to baby hamsterm (BHK21) to carry out 
further screening. Therefore, based on current research progress, there is much room 
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for further studies on the development of potential inhibitor molecules of WNV 
protease. 
 
1.7 Identification of “hit” compound by HTS  
Historically, most drugs have been derived from natural products, but there has been a 
shift away from their use with the increasing predominance of molecular approaches 
to drug discovery. Nevertheless, their structural diversity makes them a valuable 
source of novel lead compounds against newly discovered therapeutic targets. In the 
preliminary WNV NS3 protease inhibition assay, a collection of 110 compounds from 
our in-house compound library which have a history of antimicrobial, antiviral and 
anticancer activities were screened at 100 µM using high throughput screening (HTS) 
Figure 1.8 Structures and IC50 values of initial ‘‘hit’’ compounds against WNV 
NS2B-NS3 protease confirmed in the HTS. 
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technique to filter out the potential inhibitors. This initial screening provided a rapid 
identification of compounds that show potential ability to inhibit WNV NS3 protease. 
Eight compounds were found to exhibit detectable inhibition ability towards the 
WNV NS2B-NS3 protease. These compounds were further refined by cell 
cytotoxicity assays. This resulted in the identification of six compounds (Figure 1.8) 
as lead compounds. To optimize the potency of these compounds, a library of 
structurally diverse analogues of selected three scaffolds (Figure 1.8, 2-1a, 3-1a and 
4-1a) were synthesized for biological evaluation of their inhibitory activities. The 
compound 2-1a1, was of primary interest to us because, to our knowledge, this is the 
first zwitterion-type inhibitor identified and we reasoned that such an entity together 
with its surrounding amino groups could function like highly charged peptidyl 
recognition components to provide favourable binding interactions. To provide access 
to structurally diverse analogues of compound 2-1a1 for biological evaluation of their 
inhibitory activities, a focused library of 2-1a1 analogues were synthesized by 
modifying a literature procedure. Similarly, structurally diverse analogues of 
compound 3-1a1 and 4-1a1 were synthesised and evaluated for their biological 
property by SAR study.  
 
1.8 Purpose of this research work 
The main aim of this project was to identify novel and potent small molecule 
inhibitors of WNV NS2B-NS3 protease which will be stable under physiological 
condition and are non-cytotoxic to normal cells. In Section 1.1 we have highlighted 
the details on how WNV infection has been expanding rapidly over the past years and 
the growing public health concerns associated with this viral infection. Till date, there 
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is neither safe antiviral therapy nor vaccine available for human use against the WNV. 
The most potent small molecule inhibitor of WNV NS2B-NS3 protease was found to 
be unstable under physiological conditions and degraded within one hour in aqueous 
buffer. Attempts to increase the compound’s stability without compromising its 
activity have proven to be unsatisfactory. Therefore, a more specific aim of this 
project based on the screen a library of small molecules having better therapeutics 
indices via high throughput screening technique to identify ‘‘hit’’ compounds. 
Further, evaluation of selected scaffold from these initial ‘‘hit’’ compounds by SAR 
study with changing at diverse position through different functional group that would 
have better inhibition activity and their kinetics study to see the mode of interactions. 
Finally, a docking study was performed to rationalize the inhibition and kinetics result 












Chapter 2   
Discovery, Synthesis and In Vitro Evaluation of West Nile Virus Protease 
Inhibitor Based on the 9,10-Dihydro-3H,4aH-1,3,9,10a-tetraaza-phenanthren-4-
one Scaffold 
 
2.1 Synthesis of analogues of the lead compound 
To provide access to structurally diverse analogues of compound 2-1a1 for biological 
evaluation of their inhibitory activities, a focused library of 2-1a1 analogues were 
synthesized by modifying a literature procedure.100,101 The general strategy for the 
synthesis of compound 2-1a is shown in Scheme 2.1. A warm, aqueous solution of 
chloral hydrate and sodium sulfate were reacted with an acidic solution of the 
respective aniline 2-3 followed by aqueous hydroxylamine at 90 oC to give 
isonitrosoacetanilide102 2-4 which precipitated upon cooling from the reaction mixture 
in 80-95% yield. Polychronopoulos et al.103 had reported the cyclization of 2-4 with 
~68 equiv. of concentrated H2SO4. However in our hands, this large amount of 
concentrated H2SO4 hindered the precipitation for isatin 2-5. We explored the reaction 
using a reduced amount of concentrated H2SO4 and found that with 46 equiv. of 
concentrated H2SO4, the cyclization reaction proceeded equally readily and the crude 
2-5 which precipitated easily could be used in the next step of the reaction without 
purification. Compound 2-5 was subsequently reacted under reflux with 
thiosemicarbazide in 10% aqueous KOH100 to yield intermediate 2-6 which was 
precipitated from the reaction mixture at pH 5 as a yellow solid. Intermediate 2-6 was 
treated with the respective benzyl bromide derivatives and then acidified with glacial 
acetic acid to pH 5-6 to yield compound 2-7 as a pure yellow solid. Reaction of 
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compound 2-7 with various aldehydes in the presence of catalytic amounts of glacial 
acetic acid provided racemic 2-1a which could be further oxidized with 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) at room temperature104 to the corresponding 
compound 2-2a.  
Scheme 2.1 Synthesis of compounds 2-1a and 2-2a 
 
Reagents and conditions: a) Cl3CCH(OH)2, Na2SO4, HCl, H2O, NH2OH.HCl, 90 oC, 
2.5 h (80-95% yield); b) conc H2SO4, 60 oC to 80 oC, 45 min; c) NH2NHCSNH2, 10% 
aq. KOH, 115 oC, 1h, then acidify to pH 5 (52-70% yield); d) ArCH2Br, EtOH-10% 
aq KOH mixture, rt, 4h (80-90% yield); e) R2CHO, glacial acetic acid, EtOH, reflux 
10-15 min (50-90% yield); f) DDQ, CH2Cl2, 0 oC to rt, 4h (70-85% yield). 
 
2.2 Structure-activity relation studies 
A representative set of 69 analogues of compound 2-1a and 3 analogues of compound 
2-2a were synthesized and tested in a WNV assay at 100 µM concentration to filter 
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out potential inhibitors. Potential inhibitors were determined by their ability to inhibit 
the NS2B-NS3 protease activity by at least 50%. The effects of these compounds 
were then evaluated at different concentrations and the IC50 values of each compound 
were calculated using the Graphpad Prism software (Table 2.1). The Km value for the 
fluorogenic peptide substrate Pyr-RTKR-AMC for WNV NS2B-NS3 protease was 
determined, using the protocol from the SensoLyte® 440 West Nile Virus Protease 
Assay Kit, to be 3.45±0.41 µM.  
In the structure-activity relation (SAR) studies, R2 was first changed from 2-(3-
chlorophenyl)-furan-5-yl to various alkyl, aromatic or heteroaromatic groups whilst 
keeping R1 and Ar unchanged (Table 2.1, cpds 2-1a2 to 2-1a32). Replacing the 2-(3-
chlorophenyl)-furan-5-yl group in 2-1a1 with a 2-(4-nitrophenyl)-furan-5-yl, 2-(4-
bromophenyl)-furan-5-yl or 2-(4-chlorophenyl)-furan-5-yl moiety gave comparatively 
better inhibition (Table 2.1, cpds 2-1a3 to 2-1a5), indicating that a 4-substituted 
phenyl group plays an important role in the compound’s inhibitory activity. In 
addition, when R2 is a phenyl group (Table 2.1, cpd 2-1a9), the inhibitory activity was 
also much better than compound 2-1a1. Since having a phenyl group also made the 
compound more drug-like,95 we carried out further SAR studies of this novel type of 
scaffold. Aromatic rings carrying an electron-donating or electron-withdrawing group 
at different positions of the phenyl ring were synthesized (Table 2.1, cpds 2-1a13 to 
2-1a32) and the screening results showed that the presence of a p-chloro, p-bromo or 
p-thiomethyl substituent on the phenyl ring (Table 2.1, cpds 2-1a21 to 2-1a23)   
significantly amplified the compound’s inhibition activity.  
Next, we proceeded to tune the R1 group of the two strongest lead compounds, i.e. 2-
1a21 and 2-1a23, by first replacing H with an electron-withdrawing group, such as a 
halide. This did not provide any improvement in the inhibitory activities of the two 
35 
Table 2.1. IC50 values of compoundsa 2-1a and 2-2a 
Cpd R1 R2 Ar IC50 (µM) 
2-1a2 H 2-(2-chlorophenyl)-furan-5-yl C6H5 72.84±6.00 
2-1a3 H 2-(4-chlorophenyl)-furan-5-yl C6H5 13.56±0.53 
2-1a4 H 2-(4-bromophenyl)-furan-5-yl C6H5 29.41±3.97 
2-1a5 H 2-(4-nitrophenyl)-furan-5-yl C6H5 10.05±1.34 
2-1a6 H ethyl C6H5 NAb 
2-1a7 H thiophene-2-yl C6H5 45.06±2.85 
2-1a8 H 5-methylfuran-2-yl C6H5 49.17±5.51 
2-1a9 H phenyl C6H5 27.33±5.81 
2-1a10 H quinoline-3-yl C6H5 11.02±0.78 
2-1a11 H pyridine-3-yl C6H5 >100 
2-1a12 H pyridine-2-yl C6H5 >100 
2-1a13 H 2-methylphenyl C6H5 20.46±1.47 
2-1a14 H 2-chlorophenyl C6H5 29.99±2.52 
2-1a15 H 2-(methylthio)phenyl C6H5 >100 
2-1a16 H 3-phenoxyphenyl C6H5 NA 
2-1a17 H 3-carboxyphenyl C6H5 >100 
2-1a18 H 3-chlorophenyl C6H5 NA 
2-1a19 H 3-nitrophenyl C6H5 11.39±0.31 
2-1a20 H 4-fluorophenyl C6H5 45.22±3.28 
2-1a21 H 4-chlorophenyl C6H5 7.66±0.91 
2-1a22 H 4-bromophenyl C6H5 9.39±1.00 
2-1a23 H 4-(methylthio)phenyl C6H5 6.28±1.39 
2-1a24 H 4-methoxyphenyl C6H5 NA 
2-1a25 H 4-nitrophenyl C6H5 NA 
2-1a26 H 3-methyl-4-hydroxyphenyl C6H5 >100 
2-1a27 H 2-chloro-4-hydroxyphenyl C6H5 >100 
2-1a28 H 3,4-dichlorophenyl C6H5 >100 
2-1a29 H 4-hydroxy-3-nitrophenyl C6H5 >100 
2-1a30 H 4-fluoro-3-nitrophenyl C6H5 35.72±3.77 
2-1a31 H 4-bromo-3-nitrophenyl C6H5 18.73±0.99 
2-1a32 H 3,5-dibromophenyl C6H5 >100 
2-1a33 F 4-bromophenyl C6H5 >100 
2-1a34 F 4-chlorophenyl C6H5 >100 
2-1a35 F 4-(methylthio)phenyl C6H5 23.91±7.37 
2-1a36 F 3-nitrophenyl C6H5 >100 
2-1a37 Cl phenyl C6H5 >100 
2-1a38 Cl 4-chlorophenyl C6H5 16.28±2.56 
2-1a39 Cl 4-(methylthio)phenyl C6H5 >100 
2-1a40 Me 4-chlorophenyl C6H5 5.41±0.45 
2-1a41 Me 4-(methylthio)phenyl C6H5 10.70±0.72 
2-1a42 Me 2-(4-chlorophenyl)-furany5-yl C6H5 8.21±0.28 
2-1a43 Me phenyl C6H5 >100 
2-1a44 Me 2-(4-nitrophenyl)-furan-5-yl C6H5 >100 
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2-1a45 Me 4-bromophenyl C6H5 >100 
2-1a46 Me 3-nitrophenyl C6H5 >100 
2-1a47 Me 4-bromo-3-nitrophenyl C6H5 >100 
2-1a48 Et 4-chlorophenyl C6H5 NA 
2-1a49 Et 4-(methylthio)phenyl C6H5 NA 
2-1a50 H phenyl 4-MeOC6H4 NA 
2-1a51 H 3-nitrophenyl 4-MeOC6H4 NA 
2-1a52 H 4-chlorophenyl 4-MeOC6H4 8.47±2.54 
2-1a53 H 4-(methylthio)phenyl 4-MeOC6H4 5.56±0.10 
2-1a54 H 4-chlorophenyl 4-BrC6H4 >100 
2-1a55 H 4-(methylthio)phenyl 4-BrC6H4 >100 
2-1a56 H 4-chlorophenyl 3-BrC6H4 >100 
2-1a57 H 4-(methylthio)phenyl 3-BrC6H4 11.15±1.32 
2-1a58 H 4-chlorophenyl 4-ClC6H4 >100 
2-1a59 H 4-(methylthio)phenyl 4-ClC6H4 6.20±0.15 
2-1a60 H 4-chlorophenyl 3-ClC6H4 23.35±5.05 
2-1a61 H 4-(methylthio)phenyl 3-ClC6H4 11.14±2.42 
2-1a62 H 4-chlorophenyl 4-FC6H4 >100 
2-1a63 H 4-(methylthio)phenyl 4-FC6H4 13.29±1.55 
2-1a64 H 4-chlorophenyl 3-FC6H4 >100 
2-1a65 H 4-(methylthio)phenyl 3-FC6H4 13.80±2.69 
2-1a66 H 4-chlorophenyl 4-CNC6H4 >100 
2-1a67 H 4-(methylthio)phenyl 4-CNC6H4 >100 
2-1a68 Me 4-chlorophenyl 4-MeOC6H5 14.56±1.03 
2-1a69 Me 4-(methylthio)phenyl 4-MeOC6H5 11.92±1.32 
2-2a1 Me 4-chlorophenyl C6H5 NA 
2-2a2 Me 4-(methylthio)phenyl C6H5 NA 
2-2a3 Et 4-(methylthio)phenyl C6H5 NA 
[a] Data represent concentrations required to inhibit WNV NS2B–NS3 protease activity 
by 50% and are the mean±SE of triplicate experiments; compounds used are ≥98% 
pure. [b] NA: no activity. 
 
compounds (Table 2.1 cpds 2-1a33 to 2-1a39). However, if R1 was changed to an 
electron-donating methyl group (Table 2.1, cpds 2-1a40 to 2-1a47), a slight 
enhancement in the inhibition of WNV NS2B–NS3 protease was observed in one of 
the two compounds (Table 2.1 cpd 2-1a40). However, increasing the size of the alkyl 
group by replacing the methyl substituent with an ethyl group resulted in a total loss 
of inhibitory activity in the two compounds (Table 2.1 cpds 2-1a48 to 2-1a49).   
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To explore the effect of the Ar group on the biological activity of the compound, we 
replaced to the phenyl ring of the Ar group with a phenyl group containing either an 
electron-donating and electron-withdrawing substituent (Table 2.1 cpds 2-1a50 to 2-
1a69). The best inhibition was observed in compound 2-1a53 which contains a 4-
methoxyphenyl group on the Ar position and a 4-(methylthio)phenyl moiety at the R2 
position. In addition, the inhibitory activity of compound 2-1a52 was comparably to 
2-1a21. Finally, we synthesized compounds 2-1a68 and 2-1a69 to analyze the 
combined effects of the preferred substituents on R1, R2 and Ar. However, the 
inhibitory activities of compounds 2-1a68 and 2-1a69 were weaker than compounds 
2-1a23, 2-1a40 or 2-1a53, the three strongest candidates identified from our earlier 
screening efforts.  
Considering that the compounds tested thus far were always racemate compounds, we 
proceeded to investigate the influence of stereochemistry on the compounds’ 
biological activities. However, attempts to separate the R- and S- enantiomers of 2-
1a23, 2-1a40 and 2-1a53 using our own column available in lab and collaboration 
Diacel Japan with various methods proved futile as a single peak was constantly 
observed in the chiral HPLC analysis. In addition, removal of the chiral centre by 
DDQ oxidation gave a new scaffold 2a which was completely inactive as inhibitors to 
WNV NS2B-NS3 protease (Table 2.1, cpds 2-2a1 to 2-2a3). Thus compounds 2-
1a23, 2-1a40 and 2-1a53 were used for subsequent in vitro evaluations. The stabilities 
of compounds 2-1a23, 2-1a40 and 2-1a53 at 37 °C in pH 8 buffer were determined by 
analyzing the amount of compound remaining with time using LCMS-IT-TOF 
detection. Quantization of the compounds was determined by Shimadzu's LC solution 
software. Compounds 2-1a23, 2-1a40 and 2-1a53 showed excellent stability in a pH 8 
buffer after 72 h. 
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Next we evaluated the cytotoxicities of compounds 2-1a23, 2-1a40 and 2-1a53 
against baby hamster kidney fibroblasts (BHK21 cells) for incubation times of 48 and 
72 h.  
 
 Figure 2.1 MTS assay results obtained at incubation times of 48 (     ) and 72 h (     ) 
with the BHK21 cell line. Compounds were added at a final concentration of 50 µM. 
 
Vehicular control, dimethyl sulfoxide (DMSO), was also included to serve as control 
as the test compounds were dissolved in DMSO. The amount of DMSO used in the 
assay was controlled at 0.2% of the total volume. This is to ensure that DMSO does 
not result in cytotoxicity of cells. From the results obtained (Figure 2.1), compounds 
2-1a23, 2-1a40 and 2-1a53 were shown to be non-cytotoxic to BHK21 cells. To 
determine the mode of inhibition of the WNV NS2B-NS3 protease activity by 
compound 2-1a40, we followed the kinetics of inhibition using Pyr-RTKR-AMC as  
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Figure 2.2 Uncompetitive inhibition of 2-1a40 with WNV NS2B-NS3 protease. 
WNV protease assays were performed at various concentrations of 2-1a40 (0, 5.0 and 
25 μM) and substrate concentrations (3.3, 8.3, 16.7, 33.3, 83.3 μM). Double reciprocal 
plots of 1/V versus 1/[S] for 2-1a40 at each inhibitor concentration were plotted using 
the OriginPro 8. 
 
substrate. This provided a substrate concentration dependent inhibition of the NS2B-
NS3 protease activity (Figure 2.2). Lineweaver-Burk analysis of the initial velocities 
suggested that the inhibition by 2-1a40 was uncompetitive with respect to the 
substrate that possesses a Ki value of 4.47±0.37 µM. Uncompetitive inhibition by the 
compound 2-1a24, due to the absence of charge on the inhibitor that prefers active 
site of the protease. 
 
2.3 Docking analysis 
The crystal structure of the WNV NS2B-NS3 protease in complex with peptide Bz-
Nle-Lys-Arg-Arg-H (pdb 2fp7) has been reported earlier.74 To identify the potential 
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binding site of compound 2-1a40 on the NS2B-NS3 protease, in silico docking 
studies were performed by using these crystal structure coordinates. Since compound 
2-1a40 is an uncompetitive inhibitor of the WNV NS2B-NS3 protease, we focused 
our analysis on regions beyond the substrate binding sites. Earlier studies have shown 
that the integration of residues 78-87 of NS2B into the protease-cofactor complex 
affected the formation of the catalytic active sites.74,75,105 Deletion or mutagenesis of 
these residues produced an inert enzyme. Therefore the region on the NS3 protease 
where key interactions with the NS2B cofactor (residue 78-87) occur is important for 
the NS2B-NS3 protease activity and particular attention was paid to this region during 
our docking studies. 
 
Figure 2.3 Molecular docking of compound 2-1a40 onto WNV NS2B-NS3 protease. 
The WNV protease crystal structure coordinates (pdb 2fp7)74 were used for the 
molecular docking. The NS2B-NS3 protease and the enantiomers of compound 2-
1a40 are shown as a wireframe and flat ribbon model generated using Discovery 
Studio 3.1 client. (a) S-enantiomer; (b) R-enantiomer. 
 
Since compound 2-1a40 contains a chiral centre, the R- and S- enantiomers were 
separately analyzed for their interactions with the WNV NS2B-NS3 protease. Our 
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docking analysis predicted that the binding energies of the S- and R- enantiomers with 
the WNV NS2B-NS3 protease were similar (S-enantiomer: -8.10 kcal/mol; R-
enantiomer: -8.22 kcal/mol). Amino acid residues that are in close proximity (less 
than 5 Å) to the atoms of the S-enantiomers include Arg78, Leu79 and Phe85 of 
NS2B; Ser71, Lys73, Glu74, Arg76, Lys88, Pro119, Glu120, Ile123, Ala164, Ile165 
and Gln167 of the NS3 protease. Amino acid residues that are in close proximity (less 
than 5 Å) to the atoms of the R-enantiomers are Val77, Arg78 and Leu79 of NS2B; 
Lys88, Thr118, Glu120, Ile123 and Gln167 of the NS3 protease. The guanidine group 
in Arg78 of the NS2B cofactor binds strongly with the Ar group of the S-enantiomer 
via π-cation type of interactions. Strong π-cation type of interaction was also observed 
between the 4-chlorophenyl moiety of the S-enantiomer and Lys73 on the NS3 
protease (Figure 2.3a). On the other hand, the R-enantiomer could potentially form 
hydrogen bond with residue Lys73 on the NS3 protease as well as π-cation interaction 
with the same residue. However we did not observe any strong interaction between 
the R-enantiomer and the key residues from the NS2B binding cavity (Figure 2.3b). 
This indicates that the S-enantiomer more strongly interferes with the productive 
interactions of the NS2B cofactor with the NS3 protease domain and is a preferred 
isomer for the inhibition of the WNV NS3 protease. 
 
2.4 Conclusion 
This study reports an in vitro assay for the WNV NS2B-NS3 protease that yielded a 
lead inhibitor with a 9,10-dihydro-3H,4aH-1,3,9,10a-tetraaza-phenanthren-4-one 
scaffold. Refinement of this initial “hit” by synthesizing and evaluating a focussed 
library of 9,10-dihydro-3H,4aH-1,3,9,10a-tetraaza-phenanthren-4-one compounds 
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provided an analogue (S)-2-1a40 that showed low micromolar inhibition of the WNV 
NS2B-NS3 protease. Compound (S)-2-1a40 inhibited the interaction between the 
NS2B cofactor and the NS3 proteases in an uncompetitive manner.  
 
2.5 Experimental Section 
2.5.1 Chemistry 
All chemical reagents and anhydrous solvent were obtained from Aldrich, Merck, 
Lancaster or Fluka and used without further purification. Flash chromatography was 
performed with silica (Merck, 70-230 mesh) whilst TLC was carried out on pre-
coated plates (Merck silica gel 60, F254) and visualized with UV light. Purity of the 
final compound was determined by HPLC using a Shimadzu LCMS-IT-TOF system 
with a Phenomenex C18 column (50 mm x 3.0 mm, 5 μm). Purity of the compound 
was checked at 254 nm and integration was obtained with Shimadzu LCMS solution 
software. 1H and 13C NMR spectra were recorded using CDCl3, acetone-d6, or 
DMSO-d6 as solvents and tetramethylsilane (TMS) as internal reference on a Bruker 
AMX500 or a Bruker ACF 300 Fourier transform spectrometer. The following 
abbreviations were used to explain the multiplicities: s (singlet), d (doublet), t 
(triplet), dd (doublet of doublet), q (quatrate), and m (multiplet). The number of 
protons (n) for a given resonance was indicated as nH. Mass spectrometry was 
performed on a Finnigan/MAT LCQ mass spectrometer using electron spray (ESI) 
ionization. 
General procedure for the synthesis of 2-4: Chloral hydrate (3.84 g, 23.2 mmol) 
and Na2SO4 (60 g, 422 mmol) were dissolved in water (20 mL) in a 500 mL beaker 
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and warmed to 35 °C. A warm solution of the commercial available aniline or its 
derivatives 2-3 (21.5 mmol) in water (6 mL) and an aqueous solution of concentrated 
HCl (1.83 mL, 22 mmol) were added (a white precipitate of the aniline sulfate was 
formed) followed by a warm solution of hydroxylamine hydrochloride (4.72 g, 67.94 
mmol) in water (8.25 mL). The mixture was heated at 90 °C for 2.5 h and then 
allowed to cool to 50 °C before filtering. The pale cream solid obtained was washed 
by stirring with water (100 mL), filtered and dried overnight at 50 °C to give the 
corresponding isonitrosoacetanilide 2-4 in 80-95% yield. 
General procedure for the synthesis of 2-5: Concentrated sulfuric acid (18 mL, 
337.68 mmol) was heated in a 250-mL beaker to 60 °C. The respective dried 
compound 2-4 (7.3 mmol) was added in portion with stirring over 30 min so that the 
temperature did not exceed 65 °C. The mixture was then heated to 80 °C for 15 min, 
allowed to cool to 70 °C, and cooled on ice-cold water. The solution was then poured 
very slowly into ice and allowed to stand until a reddish precipitate of isatine 2-5 was 
formed. The crude solid 2-5 was filtered and used in the next step without further 
purification. 
General procedure for the synthesis of 2-6: The respective compound 2-5 (10.2 
mmol) was dissolved in 10 % aqueous KOH (10 mL, 45.5 mmol) and then treated 
with thiosemicarbazide (985 mg, 10.7 mmol). The reaction mixture was heated at 115 
oC for 1h, cooled to room temperature and then poured over ice. Acidification of the 
reaction mixture to ~pH 5 with glacial acetic acid provided yellow fluffy precipitate 
which was filtered, washed copiously with water, dried in air and then in a vacuum 
oven (at 50 °C) to afford a yellow solid 2-6 in 60-78% yield. Purification of 
compound 2-6 by column chromatography gave the pure product is 52-70%. 
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General procedure for the synthesis of 2-7: The respective crude compound 2-6 (6 
mmol) was dissolved in a mixture of ethanol (12 mL) and 10 % aq. KOH (18 mL, 
27.3 mmol) was treated with a solution of benzylbromide or benzylbromide derivative 
(6 mmol) and allowed to stir over night. Thereafter, the reaction mixture was diluted 
with ether (100 mL) and water (70 mL). The ether layer was separated and the 
aqueous layer was washed with ether (3x100 mL) and then poured over ice. Upon 
careful, dropwise addition of glacial acetic acid with vigorous shaking at 0-4 °C, 
yellow precipitate formed. This precipitate was filtered, washed with water (3x30 mL) 
and dried in a vacuum oven (at 50 °C) to provide compound 2-7 in 80-90% yield. 
General procedure for the synthesis of 2-1a: To a suspension of the respective 
compound 2-7 (0.32 mmol) in anhydrous ethanol (6 mL) was added glacial acetic acid 
(25 µL, 0.42 mmol) followed by the respective aldehyde (0.42 mmol, 1.3 equiv.). The 
reaction mixture was refluxed for 10-15 min resulting in a dark-reddish solution. 
Upon cooling to room temperature, orange-yellow solid 2-1a precipitated from the 
solution. Sometimes the hot reaction mixture contained insoluble particles which were 
removed by filtering the reaction mixture under hot condition. The filtrate was then 
cooled to room temperature to provide the crude solid compound 2-1a. The crude 
product was recrystallized with ethanol, filtered and washed with cold ethanol (2x3 
mL). In a few cases, the product was purified by column chromatography then dried 
in a vacuum oven at 50 °C. Compound 2-1a was obtained in 50-90% yield. 
General procedure for the synthesis of 2-2a: The respective compound 2-1a (0.16 
mmol) was dissolved in CH2Cl2 (10 mL) and the reaction mixture was kept at 0 °C 
followed by the slow addition of DDQ (0.2 mmol). After the addition of DDQ, the 
temperature of the reaction mixture was allowed to rise to room temperature and was 
kept at this temperature for 4 hours. During this time, the time reaction was monitored 
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by TLC. When the reaction was completed, the reaction mixture was extracted with a 
CH2Cl2/H2O mixture. The organic layer was concentrated, purified by column 
chromatography using a ethyl acetate/hexane (starting from 1:4 to 1:1) solvent system 
and dried under vacuum at 50 °C temperature to yield compound 2-2a in 70-85% 
yield. 
2.5.2 Biology 
All the compounds were tested against the WNV NS2B-NS3 protease using the 
SensoLite® 440 WNV protease assay kit (Catalog # 72079) and the active 
recombinant WNV protease (Calalog # 72081) which were purchased from Anaspec 
(USA). This protease assay kit uses a fluorogenic peptide Pyr-RTKR-AMC as 
substrate. Eight different substrate concentrations ranging from 1 to 80 μM were 
incubated in 96-well plates with 0.3μg/mL recombinant WNV protease at 37 °C in the 
buffer provided. The increase in fluorescence intensity was monitored using an 
Infinite F200 microplate reader (Tecan, Switzerland) at an excitation wavelength of 
354 nm (±10 nm) and emission wavelength of 442 nm (±15 nm). The initial velocity 
was determined from the linear portion of the progress curve, and the value of Km was 
determined using the Michaelis-Menten equation, i.e. v = Vmax [S] / ([S] + Km) to be 
3.45±0.41 µM. Triplicate measurements were taken at each data point and the data 
were reported as mean±SE. In the preliminary WNV NS2B-NS3 protease inhibition 
assay, compounds 2-1a and 2-2a were screened at a fixed concentration of 100 μM to 
filter out potential inhibitors. Compounds which showed more than 50% inhibition 
were further investigated for their IC50 determination.  
Determination of IC50: For the IC50 calculations, recombinant WNV protease 
concentration of 0.3 µg/mL and seven different concentrations of the inhibitor ranging 
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from 10 nM to 100μM were used. For each experiment, the protease was pre-
incubated with the inhibitor at 37 oC for 15 min in separate wells and the enzyme 
kinetics was initiated by adding substrate Pyr-RTKR-AMC to a final concentration 
16.7 µM. The increase in fluorescence intensity was monitored continuously using an 
Infinite F200 microplate reader at an excitation wavelength of 354 nm and emission 
wavelength at 442 nm. Fluorescence values obtained from the positive control (no 
inhibitor) were considered as 100% complex formation and those values obtained in 
the presence of inhibitors were calculated as the percentage of inhibition of the 
control. Duplicate measurements were obtained at each data point. The IC50 values 
were calculated using a sigmoidal dose-response using the Graphpad prism 3.0 
software (San Diego, USA). Duplicate measurements were recorded as the mean±SE.  
Determination of inhibition mechanism: Two different inhibitor concentrations and 
a no-inhibitor control (0 to 25 μM) were each assayed at five substrate concentrations 
ranging from 3.3 to 83.3 μM. In each assay, the enzyme and inhibitor were incubated 
at 37 °C for 15 min, followed by the addition of the substrate to start the kinetic 
measurement. The rate of substrate cleavage (v) was monitored using the F200 
microplate reader. To illustrate the inhibition mechanism, 1/V versus 1/[S] was 
plotted for at each inhibitor concentration using OriginPro 8. 
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Figure 2.4 Un-inhibition curves of compound 2-1a23, 2-1a40 and 2-1a53       
MTS Assay 
The baby hamster kidney fibroblast (BHK21) cells  were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS). 
The 1500 cells were placed in each well of three 96-well plates with a cell density of 
1.66x104 cells/mL and incubated for 24 h at 37 °C with 5% CO2. Thereafter, the 
compound of interest or DMSO was added into each well at 50 µM. Wells containing 
plain DMSO served as a vehicular control. The plate was then placed in the incubator 
for 48 and 72 h of incubation at 37 °C with 5% CO2. At the end of each individual 
incubation time point, MTS reagent solution (20µL) was added into each sample well. 
The plate was then incubated again in the dark for 2 h, gently shaken using a vortemp 
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machine for 5 min to ensure equal mixing and absorbance at 492 nm was taken using 
a spectrometer. 
2.5.3 In silico studies 
 Molecular docking simulations were performed with the AutoDock4 program. Both 
enantiomers of compound 2-1a40 were constructed in ChemBio 3D Ultra 11.0 by 
minimizing the energy. The active site of the WNV protease was prepared using the 
crystal structure of the WNV NS2B-NS3 protease in complex with peptide Bz-Nle-
Lys-Arg-Arg-H (pdb 2fp7).18 The structure was stripped of all water molecules and 
bound ligand. Hydrogen atom was added to all polar atoms of the protein followed by 
the addition of Gasteiger-Marsili charges. AutoDock simulations were performed 
using the Lamarckian Genetic Algorithms (GA) subroutine at default settings for GA 
population size, crossover rate, mutation rate, and starting with fully randomized 
ligand position, orientation and conformation. Fifty GA runs were performed for the 
inhibitor-enzyme pair and results were analyzed using Discovery Studio 3.1 client.  
 
2.6  1H and 13C NMR data of all compounds synthesized and crystal structure of 
2-1a43 and 2-2a1  
1H and 13C NMR data of compound 2-4:  
(E)-2-(Hydroxyimino)-N-phenylacetamide (2-4a) as a light brown solid (Yield: 
83%): 1H NMR (500 MHz, Acetone-d6): δ = 11.73 (s, 1H), 9.66 (s, 1H), 8.21-8.19 (m, 
2H), 8.01 (d, J = 3.8 Hz, 1H), 7.79-7.76 (m, 2H), 7.56-7.53 (m, 2H). 13C NMR (125 
MHz, Acetone-d6): δ = 160.9, 144.6, 138.8, 129.2, 124.4, 120.4, 120.3. HRMS-ESI 
m/z [M - H] calcd for C8H7N2O2: 163.0513, found: 163.0514. 
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(E)-N-(4-Fluorophenyl)-2-(hydroxyimino)acetamide(2-4b) as a light brown solid 
(Yield: 95%):  1H NMR (500 MHz, Acetone-d6): δ = 11.25 (s, 1H), 9.28 (s, 1H), 7.75-
7.71 (m, 2H), 7.50 (s, 1H), 7.06-7.03 (m, 2H). 13C NMR (125 MHz, Acetone-d6): δ = 
160.3, 159.9, 158.1, 144.2, 134.7, 121.8, 121.7, 115.2, 115.0. HRMS-ESI m/z [M + 
Na] calcd for C8H7FN2O2 Na: 205.0384, found: 205.0388. 
(E)-N-(4-Chlorophenyl)-2-(hydroxyimino)acetamide (2-4c) as a brown solid 
(Yield: 84%): 1H NMR (500 MHz, Acetone-d6): δ = 9.41 (s, 1H), 7.75-7.72 (m, 2H) 
7.51 (s, 1H), 7.29-7.27 (m, 2H). 13C NMR (125 MHz, Acetone-d6): δ = 161.2, 144.5, 
137.9, 129.2, 128.9, 122.0, 121.9. HRMS-ESI m/z [M - H] calcd for C8H6ClN2O2: 
197.0123, found: 197.0118. 
(E)-2-(Hydroxyimino)-N-p-tolylacetamide (2-4d) as a brown solid (Yield: 89%): 1H 
NMR (500 MHz, Acetone-d6): δ = 9.19 (s, 1H), 7.57 (d, J = 3.2 Hz, 2H), 7.51 (s, 1H), 
7.07 (d, J = 3.2 Hz, 2H), 2.22 (s, 3H). 13C NMR (125 MHz, Acetone-d6): δ = 160.8, 
144.5, 136.2, 133.8, 129.5, 120.3, 120.2, 20.4. HRMS-ESI m/z [M + H] calcd for 
C9H11N2O2:  179.0815 found: 179.0819. 
(E)-N-(4-ethylphenyl)-2-(hydroxyimino)acetamide (2-4e) as a brown solid (Yield: 
92%): 1H NMR (500 MHz, Acetone-d6): δ = 11.20 (s, 1H), 9.11 (s, 1H), 7.65 (d, J = 
8.15 Hz, 2H), 7.53 (s, 1H), 7.16 (d, J = 8.8 Hz, 2H) 2.62-2.58 (q, J = 7.5 Hz, 2H), 
1.17 (t, J = 8.8 Hz, 2H) 13C NMR (125 MHz, Acetone-d6): δ = 160.0, 144.3, 139.8, 
136.1, 127.9, 119.9, 119.8, 27.9, 15.2. HRMS-ESI m/z [M + H] calcd for 




1H and 13C NMR data of compound 2-6:  
6-(2-Aminophenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (2-6a). The 
crude product was purified using flash chromatography (EtOAc/hexane =1:3) to 
afford as a yellow solid (Yield: 52%).  1H NMR (500 MHz, DMSO-d6): δ =13.37 (s, 
1H), 7.32 (d, J = 7.55 Hz, 1H), 7.09 (t, J = 7.55 Hz, 1H), 6.68 (d, J = 8.2 Hz, 1H), 
6.53 (t, J = 7.55 Hz, 1H), 5.53 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 172.0, 
151.9, 146.7, 146.3, 129.6, 129.3, 114.4, 113.9, 113.8. HRMS-ESI m/z [M - H] calcd 
for C8H8N4OS: 219.0346, found: 219.0352. 
6-(2-Amino-5-fluorophenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (2-6b). 
The crude product was purified using flash chromatography (EtOAc/hexane =1:3) to 
afford as a yellow solid (Yield: 58%).  1H NMR (500 MHz, DMSO-d6): δ =13.50 (s, 
2H), 7.27-7.25 (dd, J = 10.7 Hz, 1H), 7.00-6.96 (m, 1H), 6.70-6.67 (q, J = 5.05 Hz, 
1H), 5.51 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 173.1, 153.9, 152.8, 152.1, 
146.4, 143.9, 117.5, 117.2, 116.5, 116.4, 116.3, 116.1, 114.7, 114.6. HRMS-ESI m/z 
[M - H] calcd for C9H7FN4OS: 237.0252, found: 237.0253. 
6-(2-Amino-5-chlorophenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (2-6c). 
The crude product was purified using flash chromatography (EtOAc/hexane =1:3) to 
afford as a yellow solid (Yield: 66%).  1H NMR (300 MHz, DMSO-d6): δ = 7.43 (d, J 
= 3.6 Hz, 1H), 7.11-7.09 (m, 1H), 6.79 (d, J = 14.5 Hz, 1H), 5.73 (s, 2H). 13C NMR 
(75 MHz, DMSO-d6): δ 173.2, 153.3, 145.3, 144.8, 128.7, 117.1, 116.0, 115.5. 
HRMS-ESI m/z [M - H] calcd for C9H6ClN4OS: 252.9956, found: 252.9950. 
6-(2-Amino-5-methylphenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (2-6d). 
The crude product was purified using flash chromatography (EtOAc/hexane =1:3) to 
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afford as a yellow solid (Yield: 66%).  1H NMR (300 MHz, DMSO-d6): δ = 7.13 (s, 
1H), 7.43 (m, 1H), 6.59 (d, J = 8.15 Hz, 1H), 2.13 (s, 3H). 13C NMR (75 MHz, 
DMSO-d6): δ = 172.4, 152.6, 146.5, 143.9, 130.0, 129.6, 122.3, 114.8, 114.3, 19.0. 
HRMS-ESI m/z [M - H] calcd for C11H10N4OS: 235.0648, found: 235.0651. 
6-(2-Amino-5-ethylphenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (2-6e). 
The crude product was purified using flash chromatography (EtOAc/hexane =1:4) to 
afford as a yellow solid (Yield: 70%).  1H NMR (500 MHz, DMSO-d6): δ = 13.48 (s, 
1H), 13.09 (s, 1H), 7.15 (s, 1H), 6.96 (d, J = 8.2 Hz, 1H), 6.62 (, J = 8.2 Hz, 1H), 
5.30 (s, 2H), 2.46-2.41 (q, J = 7.55 Hz, 2H), 1.10 (t, J = 7.55 Hz, 3H) 13C NMR (125 
MHz, DMSO-d6): δ 172.9, 153.4, 152.8, 147.8, 145.1, 129.9, 129.3, 115.6, 114.8, 
27.1, 15.8. HRMS-ESI m/z [M - H] calcd for C11H13N4OS: 249.0805, found: 
249.0808. 
1H and 13C NMR data of compound 2-7: 
6-(2-Aminophenyl)-3-(benzylthio)-1,2,4-triazin-5(2H)-one (2-7a) as a yellow solid 
(Yield: 83%). 1H NMR (500 MHz, DMSO-d6): δ =7.45 (d, J = 7.55 Hz, 3H), 7.36-
7.28 (m, 6H), 7.11 (t, J = 8.2 Hz, 1H), 6.74 (d, J = 8.2 Hz, 1H), 6.58 (d, J = 6.9 Hz, 
3H), 4.46 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 146.5, 135.9, 129.8, 129.2, 
128.1, 127.6, 127.5, 127.3, 126.5, 125.9, 115.2, 114.9, 114.2, 31.9.  HRMS-ESI m/z 
[M - H] calcd for C16H13N4OS: 309.0816, found: 309.0821. 
6-(2-Amino-5-fluorophenyl)-3-(benzylthio)-1,2,4-triazin-5(2H)-one (2-7b) as a 
yellow solid (Yield: 80%). 1H NMR (500 MHz, DMSO-d6): δ = 7.47-7.29 (m, 6H), 
7.01 (s, 1H), 6.75 (s, 1H), 4.46 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 161.1, 
158.2, 153.1, 151.3, 147.4, 143.2, 135.8, 128.1, 127.6, 126.5, 116.3, 116.2, 115.9, 
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115.8, 115.5, 115.3, 31.9.  HRMS-ESI m/z [M - H] calcd for C16H12FN4OS: 327.0721, 
found: 327.0728. 
6-(2-Amino-5-chlorophenyl)-3-(benzylthio)-1,2,4-triazin-5(2H)-one (2-7c) as a 
yellow solid (Yield: 87%). 1H NMR (500 MHz, DMSO-d6): δ = 7.61 (d, J = 2.5 Hz, 
1H), 7.44 (d, J = 6.95 Hz, 2H), 7.34-7.26 (m, 3H), 7.12-7.10 (dd, J = 2.55 Hz and 6.3 
Hz, 1H), 6.74 (d, J = 8.2 Hz, 1H), 4.43 (s, 2H). 13C NMR (125 MHz, DMSO-d6): δ 
163.0, 159.7, 148.5, 146.5, 137.2, 129.8, 129.3, 129.0, 128.5, 127.3, 118.2, 117.9, 
117.2, 32.9. HRMS-ESI m/z [M - H] calcd for C16H12ClN4OS: 343.0426, found: 
343.0438. 
6-(2-Amino-5-methylphenyl)-3-(benzylthio)-1,2,4-triazin-5(2H)-one (2-7d) as a 
yellow solid (Yield: 90%). 1H NMR (500 MHz, DMSO-d6): δ = 7.47-7.25 (m, 6H), 
6.93 (d, J = 13.45 Hz, 1H), 6.65 (d, J = 13.7 Hz, 1H), 4.45 (s, 2H), 2.16 (s, 3H).  13C 
NMR (125 MHz, DMSO-d6): δ = 161.1, 158.6, 148.9, 144.0, 136.0, 129.9, 129.8, 
128.0, 127.5, 126.4, 122.7, 115.9, 115.2, 31.9, 19.0.  HRMS-ESI m/z [M + H] calcd 
for C17H17N4OS: 325.1118, found: 325.1113. 
6-(2-Amino-5-ethylphenyl)-3-(benzylthio)-1,2,4-triazin-5(2H)-one (2-7e) as a 
yellow solid (Yield: 85%). 1H NMR (500 MHz, DMSO-d6): δ  = 7.45 (d, J = 7.55 Hz, 
2H), 7.36-7.25 (m, 4H), 6.98 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 8.85 Hz, 1H), 4.46 (s, 
2H), 2.48-2.43 (q, J = 7.55 Hz, 2H), 1.10 (t, J = 7.55 Hz 3H). HRMS-ESI m/z [M + 
H] calcd for C18H19N4OS: 339.1274, found: 339.1284. 
6-(2-Aminophenyl)-3-(4-methoxybenzylthio)-1,2,4-triazin-5(2H)-one (2-7f) as a 
yellow solid (Yield: 86%). 1H NMR (500 MHz, DMSO-d6): δ = 7.55 (s, H), 7.37 (d, J 
= 8.2 Hz, 2H), 7.14-7.12 (m, 1H), 6.91-6.89 (m, 3H), 6.74 (d, J = 8.8 Hz, 1H), 4.41 
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(s, 2H), 3.74 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ 158.7, 146.5, 130.3, 129.8, 
129.7, 128.4, 128.1, 118.2, 117.3, 117.0, 113.9, 113.8, 113.7, 55.1, 32.7. 
 
1H and 13C NMR data of compounds 2-1a and 2-2a: 
3-(Benzylthio)-6-(5-(2-chlorophenyl)furan-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a2) as an orange-yellow solid (Yield: 50%). 1H 
NMR (500 MHz, DMSO-d6): δ =  8.93 (d, J = 7.55  Hz, 1H), 8.45 (d, J = 3.15  Hz, 
1H), 7.51-7.19 (m, 10H), 7.06-6.96 (m, 4H) 6.66 (d, J = 3.8  Hz, 1H), 4.35-4.26 (m, 
2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.3, 160.8, 150.2, 148.5, 144.7, 137.6, 
134.7, 134.6, 130.7, 129.9, 129.5, 129.2, 128.9, 128.3, 127.8, 127.5, 127.4, 127.0, 
119.2, 115.4, 112.4, 112.3, 111.5, 71.3, 33.4. HRMS-ESI m/z [M - H] calcd for 
C27H18ClN4O2S: 497.0844, found: 497.0839. 
3-(Benzylthio)-6-(5-(4-chlorophenyl)furan-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a3) as an orange-yellow solid (Yield: 57%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.92 (d, J = 13.4 Hz, 1H), 8.44 (s, 1H), 7.52-
7.21(m, 11H), 7.07-6.96 (m, 4H), 6.62 (s, 1H), 4.35-4.23 (m, 2H).13C NMR (125 
MHz, DMSO-d6): δ =170.4, 160.9, 152.8, 146.3, 144.8, 137.7, 134.7, 134.6, 134.6, 
132.5, 129.9, 128.9, 128.4, 128.2, 127.1, 125.1, 119.3, 115.4, 112.9, 112.4, 107.3, 
71.3, 33.5. HRMS-ESI m/z [M + H] calcd for C27H20ClN4O2S: 499.0990 found: 
499.0993. 
3-(Benzylthio)-6-(5-(4-bromophenyl)furan-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a4) as an orange-yellow solid (Yield: 54%). 1H 
NMR (300 MHz, DMSO-d6): δ = 8.83 (d, J = 8.16 Hz, 1H), 8.45 (d, J = 3.51 Hz, 
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1H), 7.46-7.06 (m, 11H), 6.89 (t, J = 7.59 Hz, 2H), 4.34-4.22 (m, 2H). 13C NMR (75 
MHz, DMSO-d6): δ = 170.3, 163.4, 161.5, 161.0, 144.7, 137.6, 134.9, 132.2, 132.1, 
130.0, 128.9, 128.8, 128.4, 127.1, 76.0, 33.5. HRMS-ESI m/z [M + H] calcd for 
C27H20BrN4O2S: 543.0485, found: 543.0493 and HRMS (ESI, C27H1981BrN4O2S + H) 
calcd: 545.0464, found: 545.0469. 
3-(Benzylthio)-6-(5-(4-nitrophenyl)furan-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a5) as an orange-yellow solid (Yield: 52%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.93 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 3.15 Hz, 1H), 
8.36 (d, J = 8.8 Hz, 2H), 8.24-8.13 (m, 2H), 7.49 (t, J = 7.55 Hz, 1H), 7.37 (d, J = 
7.55 Hz, 2H), 7.28-7.21 (m, 3H), 7.11 (d, J = 8.2 Hz, 2H), 6.93 (t, J = 7.55 Hz, 1H), 
4.33-4.23 (m, 2H). HRMS-ESI m/z [M +Na] calcd for C27H19N5O4SNa: 532.5010, 
found: 532.1065. 
3-(Benzylthio)-6-ethyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate 
(2-1a6). The crude product was purified using flash chromatography (EtOAc/hexane 
=1:4) to afford as an orange-yellow solid (Yield: 62%). 1H NMR (300 MHz, DMSO-
d6): δ = 8.87-8.84 (d, J = 7.23 Hz, 1H), 7.84 (d, J = 3.3 Hz, 1H), 7.40-7.33 (m, 3H), 
7.26-7.21 (m, 3H), 6.96-6.85 (m, 2H), 5.54-5.48 (m, 2H), 1.85-1.71 (m, 2H), 0.86 (t, J 
= 7.39 Hz, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 170.4, 161.2, 144.2, 137.9, 
134.7, 134.1, 130.1, 129.1, 128.5, 127.3, 118.8, 115.7, 112.4, 77.3, 33.6, 23.8, 9.7. 
HRMS-ESI m/z [M + H] calcd for C19H19N4OS: 351.1274, found: 351.1279. 
3-(Benzylthio)-6-(thiophen-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a7) as an orange-yellow solid (Yield: 66%). 1H NMR (500 MHz, 
DMSO-d6): δ  =  8.88 (d, J = 7.6  Hz 1H), 8.52 (d, J = 3.2  Hz, 1H), 7.52-7.43 (m, 
4H), 7.32-7.23 (m, 3H), 7.15 (d, J = 3.75 Hz, 1H), 7.09-7.08 (m, 2H), 6.96-6.94 (m, 
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2H), 4.38-4.30 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.5, 160.8, 144.2, 
138.5, 137.6, 134.9, 133.7, 129.9, 128.9, 128.4, 127.9, 127.8, 127.1, 126.8, 119.4, 
115.8, 111.9, 73.7, 33.5. HRMS-ESI m/z [M + H] calcd for C21H17N4OS2: 405.0838, 
found: 405.0844.  
3-(Benzylthio)-6-(5-methylfuran-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a8) as an orange-yellow solid (Yield: 60%). 1H 
NMR (300 MHz, DMSO-d6): δ = 8.91-8.88 (d, J = 8.19 Hz, 1H), 8.37 (s, 1H), 7.49-
7.24 (m, 6H), 7.04-6.84 (m, 3H), 6.26 (d, J= 2.94 Hz, 1H), 6.02 (s, 1H), 4.35-4.23 (m, 
2H), 2.15 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ = 170.2, 160.9, 153.4, 146.4, 
144.7, 137.7, 134.7, 134.2, 129.9, 128.9, 128.4, 127.1, 119.1, 115.2, 112.0, 111.7, 
106.8, 71.6, 33.4, 13.2. HRMS-ESI m/z [M + H] calcd for C22H19N4O2Sd: 403.1223, 
found: 403.1234. 
3-(Benzylthio)-6-phenyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-
olate (2-1a9) as an orange-yellow solid (Yield: 68%). 1H NMR (500 MHz, DMSO-
d6): δ = 8.83-8.82 (d, J = 6.9 Hz, 1H), 8.5-8.4 (d, J = 3.8 Hz, 1H), 7.42-7.24 (m, 
10H), 7.08-7.7.06 (d, J = 8.15 Hz, 1H), 6.90-6.86 (m, 2H), 4.34-4.24 (m, 2H). 13C 
NMR (125 MHz, DMSO-d6): δ = 170.3, 161.0, 144.8, 137.6, 135.9, 134.8, 134.4, 
129.9, 129.2, 128.9, 128.6, 128.3, 127.1, 126.3, 119.0, 115.4, 112.0, 76.4, 33.5. 
HRMS-ESI m/z [M +H] calcd for C23H19N4OS: 399.1274, found: 399.1274. 
3-(Benzylthio)-6-(quinolin-3-yl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a10) as an orange-yellow solid (Yield: 55%).  1H NMR (300 MHz, 
DMSO-d6): δ = 8.99 (s, 1H), 8.88-8.86 (d, J = 8.22 Hz, 1H), 8.53-8.52(d, J = 2.64 
Hz, 1H), 8.27 (s, 1H), 8.03-7.96 (m, 2H), 7.79 (t, J = 7.08 Hz, 1H), 7.64-7.61 (m, 
1H), 7.44 (t, J = 1.29 Hz, 1H), 7.28-7.07 (m, 7H), 6.92 (t, J = 8.07 Hz, 1H), 4.29-4.16 
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(m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.3, 161.0, 149.1, 147.5, 144.6, 
137.5, 135.0, 134.7, 134.4, 130.5, 130.2, 128.8, 128.6, 128.4, 128.2, 127.3, 127.0, 
126.6, 119.4, 115.6, 112.5, 75.4, 33.4. HRMS-ESI m/z [M + H] calcd for 
C26H20N5OS: 450.1383, found: 450.1369. 
3-(Benzylthio)-6-(pyridin-3-yl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a11). as an orange-yellow solid (Yield: 68%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.87-8.84 (d, J = 8.04 Hz, 1H), 8.57-8.46(m, 3H), 7.70 (d, J = 7.89 
Hz, 1H), 7.49-6.90 (m, 10H), 4.32-4.20 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 
= 170.9, 161.5, 150.9, 148.3, 145.0, 138.0, 135.5, 135.3, 135.2, 130.6, 129.5, 129.4, 
129.0, 128.9, 127.6, 120.0, 116.1, 112.7, 75.6, 34.0. HRMS-ESI m/z [M + H] calcd for 
C22H18N5OS: 400.1227, found: 400.1217. 
3-(Benzylthio)-6-(pyridin-2-yl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a12). as an orange-yellow solid (Yield: 87%).. 1H NMR (500 MHz, 
DMSO-d6): δ = 8.85 (d, J = 8.2,  Hz, 1H), 8.53 (d, J = 3.8 Hz, 1H), 8.42 (d, J = 4.4 
Hz, 1H), 7.85-7.81 (m, 1H), 7.52 (d, J = 7.6  Hz, 1H), 7.39-7.33 (m, 4H), 7.27-7.21 
(m, 3H), 6.96 (t, J = 10.1 Hz, 2H), 6.96 (t, J = 7.55 Hz, 1H), 4.35-4.24 (m, 2H). 13C 
NMR (125 MHz, DMSO-d6): δ = 170.1, 161.2, 154.6, 148.9, 144.0, 137.7, 137.4, 
135.3, 134.5, 129.8, 128.9, 128.3, 127.1, 124.4, 119.0, 115.5, 112.6, 76.8, 33.4. 
HRMS-ESI m/z [M + H] calcd for C22H18N5OS: 400.1227, found: 400.1214. 
3-(Benzylthio)-6-o-tolyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-
olate (2-1a13). as an orange-yellow solid (Yield: 77%). 1H NMR (500 MHz, DMSO-
d6): δ  = 8.93 (d, J = 8.2  Hz, 1H), 8.13 (s, 1H), 7.43-7.16 (m, 11H), 6.97-6.85 (m, 
3H), 4.10-4.02 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ =169.8, 161.1, 145.5, 
137.7, 137.1, 135.8, 134.5, 133.1, 131.1, 130.1, 129.6, 128.8, 128.3, 127.4, 127.0, 
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126.1, 118.9, 115.2, 112.4, 75.5, 33.3, 19.3. HRMS-ESI m/z [M + H] calcd for 
C24H21N4OS: 413.1431, found: 413.1435. 
3-(Benzylthio)-6-(2-chlorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a14) as an orange-yellow solid (Yield: 74%). 1H NMR (500 MHz, 
DMSO-d6): δ = 8.94 (d, J = 7.6 Hz, 1H), 8.23 (d, J = 1.9 Hz, 1H), 7.59 (d, J = 8.2 
Hz, 1H), 7.49-7.36 (m, 4H), 7.22-7.20 (m, 5H), 6.98-6.92 (m, 3H), 4.13-4.04 (m, 2H). 
13C NMR (75 MHz, DMSO-d6): δ = 170.0, 160.9, 144.9, 137.6, 136.1, 134.7, 132.6, 
132.5, 131.5, 130.2, 130.1, 129.3, 128.8, 128.3, 127.7, 127.0, 119.1, 115.2, 112.1, 
75.1, 33.3. HRMS-ESI m/z [M + H] calcd for C23H18ClN4OS: 433.0884, found: 
433.0872. 
3-(Benzylthio)-6-(2-(methylthio)phenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a15) as an orange-yellow solid (Yield: 71%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.95 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 1.85 Hz, 1H), 
7.53 (d, J = 7.55 Hz, 1H), 7.47-7.41 (m, 2H), 7.37 (d, J = 7.55 Hz, 1H), 7.26-7.17 (m, 
6H), 6.96-6.91 (m, 3H), 4.12-4.04 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 
169.9, 160.9, 145.0, 138.2, 137.7, 135.9, 134.6, 133.3, 130.4, 130.2, 128.8, 128.1, 
127.0125.7, 119.1, 115.3, 112.2, 75.7, 33.3, 16.6. HRMS-ESI m/z [M + H] calcd for 
C24H21N4OS2: 445.1151 found: 445.1151.  
3-(Benzylthio)-6-(3-phenoxyphenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-
5-ium-1-olate (2-1a16) as an orange-yellow solid (Yield: 79%). 1H NMR (500 MHz, 
DMSO-d6): δ = 8.83 (d, J = 8.2  Hz, 1H), 8.46 (d, J = 3.15  Hz, 1H), 7.47-6.89 (m, 
18H), 4.33-4.25 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.3, 160.9, 156.9, 
155.7, 144.7, 138.0, 137.6, 134.9, 134.4, 130.5, 130.1, 129.9, 128.9, 128.4, 127.1, 
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123.8, 121.0, 119.1, 118.9, 118.8, 116.2, 115.4, 112.1, 76.0, 33.5. HRMS-ESI m/z [M 
+ H] calcd for C29H23N4O2S: 491.1536, found: 491.1532. 
3-(Benzylthio)-6-(3-carboxyphenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-
5-ium-1-olate (2-1a17) as an orange-yellow solid (Yield: 73%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.83 (d, J = 7.59 Hz, 1H), 8.54 (s, 1H), 7.97-7.90 (m, 2H), 7.49-7.24 
(m, 8H), 7.02-6.89 (m, 3H), 4.33-4.21 (m, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 
170.3, 166.6, 160.9, 144.7, 137.5, 136.4, 134.9, 134.5, 131.2, 130.8, 130.1, 130.0, 
129.1, 128.8, 128.3, 127.4, 127.0, 119.1, 115.5, 112.1, 76.1, 33.4. HRMS-ESI m/z [M 
+ H] calcd for C24H19N4O3S: 443.1172, found: 443.1168. 
3-(Benzylthio)-6-(3-chlorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a18) as an orange-yellow solid (Yield: 69%).  1H NMR (500 MHz, 
DMSO-d6): δ = 8.81 (d, J = 7.96 Hz, 1H), 8.48 (d, J = 3.51 Hz, 1H), 7.49-7.21 (m, 
10H), 7.14 (d, J = 8.16 Hz, 1H), 6.93-6.81 (m, 2H), 4.34-2.21 (m, 2H). 13C NMR (75 
MHz, DMSO-d6): δ = 170.3, 160.9, 144.5, 138.3, 137.6, 134.8, 134.6, 133.3, 130.6, 
130.0, 129.3, 128.8, 128.3, 127.0, 126.4, 125.2, 119.2, 115.5, 112.1, 75.8, 33.4. 
HRMS-ESI m/z [M + H] calcd for C23H18ClN4OS: 433.0884, found: 433.0879. 
3-(Benzylthio)-6-(3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a19) as an orange-yellow solid (Yield: 63%). 1H NMR (500 MHz, 
DMSO-d6): δ = 8.84 (d, J = 8.2 Hz, 1H), 8.58 (d, J = 3.15 Hz, 1H), 8.22 (t, J = 13.85 
Hz, 2H), 7.73-7.63 (m, 2H), 7.49 (t, J = 7.55 Hz, 1H), 7.37 (d, J = 7.55 Hz, 2H), 
7.28-7.21 (m, 3H), 7.11 (d, J = 8.2 Hz, 2H), 6.93 (t, J = 7.55 Hz, 1H), 4.33-4.23 (m, 
2H).13C NMR (125 MHz, DMSO-d6): δ = 169.5, 159.9, 146.8, 143.4, 137.0, 136.5, 
134.0, 133.7, 132.1, 129.4, 129.1, 127.8, 127.3, 126.1, 123.2, 120.7, 118.5, 114.6, 
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111.2, 74.6, 32.5. HRMS-ESI m/z [M + H] calcd for C23H18N5O3S: 444.1125, found: 
444.1127. 
3-(Benzylthio)-6-(4-fluorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a20) as an orange-yellow solid (Yield: 79%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.92 (d, J = 8.16 Hz, 1H), 8.44 (d, J = 2.34 Hz, 1H), 7.57-7.21 (m, 
9H), 7.07-6.95 (m, 3H), 6.61(d, J= 3.51 Hz, 1H), 4.35-4.23 (m, 2H). 13C NMR (75 
MHz, DMSO-d6): δ = 170.3, 163.4, 161.5, 161.0, 144.7, 137.6, 134.9, 134.4, 132.1, 
132.1, 130.0, 128.9, 128.9, 128.8, 128.4, 127.1, 119.2, 115.7, 115.5, 112.1, 76.0, 33.5. 
HRMS-ESI m/z [M + H] calcd for C23H18FN4OS: 417.1180, found: 417.1168. 
3-(Benzylthio)-6-(4-chlorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a21) as an orange-yellow solid (Yield: 76%). 1H NMR (500 MHz, 
Acetone-d6): δ = 9.05-9.01 (dd, J = 5.8 Hz and 1.47 Hz, 1H), 7.60-7.16 (m, 10H), 
7.01-6.98 (m, 1H), 6.96-6.37 (m, 1H), 6.31 (d, J = 13.8 Hz, 1H), 4.42-4.28 (m, 2H). 
13C NMR (125 MHz, DMSO-d6): δ = 170.3, 160.9, 144.5, 137.5, 134.9, 134.8, 134.0, 
130.0, 128.8, 128.6, 128.4, 128.3, 127.0, 119.2, 115.5, 112.1. HRMS-ESI m/z [M + 
H] calcd for C23H18ClN4OS: 433.0884, found: 433.0886. 
3-(Benzylthio)-6-(4-bromophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a22) as an orange-yellow solid (Yield: 86%).  1H NMR (500 MHz, 
DMSO-d6): δ = 8.83-8.82 (m, 1H), 8.48 (d, J = 3.8 Hz, 1H),  7.55-7.53 (m, 2H), 7.47-
7.44 (m, 1H), 7.37 (d, J = 6.95 Hz, 2H), 7.30-7.23 (m, 5H), 7.06 (d, J = 8.15 Hz, 1H), 
6.90-6.88 (m, 2H), 4.34-4.24 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.3, 
160.9, 144.5, 137.6, 135.3, 134.9, 134.4, 131.6, 130.0, 128.9, 128.7, 128.4, 127.1, 
122.7, 119.2, 115.5, 112.1, 75.9, 33.5. HRMS-ESI m/z [M + H] calcd for 
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C23H18BrN4OS 477.0379, found: 477.0379 and HRMS-ESI m/z [M + H] calcd for 
C23H1881BrN4OS: 479.0359 found: 479.0366. 
3-(Benzylthio)-6-(4-(methylthio)phenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a23) as an orange-yellow solid (Yield: 71%).  1H 
NMR (300 MHz, DMSO-d6): δ = 8.84-8.81 (d, J = 8.16 Hz, 1H), 8.45 (d, J = 3.51 
Hz, 1H), 7.46-7.21 (m, 11H), 7.06 (d, J = 8.19 Hz, 1H), 6.89-6.85 (m, 2H), 4.37-4.24 
(m, 2H), 2.42 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 169.2, 159.9, 143.7, 
138.9, 136.6, 133.8, 133.3, 131.2, 128.9, 127.86, 127.3, 126.0, 125.8, 124.6, 118.0, 
114.4, 111.0, 75.2, 32.4, 13.2. HRMS-ESI m/z [M + H] calcd for C24H21N4OS2: 
445.1151, found: 445.1132. 
3-(Benzylthio)-6-(4-methoxyphenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-
5-ium-1-olate (2-1a24) as an orange-yellow solid (Yield: 51%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.84-8.82 (d, J = 7.89 Hz, 1H), 8.5 (d, J = 3.51 Hz, 1H), 7.48-7.22 
(m, 7H), 7.07 (d, J = 8.19 Hz, 1H), 6.92-6.80 (m, 5H), 4.37-4.24 (m, 2H), 3.66 (s, 
3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.2, 160.9, 159.2, 144.8, 137.6, 137.5, 
134.8, 134.4, 129.9, 129.9, 128.8, 128.3, 115.4, 114.1, 112.5, 112.0, 76.3, 55.0, 33.4. 
HRMS-ESI m/z [M + H] calcd for C24H21N4O2S: 429.1380, found: 429.1382. 
3-(Benzylthio)-6-(4-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a25) as an orange-yellow solid (Yield: 85%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.81 (d, J = 7.89 Hz, 1H), 8.6 (d, J = 3.51 Hz, 1H), 8.17 (d, J = 8.76 
Hz), 7.57-7.23 (m, 8H), 7.11-7.07 (m, 2H), 6.90 (t, J = 7.29 Hz, 1H), 4.37-4.24 (m, 
2H). 13C NMR (75 MHz, DMSO-d6): δ =170.5, 160.8, 147.9, 144.2, 142.9, 137.5, 
134.9, 134.6, 130.0, 128.8, 128.3, 127.9, 127.1, 123.7, 119.4, 115.7, 112.2, 75.6, 33.5.  
HRMS-ESI m/z [M + H] calcd for C23H18N5O3S: 444.1125, found: 444.1119. 
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3-(Benzylthio)-6-(4-hydroxy-3-methylphenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a26) as an orange-yellow solid (Yield: 72%). 1H 
NMR (500 MHz, DMSO-d6): δ  =  9.61 (s, 1H), 8.86 (d, J = 8.15  Hz, 1H), 8.34 (d, J 
= 2.5  Hz, 1H), 7.46-7.24 (m, 6H), 7.04 (d, J = 7.6  Hz, 2H), 6.93-6.87 (m, 2H), 6.72-
6.68 (m, 2H), 4.33-4.22 (m, 2H), 2.03 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 
170.1, 161.1, 156.4, 137.7, 134.7, 134.2, 129.9, 128.9128.8, 128.3, 127.0, 125.9, 
125.2, 124.1, 118.8, 115.2, 114.4, 111.9, 76.8, 33.4, 16.0. HRMS-ESI m/z [M + H] 
calcd for C24H21N4O2S: 429.1380, found: 429.1394. 
3-(Benzylthio)-6-(2-chloro-4-hydroxyphenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a27) as an orange-yellow solid (Yield: 70%). 1H 
NMR (500 MHz, DMSO-d6): δ = 10.30 (s, 1H), 8.92 (d, J = 7.55 Hz, 1H), 8.16 (s, 
1H), 7.44-7.21 (m, 7H), 6.95-6.77 (m, 5H), 4.14-4.06 (m, 2H). HRMS-ESI m/z [M + 
Na] calcd for C23H17ClN4O2SNa: 471.0653 found: 471.0639. 
3-(Benzylthio)-6-(3,4-dichlorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a28) as an orange-yellow solid (Yield: 68%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.83 (d, J = 6.95  Hz, 1H), 8.44 (d, J = 3.15 Hz, 
1H), 7.61-7.6 (m, 2H), 7.49-7.45 (m, 1H), 7.36-7.23 (m, 6H), 7.06 (d, J = 8.15 Hz, 
1H), 6.93-6.90 (m, 2H), 4.32-4.21 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 
170.3, 160.9, 137.6, 136.8, 134.9, 134.7, 132.1, 131.4, 130.9, 130.1, 128.8, 128.4, 
127.1, 127.0, 119.4, 115.5, 112.2, 75.4, 33.5. HRMS-ESI m/z [M + H] calcd for 
C23H17Cl2N4OS: 467.0495, found: 467.0484. 
3-(Benzylthio)-6-(4-hydroxy-3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a29) as an orange-yellow solid (Yield: 57%). 1H 
NMR (300 MHz, DMSO-d6): δ = 11.33 (s, 1H), 8.84 (d, J = 8.19 Hz, 1H), 8.40 (d, J 
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= 2.91 Hz, 1H), 7.90 (d, J = 2.04 Hz, 1H), 7.50-7.22 (m, 7H), 7.11-7.05 (m, 2H), 
6.94-6.85 (m, 2H), 4.32-4.19 (m, 2H). 13C NMR (75 MHz, DMSO-d6): δ = 170.2, 
160.9, 152.8, 144.6, 137.6, 136.4, 134.8, 134.5, 133.3, 130.1, 128.8, 128.3, 127.0, 
126.6, 124.0, 119.5, 119.3, 115.4, 112.1, 75.6, 33.4. HRMS-ESI m/z [M + H] calcd for 
C23H18N5O4S: 460.1074, found: 460.1073. 
3-(Benzylthio)-6-(4-fluoro-3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a30) as an orange-yellow solid (Yield: 59%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.85 (d, J = 1.3 Hz, 1H), 8.83 (d, J = 1.3 Hz, 1H),  
8.50 (d, J = 3.15 Hz, 1H), 8.17-8.15 (m, 1H), 7.73-7.70 (m, 1H), 7.58-7.54 (m, 1H), 
7.507.46 (m,1H), 7.37-7.35 (m, 2H), 7.29-7,20 (m, 3H), 7.09-7.08 (d, J = 8.2  Hz, 
1H), 7.02 (d, J = 3.15 Hz, 1H) 4.31-4.22 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ  
= 170.4,160.9, 155.9, 153.8, 144.2, 137.5, 136.8, 136.6, 134.9, 134.8, 134.7, 134.6, 
133.3, 133.2, 128.8, 128.3, 127.0, 124.9, 119.5, 119.0, 118.9, 115.6, 112.2, 75.1, 33.5. 
HRMS-ESI m/z [M + H] calcd for C23H17FN5O3S: 462.1031, found: 462.1029. 
3-(Benzylthio)-6-(4-bromo-3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a31) as an orange-yellow solid (Yield: 67%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.84 (d, J = 8.2 Hz, 1H), 8.49 (d, J = 8.2 Hz, 1H),  
8.03 (d, J = 1.9 Hz, 1H), 7.9 (d, J = 8.2 Hz, 1H), 7.54-7.47 (m, 2H), 7.36 (d, J = 7.55 
Hz, 2H), 7.30-7.24 (m, 3H), 7.06 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 3.15 Hz, 1H), 6.94 
(t, J = 8.15 Hz, 1H), 4.33-4.22 (m, 2H).13C NMR (125 MHz, DMSO-d6): δ = 170.4, 
160.9, 149.5, 144.1, 137.5, 137.4, 135.0, 134.8, 131.9, 130.2, 128.8, 128.3, 127.0, 
124.0, 119.5, 115.7, 114.1, 112.3, 75.3, 33.5. HRMS-ESI m/z [M + H] calcd for 
C23H1779BrN5O3S: 522.0230, found: 522.0221 and HRMS-ESI m/z [M + H] calcd for 
C23H1781BrN5O3S: 524.0210 found: 524.0208. 
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3-(Benzylthio)-6-(3,5-dibromophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a32) as an orange-yellow solid (Yield: 65%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.84 (d, J = 8.15,  Hz, 1H), 8.42 (d, J = 3.15 Hz, 
1H),7.86 (s, 1H), 7.56 (s, 2H), 7.47 (m, 1H), 7.35-7.23 (m, 5H), 7.06 (d, J = 8.2 Hz, 
1H), 6.93 (m, 2H), 4.31-4.19 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 170.2, 
160.9, 144.4, 140.2, 137.7, 135.0, 134.9, 130.2, 128.9, 128.8, 128.3, 127.1, 122.6, 
119.5, 115.4, 112.2, 75.2, 33.4. HRMS-ESI m/z [M - H] calcd for C23H15Br2N4OS: 
552.9339, found: 552.9341, HRMS-ESI m/z [M - H] calcd for C23H15Br81BrN4OS: 
554.9318, found: 554.9318, HRMS-ESI m/z [M - H] calcd for C23H1581Br2N4OS: 
556.9298, found: 556.9390. 
3-(Benzylthio)-6-(4-bromophenyl)-10-fluoro-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a33) as an orange-yellow solid (Yield: 84%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.62 (d, J = 8.85 Hz, 1H), 8.38 (s, 1H), 7.55-7.11 
(m, 11H), 6.91 (s, 1H), 4.33-4.24 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 
171.0, 160.9, 155.9, 154.0, 141.1, 137.5, 134.9, 133.4, 131.6, 128.8, 128.7, 128.3, 
127.0, 122.7, 122.5, 122.3, 117.4, 117.3, 114.9, 114.7, 112.7, 112.6, 76.4, 33.5. 
HRMS-ESI m/z [M - H] calcd for C23H15BrFN4OS: 493.0139 found: 493.0150 and 
HRMS-ESI m/z [M - H] calcd for C23H1581BrFN4OS: 495.0119 found: 495.0136. 
3-(Benzylthio)-6-(4-chlorophenyl)-10-fluoro-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a34) as an orange-yellow solid (Yield: 62%). 1H 
NMR (500 MHz, DMSO-d6): δ  = 8.63-8.60 (m, 1H), 8.38 (d, J = 3.8 Hz, 1H), 7.44-
7.22 (m, 10H), 7.11-7.09 (dd, J = 5.05 and 3.8 Hz, 1H) 6.93 (d, J = 3.8 Hz, 1H), 
4.33-4.23 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 171.0, 160.9, 155.9, 154.0, 
141.1, 137.4, 134.5, 134.1, 133.3, 128.8, 128.6, 128.5, 128.3, 127.0, 122.5, 122.3, 
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117.4, 117.3, 114.9, 114.6, 112.7, 112.6, 76.4, 33.5. HRMS-ESI m/z [M +Na] calcd 
for C23H16ClFN4OSNa: 473.0610, found: 473.0614. 
3-(Benzylthio)-10-fluoro-6-(4-(methylthio)phenyl)-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a35) as an orange-yellow solid 
(Yield: 66%). 1H NMR (500 MHz, DMSO-d6): δ = 8.61 (d, J = 8.85 Hz, 1H), 8.36 (s, 
1H),  7.39-7.21 (m, 10H), 7.10 (m, 1H) 6.86 (d, J = 2.55 Hz, 1H), 4.34-4.25 (m, 2H), 
2.41 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.9, 160.9, 155.8, 153.9, 141.3, 
140.0, 137.5, 133.2, 131.9, 128.9, 128.4, 127.1, 127.0, 125.6, 122.5, 122.3, 117.3, 
117.2, 114.8, 114.6, 112.5, 76.7, 33.5, 14.2. HRMS-ESI m/z [M +Na] calcd for 
C24H19FN4OS2Na: 485.0877, found: 485.0881. 
3-(Benzylthio)-10-fluoro-6-(3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a36) as an orange-yellow solid (Yield: 78%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.62 (d, J = 10.1 Hz, 1H), 8.48 (s, 1H),  8.25-8.20 
(m, 2H), 7.74-7.62 (m, 2H) 7.40-7.10 (m, 8H), 4.31-4.21 (m, 2H). 13C NMR (125 
MHz, DMSO-d6): δ 171.0, 160.9, 156.0, 155.9, 154.1, 147.8, 140.9, 137.6, 137.4, 
133.7, 133.2, 130.3, 128.8, 128.3, 124.2, 122.6, 122.4, 121.8, 117.5, 117.4, 115.0, 
114.8, 112.8, 112.7, 76.0, 33.5. HRMS-ESI m/z [M - H] calcd for C23H15FN5O3S: 
460.0885, found: 460.0888. 
3-(Benzylthio)-10-chloro-6-phenyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a37) as an orange-yellow solid (Yield: 73%). 1H NMR (500 MHz, 
DMSO-d6): δ = 8.88 (d, J = 2.55 Hz, 1H), 8.63 (d, J = 3.15 Hz, 1H), 7.49-7.23 (m, 
11H), 7.1 (d, J = 3.8 Hz, 1H), 6.94 (d, J = 3.15 Hz, 1H), 4.34-4.24 (m, 2H). 13C NMR 
(125 MHz, DMSO-d6): δ = 170.9, 160.9, 143.5, 137.5, 135.6, 134.2, 133.2, 129.4, 
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128.8, 128.7, 128.3, 127.1, 126.4, 122.5, 117.2, 112.9, 76.7, 33.5. HRMS-ESI m/z [M 
- H] calcd for C23H16ClN4OS: 431.0739, found: 431.0750. 
3-(Benzylthio)-10-chloro-6-(4-chlorophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a38) as an orange-yellow solid (Yield: 57%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.87 (d, J = 2.55 Hz, 1H), 8.61 (d, J = 3.15 Hz, 
1H), 7.50 (d, J = 2.55 Hz, 1H), 7.48 (d, J = 3.5 Hz, 2H), 7.43-7.24 (m, 7H), 7.08 (d, J 
= 8.5 Hz, 1H), 6.95 (d, J = 3.15 Hz, 1H), 4.33-4.23 (m, 2H). 13C NMR (125 MHz, 
DMSO-d6): δ = 170.9, 160.9, 143.3, 137.5, 134.6, 134.3, 134.2, 133.4, 131.1, 128.9, 
128.7, 128.5, 128.4, 127.1, 122.7, 117.2, 113.0, 76.1, 33.5. HRMS-ESI m/z [M - H] 
calcd for C23H15Cl2N4OS: 465.0349 found: 465.0361. 
3-(Benzylthio)-10-chloro-6-(4-(methylthio)phenyl)-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a39) as an orange-yellow solid 
(Yield: 74%). 1H NMR (500 MHz, DMSO-d6): δ = 8.86 (d, J = 3.25 Hz, 1H), 8.5-8.4 
(d, J = 4.35 Hz, 1H), 7.51 (d, J = 3.55 Hz, 1H), 7.47 (d, J = 3.55 Hz, 2H), 7.39-7.24 
(m, 7H), 7.07 (d, J = 14.5 Hz, 1H),  6.88 (d, J = 3.2 Hz, 1H) , 4.35-4.23 (m, 2H) 2.41 
(s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.9, 160.9, 143.5, 140.2, 137.5, 
143.3, 133.2, 131.9, 128.9, 128.5, 128.3, 127.1, 126.9, 125.5, 122.5, 117.1, 112.9, 
76.5, 33.5, 14.2. HRMS-ESI m/z [M + H] calcd for C24H20ClN4OS2: 479.0762, found: 
479.0742. 
3-(Benzylthio)-6-(4-chlorophenyl)-10-methyl-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a40) as an orange-yellow solid (Yield: 79%). 1H 
NMR (300 MHz, DMSO-d6): δ = 8.64 (s, 1H), 8.29 (d, J = 3.8 Hz, 1H), 7.40-7.38 (m, 
4H), 7.30-7.24 (m, 6H), 6.99 (d, J = 8.2 Hz, 1H), 6.87 (d, J = 3.8 Hz, 1H), 4.34-4.24 
(m, 2H), 2.22 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ  = 169.3, 159.9, 141.3, 
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136.6, 135.0, 133.9, 133.3, 132.9, 128.5, 127.9, 127.6, 127.0, 126.0, 114.7, 111.4, 
75.0, 32.5, 19.4. HRMS-ESI m/z [M + H] calcd for C24H20ClN4OS: 447.1041, found: 
447.1042. 
3-(Benzylthio)-10-methyl-6-(4-(methylthio)phenyl)-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a41) as an orange-yellow solid 
(Yield: 72%). 1H NMR (300 MHz, DMSO-d6): δ = 8.63 (s, 1H), 8.27 (s, 1H), 8.39 (d, 
J = 7.6 Hz, 1H), 7.29 (d, J = 5.7 Hz, 2H), 7.26-7.19 (m, 8H), 6.98 (d, J = 8.2 Hz, 
1H), 6.80 (d, J = 3.15 Hz, 1H), 4.35-4.25 (m, 2H), 2.24 (s, 3H),  2.22 (s, 3H). 13C 
NMR (125 MHz, DMSO-d6): δ = 170.7, 161.5, 143.1, 140.3, 138.1, 136.5, 134.6, 
132.8, 129.9, 129.4, 128.8, 128.4, 127.6, 127.3, 126.1, 116.1, 112.8, 76.9, 34.0, 20.9, 
14.7. HRMS-ESI m/z [M + H] calcd for C25H23N4OS2: 459.1308, found: 459.1306. 
3-(Benzylthio)-6-(5-(4-chlorophenyl)furan-2-yl)-10-methyl-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a42) as an orange-yellow solid 
(Yield: 64%). 1H NMR (300 MHz, DMSO-d6): δ = 8.74 (s, 1H), 8.28 (s, 1H), 7.46-
7.27 (m, 9H), 6.96 (m, 3H), 6.59 (s, 1H), 4.30 (s, 2H), 2.31 (s, 3H). HRMS-ESI m/z 
[M + H] calcd for C28H22ClN4O2S: 513.1147 found: 513.1124. 
3-(Benzylthio)-10-methyl-6-phenyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-
5-ium-1-olate (2-1a43) as an orange-yellow solid (Yield: 58%). 1H NMR (300 MHz, 
DMSO-d6): δ = 8.65 (s, 1H), 8.31 (d, J = 3.8 Hz, 1H), 7.40-7.24 (m, 11H), 6.99 (d, J 
= 8.85 Hz, 1H), 6.86 (d, J = 3.15 Hz, 1H), 4.36-4.25 (m, 2H), 2.22 (s, 3H). 13C NMR 
(125 MHz, DMSO-d6): δ = 169.2, 159.9, 141.6, 136.6, 134.9, 133.2, 128.4, 128.1, 
127.9127.6, 127.3, 126.8, 126.1, 125.3, 114.7, 111.3, 75.6, 32.5, 19.4. HRMS-ESI m/z 
[M - H] calcd for C24H21N4OS: 411.1285 found: 411.1286. 
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Crystal data of compound 2-1a43:  Chemical formula = C24H20N4OS, FW = 412.50, 
monoclinic, space group C2/c, a = 25.0003(14) A˚ , b = 7.7488(4) A˚ , c = 
24.1800(14) Å, V = 4078.0(4)A˚3, Z = 8, T = 223 (2) K, d(calcd) = 1.344 Mg.m-3, F 
(000) = 1728.The final R value was R1 = 0.0516 and wR2 = 0.1301 with I > 2s(I). 
 
3-(Benzylthio)-10-methyl-6-(5-(4-nitrophenyl)furan-2-yl)-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a44) as an orange-yellow solid 
(Yield: 69%). 1H NMR (500 MHz, DMSO-d6): δ = 8.74 (s, 1H), 8.34-8.11 (m, 3H), 
7.71 (d, J = 7.55 Hz, 2H), 7.40-7.22 (m, 8H), 6.99 (d, J = 8.2 Hz, 2H), 6.67 (s, 1H) 
4.34-4.25 (m, 2H), 2.29 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.4, 160.9, 
151.8, 159.0, 146.3, 142.5, 137.7, 135.9, 135.1, 134.6, 129.5, 128.9, 128.4, 127.1, 
124.4, 124.2, 115.7, 113.4, 112.6, 110.8, 71.7, 33.5, 20.5. HRMS-ESI m/z [M - H] 
calcd for C28H20N5O4S: 522.1241 found: 522.1243. 
3-(Benzylthio)-6-(4-bromophenyl)-10-methyl-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a45) as an orange-yellow solid (Yield: 90%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.63 (s, 1H), 8.34-8.11 (m, 3H), 7.71 (d, J= 7.55 
Hz, 2H), 7.40-7.22 (m, 8H), 6.99 (d, J= 8.2 Hz, 2H), 6.67 (s, 1H) 4.34-4.25 (m, 2H), 
2.29 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ =170.3, 160.9, 142.4, 137.6, 136.1, 
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135.4, 134.3, 131.6, 129.5, 128.9, 128.6, 128.4, 128.1, 127.1, 122.6, 115.7, 112.4, 
76.1, 33.5, 20.4. HRMS-ESI m/z [M - H] calcd for C24H18BrN4OS: 491.0536 found: 
491.0534. 
3-(Benzylthio)-10-methyl-6-(3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a46) as a orange-yellow solid (Yield: 61%). 1H 
NMR (300 MHz, DMSO-d6): δ = 8.65 (s, 1H), 8.39 (d, J = 3.2 Hz, 1H), 8.22-8.18 (m, 
2H), 7.70-7.61 (m, 2H), 7.38-7.21 (m, 6H), 7.05-7.02 (m, 2H), 4.33-4.23 (m, 2H), 
2.23 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ  = 170.3, 160.8, 147.8, 142.1, 138.0, 
137.5, 136.1, 134.5, 133.0, 130.3, 129.5, 128.8, 128.3,4, 128.3, 127.0, 124.1, 121.6, 
115.8, 112.4, 75.7, 33.5, 20.4. HRMS-ESI m/z [M + H] calcd for C24H20N5O3S: 
458.1281 found: 458.1274. 
3-(Benzylthio)-6-(4-bromo-3-nitrophenyl)-10-methyl-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a47) as an orange-yellow solid 
(Yield: 82%). 1H NMR (300 MHz, DMSO-d6): δ = 8.65 (s, 1H), 8.30 (d, J = 3.75 Hz, 
1H), 8.00 (d, J = 1.9 Hz, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.51-7.49 (m, 1H), 7.37-7.23 
(m, 6H), 7.00-6.96 (m, 2H), 4.32-4.21 (m, 2H), 2.23 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6): δ = 170.3, 160.9, 149.5, 141.9, 137.5, 137.4, 135.9, 134.9, 134.8, 131.8, 
129.9, 128.8, 128.4, 128.3, 127.1, 123.9, 115.9, 114.0, 112.6, 75.4, 33.5, 20.4. 
HRMS-ESI m/z [M + H] calcd for C24H19BrN5O3S: 536.0386 found: 536.0371 and 
HRMS (ESI, C24H18BrN5O3S + H) calcd: 538.0366 found: 538.0345. 
3-(Benzylthio)-6-(4-chlorophenyl)-10-ethyl-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a48). The crude product was purified using flash 
chromatography (EtOAc/hexane =1:4) to afford as an orange-yellow solid (Yield: 
80%):  1H NMR (500 MHz, DMSO-d6): δ = 8.69 (t, J = 19.6 Hz, 1H), 8.33-8.26 (m, 
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1H), 7.44-7.24 (m, 11H), 7.06-6.96 (m, 1H), 6.91-6.83 (m, 1H),  4.34-4.22 (m, 2H),  
2.22 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ   169.3, 159.9, 141.3, 136.6, 135.0, 
133.9, 133.3, 132.9, 128.5, 127.9, 127.6, 127.0, 126.0, 114.7, 111.4, 75.0, 32.5, 19.4. 
HRMS-ESI m/z [M + H] calcd for C25H22ClN4OS: 461.1197, found: 461.1207. 
3-(Benzylthio)-10-ethyl-6-(4-(methylthio)phenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a49). The crude product was purified using flash 
chromatography (EtOAc/hexane =1:4) to afford as an orange-yellow solid (Yield: 
75%):  1H NMR (500 MHz, DMSO-d6): δ = 8.80 (s, 1H), 8.38 (d, J= 3.15  Hz, 1H), 
7.59-7.29 (m, 11H), 7.10 (d, J = 3.2  Hz, 1H), 6.91 (d, J = 3.15  Hz, 1H), 4.45-4.35 
(m, 2H),  2.65-2.59 (q, J = 7.55  Hz, 2H), 1.24 (t, J = 7.6  Hz, 3H). 13C NMR (125 
MHz, DMSO-d6): δ = 170.1, 160.9, 142.7, 139.8, 137.6, 134.8, 134.2, 134.1, 132.3, 
128.8, 128.3, 126.9, 126.8, 125.6, 115.6, 112.2, 76.3, 33.5, 27.4, 14.2. HRMS-ESI m/z 
[M + H] calcd for C26H25N4OS2: 473.1464, found: 473.1476. 
3-(4-Methoxybenzylthio)-6-phenyl-6,7-dihydro-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-1a50) as an orange-yellow solid (Yield: 67%). 1H NMR (500 MHz, 
DMSO-d6): δ = 8.83 (d, J = 3.2 Hz, 1H), 8.48 (d, J = 3.15 Hz), 7.47-7.29 (m, 8H), 
7.07 (d, J= 3.2 Hz, 1H), 6.91-6.84 (m, 4H), 4.29-4.20 (m, 2H), 3.72 (s, 3H HRMS-
ESI m/z [M - H] calcd for C2419N4O2S: 427.1234 found: 427.1228. 
3-(4-Methoxybenzylthio)-6-(3-nitrophenyl)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a51) as an orange-yellow solid (Yield: 63%). 1H 
NMR (500 MHz, DMSO-d6): δ = 8.84 (d, J = 7.6 Hz, 1H), 8.58 (s, 1H) 8.24-8.21 (m, 
2H), 7.73-7.65 (m, 2H), 7.49 (d, J = 6.35 Hz, 1H), 7.28 (d, J= 6.35 Hz, 2H), 7.10 (d, 
J= 3.8 Hz, 2H), 6.94-6.81 (m, 3H), 4.27-4.17 (m, 2H), 3.71 (s, 3H). 13C NMR (125 
MHz, DMSO-d6): δ = 171.1, 161.4, 158.9, 148.3, 144.9, 138.5, 135.5, 135.1, 130.9, 
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130.6, 130.5, 129.7, 124.7, 122.2, 119.9, 116.1, 114.2, 112.7, 76.1, 55.5, 33.6. 
HRMS-ESI m/z [M - H] calcd for C24H20N5O4S: 472.1085 found: 472.1086. 
6-(4-Chlorophenyl)-3-(4-methoxybenzylthio)-6,7-dihydro-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-1a52) as an orange-yellow solid (Yield: 76%).1H 
NMR (500 MHz, DMSO-d6): δ = 8.84 (d, J = 8.2 Hz, 1H), 8.47 (d, J = 3.75 Hz, 1H), 
7.47-7.29 (m, 7H), 7.07 (d, J = 8.2 Hz, 2H), 6.92-6.83 (m, 4H), 4.29-4.19 (m, 2H), 
3.72 (s, 3H). 13C NMR (125 MHz, DMSO-d6):  δ = 171.0, 161.4, 158.9, 145.0, 135.4, 
135.4, 134.9, 134.5, 130.6, 130.5, 129.7, 129.2, 128.9, 119.7, 116.0, 114.3, 112.6, 
76.4, 55.5, 33.6. HRMS-ESI m/z [M - H] calcd for C24H18ClN4O2S: 461.0844, found: 
461.0865. 
3-(4-Methoxybenzylthio)-6-(4-(methylthio)phenyl)-6,7-dihydro-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-1-olate (2-1a53) as an orange-yellow solid 
(Yield: 71%). 1H NMR (500 MHz, DMSO-d6): δ = 8.83 (d, J = 3.2 Hz, 1H), 8.45 (s, 
1H) 7.46 (t, J = 7.55 Hz, 1H), 7.31 (d, J= 8.15 Hz, 2H), 7.21 (d, J= 6.35 Hz, 4H), 
7.06 (d, J= 3.2 Hz, 1H), 6.90-6.83 (m, 4H), 4.30-4.20 (m, 2H),  3.72 (s, 3H), 2.41 (s, 
3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.9, 161.5, 158.9, 145.2, 140.5, 135.3, 
134.8, 132.8, 132.8, 130.6, 130.5, 129.8, 127.4, 126.1, 119.6, 115.9, 114.3, 112.6, 
76.7, 55.5, 33.6, 14.7. HRMS-ESI m/z [M - H] calcd for C25H21N4O2S2: 473.1111, 
found: 473.1117. 
3-(4-Bromobenzylthio)-6-(4-chlorophenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a54) as an orange-yellow solid 
(Yield: 88%). 1H NMR (500 MHz, DMSO-d6): δ = 8.83 (s, 1H), 8.50 (s, 1H), 7.74 – 
6.69 (m, 12H), 4.25 (m, 2H).  13C NMR (125 MHz, DMSO-d6): δ = 170.07, 160.93, 
144.62, 137.45, 134.95, 134.86, 134.55, 134.07, 131.17, 131.06, 130.07, 128.67, 
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128.40, 120.17, 119.22, 115.54, 112.09, 75.88, 32.77. HRMS-ESI m/z [M - H] calcd 
for C23H15BrClN4OS - H) calcd: 508.9844, found: 508.9830, HRMS-ESI m/z [M - H] 
calcd for C23H15 81BrClN4OS: 510.9823, found: 510.9809. 
3-(4-Bromobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a55) as an orange-yellow solid 
(Yield: 81%). 1H NMR (500 MHz, DMSO-d6): δ = 8.83 (s, 1H), 8.47 (s, 1H), 7.26 
(dd, J = 136.3, 49.0 Hz, 10H), 6.86 (d, J = 16.5 Hz, 2H), 4.26 (m, 2H), 2.40 (s, 3H). 
13C NMR (125 MHz, DMSO-d6): δ = 169.99, 160.97, 144.81, 140.02, 137.51, 134.91, 
134.41, 132.20, 131.18, 131.05, 130.03, 126.90, 125.56, 120.16, 119.06, 115.46, 
112.02, 76.23, 32.78, 14.24. HRMS-ESI m/z [M - H] calcd for C24H18BrClN4OS2: 
521.0111, found: 521.0113, HRMS-ESI m/z [M - H] calcd for C24H18 81BrClN4OS2: 
523.0090, found: 523.0090.   
3-(3-Bromobenzylthio)-6-(4-chlorophenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a56) as an orange-yellow solid 
(Yield: 57%). 1H NMR (500 MHz, DMSO): δ = 8.86 (s, 1H), 8.62-6.93 (m, 12H), 
8.54 (s, 1H), 4.33 (s, 1H). 13C NMR (125 MHz, DMSO-d6): δ = 170.04, 160.95, 
144.64, 140.85, 134.94, 134.55, 134.06, 131.49, 130.46, 129.94, 128.68, 128.39, 
127.96, 121.53, 119.23, 115.54, 112.10, 75.89, 32.74. HRMS-ESI m/z [M - H] calcd 
for C23H15BrClN4OS - H) calcd: 508.9844, found: 508.9842, HRMS-ESI m/z [M - H] 
calcd for C23H15 81BrClN4OS calcd: 510.9823, found: 510.9819.   
3-(3-Bromobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a57) as an orange-yellow solid 
(Yield: 60%). 1H NMR (500 MHz, DMSO-d6): δ = 8.84 (s, 1H), 8.49 (s, 1H), 8.11 – 
6.40 (m, 12H), 4.30 (m, 2H), 2.40 (s, 3H).  13C NMR (125 MHz, DMSO-d6): δ = 
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169.96, 160.98, 144.84, 140.90, 139.99, 134.92, 134.41, 132.19, 131.49, 130.47, 
129.95, 127.98, 126.90, 125.62, 121.53, 119.07, 115.46, 112.04, 76.24, 32.74, 14.25. 
HRMS-ESI m/z [M - H] calcd for C24H18BrClN4OS2: 521.0111, found: 521.0114, 
HRMS-ESI m/z [M - H] calcd for C24H18 81BrClN4OS2: 523.0090, found: 523.0093.     
3-(4-Chlorobenzylthio)-6-(4-chlorophenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a58) as an orange-yellow solid 
(Yield: 84%). 1H NMR (500 MHz, DMSO-d6): δ = 8.80 (d, J = 6.9 Hz, 1H), 8.47 (s, 
1H), 7.58 – 7.15 (m, 9H), 7.04 (d, J = 6.8 Hz, 1H), 6.88 (s, 2H), 4.25 (m, 2H). 13C 
NMR (125 MHz, DMSO-d6): δ = 170.10, 160.95, 144.65, 137.05, 134.97, 134.91, 
134.59, 134.08, 131.68, 130.75, 130.09, 128.71, 128.43, 128.29, 119.25, 115.56, 
112.11, 75.89, 32.71. HRMS-ESI m/z [M - H] calcd for C23H15Cl2N4OS: 465.0349, 
found: 465.0355.  
3-(4-Chlorobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a59) as an orange-yellow solid 
(Yield: 73%). 1H NMR (500 MHz, DMSO-d6): δ  = 8.82 (s, 1H), 8.46 (s, 1H), 7.69 – 
6.54 (m, 12H), 4.28 (m, 2H), 2.41 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 
170.01, 160.95, 144.82, 140.01, 137.09, 134.91, 134.44, 132.23, 131.65, 130.72, 
130.02, 128.28, 126.91, 125.58, 119.07, 115.46, 112.03, 76.23, 32.70, 14.22. HRMS-
ESI m/z [M - H] calcd for C24H18ClN4OS2: 477.0616, found: 477.0612. 
3-(3-Chlorobenzylthio)-6-(4-chlorophenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a60) as an orange-yellow solid 
(Yield: 71%). 1H NMR (500 MHz, DMSO-d6): δ  = 8.83 (s, 1H), 8.50 (s, 1H), 7.38 
(dd, J = 51.0, 31.1 Hz, 10H), 7.07 (s, 1H), 6.91 (s, 2H), 4.29 (m, 2H). 13C NMR (125 
MHz, DMSO-d6): δ = 170.04, 160.95, 144.65, 140.61, 134.96, 134.86, 134.58, 
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134.06, 132.90, 130.19, 130.08, 128.69, 128.65, 128.40, 127.60, 127.06, 119.24, 
115.54, 112.11, 75.89, 32.76. HRMS-ESI m/z [M - H] calcd for C23H15Cl2N4OS: 
465.0349, found: 465.0345.   
3-(3-Chlorobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a61) as an orange-yellow solid 
(Yield: 75%). 1H NMR (500 MHz, DMSO-d6): δ = 8.83 (s, 1H), 8.47 (s, 1H), 7.60 – 
6.98 (m, 11H), 6.86 (d, J = 19.3 Hz, 2H), 4.30 (m, 2H), 2.40 (s, 3H). 13C NMR (125 
MHz, DMSO-d6): δ = 170.46, 161.47, 145.34, 141.14, 140.49, 135.42, 134.93, 
133.40, 132.69, 130.70, 130.51, 129.14, 128.11, 127.56, 127.39, 126.11, 119.57, 
115.95, 112.53, 76.73, 33.25, 14.73. HRMS-ESI m/z [M - H] calcd for 
C24H18ClN4OS2: 477.0616, found: 477.0617.  
6-(4-Chlorophenyl)-3-(4-fluorobenzylthio)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a62) as an orange-yellow solid 
(Yield: 62%). 1H NMR (500 MHz, DMSO-d6): δ = 8.84 (s, 1H), 8.51 (s, 1H), 7.18 
(dd, J = 181.4, 64.2 Hz, 12H), 4.28 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 
170.26, 162.24, 160.99, 160.30, 144.62, 134.92, 134.54, 134.09, 134.02, 130.88, 
130.82, 130.07, 128.69, 128.44, 119.24, 115.56, 115.18, 115.01, 112.14, 75.93, 32.70. 
HRMS-ESI m/z [M - H] calcd for C23H15ClFN4OS: 449.0645, found: 449.0635.  
3-(4-Fluorobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a63) as an orange-yellow solid 
(Yield: 80%).  1H NMR (500 MHz, DMSO-d6): δ = 8.84 (s, 1H), 8.45 (s, 1H), 7.14 
(dd, J = 103.2, 70.5 Hz, 12H), 4.29 (d, J = 10.2 Hz, 2H), 2.41 (s, 3H). 13C NMR (125 
MHz, DMSO-d6): δ = 170.19, 162.89, 161.01, 159.66, 144.80, 140.04, 134.89, 
134.42, 134.09, 132.28, 130.91, 130.80, 130.02, 126.94, 125.64, 119.10, 115.50, 
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115.25, 114.97, 112.09, 76.30, 32.71, 14.26. HRMS-ESI m/z [M - H] calcd for 
C24H18FN4OS2: 461.0912, found: 461.0924.  
6-(4-Chlorophenyl)-3-(3-fluorobenzylthio)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a64) as an orange-yellow solid 
(Yield: 82%). 1H NMR (500 MHz, DMSO-d6): δ = 8.82 (d, J = 8.3 Hz, 1H), 8.48 (s, 
1H), 7.56 – 7.16 (m, 8H), 7.07 (t, J = 8.0 Hz, 2H), 6.98 – 6.79 (m, 2H), 4.30 (m, 2H). 
13C NMR (125 MHz, DMSO-d6): δ = 170.08, 163.61, 160.94, 160.38, 144.62, 140.90, 
140.80, 134.94, 134.89, 134.58, 134.06, 130.30, 130.19, 130.06, 128.67, 128.41, 
124.95, 119.24, 115.75, 115.55, 115.46, 114.05, 113.77, 112.12, 75.91, 32.87. 
HRMS-ESI m/z [M - H] calcd for C23H15ClFN4OS: 449.0645, found: 449.0639.  
3-(3-Fluorobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a65) as an orange-yellow solid 
(Yield: 71%). 1H NMR (500 MHz, DMSO-d6): δ = 8.83 (s, 1H), 8.47 (s, 1H), 7.74 – 
6.67 (m, 12H), 4.32 (m, 2H), 2.40 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 
170.00, 162.96, 160.98, 144.82, 140.90, 140.84, 139.99, 134.90, 134.41, 132.22, 
130.28, 130.22, 130.01, 126.90, 125.60, 124.99, 119.06, 115.70, 115.53, 115.45, 
113.99, 113.83, 112.04, 76.23, 32.85, 14.22. HRMS-ESI m/z [M - H] calcd for 
C24H18FN4OS2: 461.0912, found: 461.0923.   
6-(4-Chlorophenyl)-3-(4-cyanobenzylthio)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a66) as an orange-yellow solid 
(Yield: 71%). 1H NMR (500 MHz, DMSO-d6): δ = 8.82 (d, J = 8.2 Hz, 1H), 8.46 (d, J 
= 3.4 Hz, 1H), 7.72 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.46 (t, J = 7.5 Hz, 
1H), 7.40 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 8.2 Hz, 1H), 6.89 (dd, J = 10.1, 5.6 Hz, 
2H), 4.35 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 169.76, 160.86, 144.62, 
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144.10, 134.96, 134.80, 134.65, 134.07, 132.16, 130.04, 129.80, 128.64, 128.39, 
119.23, 118.69, 115.54, 112.07, 109.74, 75.89, 33.02. HRMS-ESI m/z [M - H] calcd 
for C24H15ClN5OS: 456.0691, found: 456.0700.  
3-(4-Cyanobenzylthio)-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a67) as an orange-yellow solid 
(Yield: 65%).  1H NMR (500 MHz, DMSO-d6): δ = 8.82 (d, J = 7.6 Hz, 1H), 8.44 (s, 
1H), 7.72 (d, J = 7.3 Hz, 2H), 7.58 (d, J = 7.2 Hz, 2H), 7.45 (d, J = 7.1 Hz, 1H), 7.17 
(d, J = 8.0 Hz, 4H), 7.06 (d, J = 7.6 Hz, 1H), 6.88 (t, J = 7.0 Hz, 1H), 6.81 (s, 1H), 
4.36 (m, 2H), 2.41 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ 169.67, 160.87, 
144.80, 144.16, 140.02, 134.91, 134.49, 132.16, 129.99, 129.79, 126.88, 125.55, 
119.04, 118.70, 115.44, 111.98, 109.71, 76.22, 33.02, 14.20. HRMS-ESI m/z [M - H] 
calcd for C25H18N5OS2: 469.1031, found: 469.0959. 
6-(4-Chlorophenyl)-3-(4-methoxybenzylthio)-10-methyl-1-oxo-6,7-dihydro-1H-
[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a68) as an orange-yellow solid 
(Yield: 68%). 1H NMR (500 MHz, DMSO-d6): δ = 8.64 (s, 1H), 8.31 (s, 1H), 7.64 – 
7.15 (m, 7H), 7.07 – 6.73 (m, 4H), 4.24 (m, 2H), 3.72 (s, 3H), 2.22 (s, 3H). 13C NMR 
(125 MHz, DMSO-d6): δ = 170.45, 160.97, 158.39, 142.36, 136.03, 135.02, 134.25, 
133.95, 130.12, 129.49, 129.21, 128.67, 128.34, 128.08, 115.77, 113.80, 112.39, 
76.06, 55.01, 33.15, 20.41. HRMS-ESI m/z [M - H] calcd for C25H20ClN4O2S calcd: 
475.1001, found: 475.1003.  
3-(4-Methoxybenzylthio)-10-methyl-6-(4-(methylthio)phenyl)-1-oxo-6,7-dihydro-
1H-[1,2,4]triazino[1,6-c]quinazolin-5-ium-4(2)-ide (2-1a69) as an orange-yellow 
solid (Yield: 76%). 1H NMR (500 MHz, DMSO-d6): δ = 8.63 (s, 1H), 8.28 (s, 1H), 
7.45 – 7.08 (m, 7H), 6.99 (d, J = 7.9 Hz, 1H), 6.83 (d, J = 7.8 Hz, 3H), 4.25 (m, 2H), 
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3.72 (s, 3H), 2.40 (s, 3H), 2.22 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 170.37, 
161.00, 158.39, 142.55, 139.85, 135.99, 134.12, 132.36, 130.12, 129.44, 129.28, 
127.90, 126.85, 125.61, 115.68, 113.81, 112.32, 76.39, 55.02, 33.15, 20.41, 14.22. 
HRMS-ESI m/z [M - H] calcd for C26H23N4O2S2: 487.1268, found: 487.1277.  
3-(Benzylthio)-10-methyl-6-(4-chlorophenyl)-[1,2,4]triazino[1,6-c]quinazolin-5-
ium-1-olate (2-2a1) as a yellow solid (Yield: 82%).  1H NMR (500 MHz, DMSO): δ 
= 9.83 (s, 1H), 8.11 (d, J = 8.2 Hz, 1H), 8.00 (dd, J = 8.2Hz and 1.25 Hz, 1H), 7.94-
7.92 (m, 2H), 7.65-7.63 (m, 2H), 7.25-7.21 (m, 3H), 7.15-7.14 (m, 2H), 4.16 (s, 1H), 
2.65 (s, 3H), 2.54 (m, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 169.5, 162.0, 149.5, 
143.5, 141.6, 137.6, 135.2, 135.1, 132.3, 131.8, 128.7, 128.3, 128.1, 127.9, 127.1, 
127.0, 119.7, 33.4, 21.8. HRMS-ESI m/z [M + H] calcd for C24H18ClN4OS: 445.0884 
found: 445.0900. 
Crystal data of compound 2-2a1:  
Chemical formula = C24H17ClN4O1.25S, FW = 448.93, monoclinic, space group 
P2(1)/c, a = 12.3523(19) A˚ , b = 8.2615(13) A˚ , c = 20.944(3) Å, V = 2106.6(6)A˚3, 
Z = 4, T =  
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223 (2) K, d(calcd) = 1.416 Mg.m-3, F (000) = 928.The final R value was R1 = 0.0538 
and wR2 = 0.1309 with I > 2s(I).  A small residual peak was treated as partially 
occupied water (25%). H atoms of the waters were not located. 
3-(Benzylthio)-10-methyl-6-(4-(methylthio)phenyl)-[1,2,4]triazino[1,6-
c]quinazolin-5-ium-1-olate (2-2a2). as a yellow solid (Yield: 70%). 1H NMR (500 
MHz, DMSO-d6): δ = 9.79 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 1.85 Hz, 
1H), 7.90-7.89 (m, 2H), 7.44-7.42 (m, 2H), 7.26-7.16 (m, 5H), 4.19 (s, 2H), 2.63 (s, 
3H), 2.54 (m, 3H). 13C NMR (125 MHz, DMSO-d6):  δ = 169.5, 162.2, 150.1, 143.5, 
142.0, 141.3, 137.7, 137.5, 135.1, 131.1, 128.9, 128.8, 128.3, 127.9, 127.0, 124.4, 
119.5, 33.4, 21.9, 14.2 . HRMS-ESI m/z [M + H] calcd for C25H21N4OS2: 457.1151 
found: 457.1161. 
3-(Benzylthio)-10-ethyl-6-(4-(methylthio)phenyl)-[1,2,4]triazino[1,6-c]quinazolin-
5-ium-1-olate (2-2a3). as a yellow solid (Yield: 85%). 1H NMR (500 MHz, DMSO-
d6): δ = 9.86 (s, 1H), 8.13-8.10 (m, 2H), 7.88 (d, J = 8.15 Hz, 2H), 7.43 (d, J = 8.85 
Hz, 2H), 7.26-7.16 (m, 5H), 4.21 (s, 2H), 2.97-2.92 (q, J = 7.55 Hz, 2H), 2.53 (s, 3H), 
1.33 (t, J = 8.2 Hz, 3H) . 13C NMR (125 MHz, DMSO-d6): δ = 169.4, 162.3, 150.2, 
147.2, 143.8, 141.9, 137.6, 136.5, 135.3, 131.1, 128.9, 128.8, 128.3, 128.2, 127.0, 
125.9, 124.4, 119.6, 33.4, 28.8, 15.4, 14.2. HRMS-ESI m/z [M + H]+: calcd for 







Synthesis and the Biological Evaluation of 2-{6-[2-(5-Phenyl-4H-[1,2,4]triazol-3-
ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamides as Potential Anti-
West Nile Virus Agents 
 
3.1 Synthesis of analogues of the lead compound 
To optimize the potency of scaffold 3-1a, a library of structurally diverse analogues of 
compound 3-1a1 was synthesized for biological evaluation of their inhibitory 
activities.  To the best of our knowledge, the synthesis of compound 3-1a has not 
been reported earlier. To develop a synthetic strategy to prepare compound 3-1a 
expediently, we carried out a retrosynthetic analysis of the compound (Figure 3.1). 
Disconnection of compound 3-1a at the amide and C-S bonds gave 4 fragments: 
triazole 3-2a, amino benzothiazole (or benzoimidazole) -2-thione 3-3, amine 3-4 and 
bromoacetyl bromide. 
 
Figure 3.1 Retrosynthesis of compound 3-1a. 
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Compound 3-2a was prepared from the respective benzoic acid 3-5 (Scheme 3.1a) by 
first treating it with either (i) methanol and concentrated H2SO4 under microwave 
irradiation for 15 min, or (ii) oxalyl chloride and DMF at room temperature for 2.5 
h106 to provide  the respective methyl ester 3-6a or acyl chloride 3-6b  in good yields. 
Li and coworkers107 have previously reported that reacting compound 3-6a (R1=H) 
with hydrazine hydrate in ethanol under overnight reflux gave benzohydrazide 3-7 in 
83% yield. To shorten the reaction time, we explored refluxing compound 3-6a with 
neat hydrazine hydrate. The reaction was completed within 20 min and the 
benzohydrazide 3-7 that formed precipitated from the cold reaction mixture in good 
yield. Conversion of 3-7 to compound 3-8 was adapted from an earlier reported 
procedure where the reaction was performed on the surface of silica gel under  
Scheme 3.1 Synthesis of compound 3-2a 
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microwave irradiation.108 However, we found that treating compound 3-7 with 
alkylisothiocyanate under microwave irradiation at 130 oC and in the absence of silica 
gel gave compound 3-8 in higher yields (76-86%). It is worth noting that when R1 ≠ 
NH2, compound 3-8 could be obtained directly from acyl chloride 3-6b by reacting it 
with thiosemicarbazide at room temperature.109 With compound 3-8 in our hands, we 
proceeded with the cyclization reaction in sodium hydroxide solution under 
microwave irradiation at 150 oC. The reaction was completed in 3 min (versus 1h 
under conventional reflux) to provide 1,2,4-triazole-5(4H)-thione 3-2a in good yield. 
We have also synthesized compound 3-2a12 from 3-2a6 by reducing the nitro group 
with iron and concentrated HCl (Scheme 3.1b). 
Scheme 3.2 Synthesis of compound 3-3 
 
 
Compound 3-3 was prepared by first treating 2-aminothiophenol or o-
phenylenediamine 3-9 with CS2 in the presence of KOH under microwave irradiation 
to provide intermediate 3-10 (Scheme 3.2). Nitration of compound 3-10 followed by 
reduction of the nitro group with iron powder and concentration HCl afforded 
compound 3-3 in moderately good yield.  
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Compounds 3-2, 3-3 and various commercially available amines or anilines 3-4 were 
coupled as shown in Scheme 3.3. Compound 3-4 was treated with bromoacetyl 
bromide to yield compound 3-12 which was then reacted with the thiolate anion, 
generated in situ from the reaction of compound 3-3 with KOH, to provide compound 
3-13. Subsequent coupling of the amino group on 3-13 with another molecule of 
bromoacetyl bromide gave intermediate 3-14 which precipitated readily from the  
Scheme 3.3 Synthesis of compound 3-1a 
 
reaction mixture. Finally, regioselective coupling of compound 3-2a with compound 
3-14 under basic conditions gave compound 3-1a in moderately good yield.  
 
3.2 Structure-activity relation studies 
A representative set of 40 analogues of compound 3-1a were synthesized and tested in 
a WNV assay at 50 µM concentration to identify potential inhibitors. Inhibitors 
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exhibiting more than 50% inhibition were further evaluated for their effects at 
different concentrations and the IC50 values of each compound were calculated using 
the Graphpad Prism software (Table 3.1). The fluorogenic peptide Pyr-RTKR-AMC 
was used as a substrate for the WNV NS2B-NS3 protease and the Km value was 
determined, using the protocol from the SensoLyte® 440 West Nile Virus Protease 
Assay Kit, to be 3.45±0.41 µM. 
In our preliminary SAR studies, we examined the effects of substituents on the 
inhibitory activity of the compound by varying the X, R1, R2 and R5 groups of 
compound 3-1a1 (Table 3.1, cpds 3-1a2 to 3-1a10). However, these changes did not 
provide any significant improvement in the activity. Hence, we proceeded to screen 
the inhibitory activity of the unsubstituted compound by changing both R1 and R2 on 
compound 3-1a1 to H (Table 3.1, cpd 3-1a11). To our delight, an enhancement in the 
inhibition of the WNV NS2B-NS3 protease was observed, indicating that the 5-
phenyl-1,2,4-triazole group plays an important role in the compound’s inhibitory  
Table 3.1 IC50 values of compound 3-1aa 
 Cpd R
1 R2 X R3 n R4 R5 IC50 (µM) 
3-1a2 p-NH2 Me S H 1 H F 45.67±6.40 
3-1a3 p-NH2 Me S H 1 H OMe >50 
3-1a4 p-NH2 Me NH H 1 H H NAb 
3-1a5 p-NH2 Me NH H 1 H F NA 
3-1a6 p-NH2 Et S H 1 H H NA 
3-1a7 p-NH2 Et S H 1 H F NA 
3-1a8 H Me S H 1 H H >50 
3-1a9 H Me S H 1 H F >50 
3-1a10 H Et S H 1 H H NA 
3-1a11 H H S H 1 H H 14.27±2.51 
3-1a12 H H S H 1 H F 29.28±3.62 
3-1a13 H H S H 1 H OMe >50 
3-1a14 H H S H 1 H Me >50 
3-1a15 H H NH H 1 H H NA 
3-1a16 H H NH H 1 H F NA 
3-1a17 H H NH H 1 H OMe   NA 
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3-1a18 H H S Me 1 H H NA 
3-1a19 H H S H 0 H H >50 
3-1a20 H H S H 0 H F >50 
3-1a21 H H S H 0 H Cl 10.93±2.58 
3-1a22 H H S H 0 H OMe 8.79±0.23 
3-1a23 H H S H 0 H Me 7.13±0.87 
3-1a24 H H S H 0 H Et 3.35±0.15 
3-1a25 H H S H 0 H n-Pr 4.15±0.63 
3-1a26 H H S H 0 F H >50 
3-1a27 H H S H 0 Cl H >50 
3-1a28 H H S H 0 OMe H 29.44±4.78 
3-1a29 H H S H 0 Et H >50 
3-1a30 H H NH H 0 H Et NA 
3-1a31 H Me S H 0 H  Et NA 
3-1a32 p-NH2 H S H 0 H Et >50 
3-1a33 p-NO2 H S H 0 H Et >50 
3-1a34 p-OH H S H 0 H Et >50 
3-1a35c cyclohexyl H S H 0 H Et >50 
3-1a36d n-Pr H S H 0 H Et NA 
3-1a37 o-Me H S H 0 H Et 5.63±1.44 
3-1a38e pyridine-4-yl H S H 0 H Et >50 
3-1a39 p-NH2 Me S H 0 H Et 20.06±3.59 
3-1a40f H H S H 0 - - 29.76±2.8 
[a] Data represent the concentrations required to inhibit the WNV NS2B-NS3 protease 
activity by 50% and are the mean±SE of triplicate experiments; compounds used are 
≥95% pure. [b] NA: no activity. [c] Phenyl group containing R1 was replaced by a 
cyclohexyl ring. [d] Phenyl group containing R1 was replaced by a n-propyl group. [e] 
Phenyl group containing R1 was replaced by a pyridine-4-yl ring. [f] Phenyl group 







activity. Further modifications by varying the X and R5 groups on compound 3-1a11 
(Table 3.1, cpds 3-1a12 to 3-1a18) resulted in a loss of the inhibitory activity. Next 
we proceeded to explore the effect of the methylene linker. Analogues of 3-1a11 were 
synthesized with various aniline derivative 3-4 (Table 3.1, cpds 3-1a19 to 3-1a29) and 
the screening results showed that the presence of alkyl substituent on R5 (Table 3.1, 
cpds 3-1a23 to 3-1a25) significantly amplified the compound’s inhibition activity. 
The best inhibition was observed in compound 3-1a24 which contains an ethyl group 
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at the para-position (=R5) of the phenyl ring. Further tuning of compound 3-1a24 by 
varying the substituents on X, R1 and R2 (Table 3.1, cpds 3-1a30 to 3-1a39) did not 
result in further improvement of the inhibitory activity, confirming the importance of 
the 5-phenyl-1,2,4-triazole and benzothiazole fragments in the compound’s inhibitory 
activity. In addition, replacing the phenyl ring with a cyclohexyl moiety (Table 3.1, 
cpd 3-1a40) provided a compound with modest inhibition against the WNV NS2B-
NS3 protease.  
 
Figure 3.2 MTS assay results obtained at incubation times of 24 (      ), 48 (      ) and 
72 h (     ) with the BHK21 cell line. Compounds were added at a final concentration 
of 25 µM. 
 
The stabilities of compounds 3-1a22, 3-1a23, 3-1a24, 3-1a25 and 3-1a37 in the assay 
buffer (pH 8) were determined by analyzing the amount of compound remaining with 
time using LCMS-IT-TOF detection. Quantization of the compounds was determined 
by Shimadzu's LCsolution software. Compounds 3-1a22, 3-1a23, 3-1a24, 3-1a25 and 
3-1a37 showed excellent stability in a pH 8 buffer after 72 h at 37 oC without any 
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degradation. Next, we evaluated the cytotoxicities of compounds 3-1a22, 3-1a23, 3-
1a24, 3-1a25 and 3-1a37 against baby hamster kidney fibroblast (BHK21) cells at 
different incubation timings. Vehicular control, dimethyl sulfoxide (DMSO), was also 
included to serve as control as the test compounds were dissolved in DMSO. The 
amount of DMSO used in the assay was controlled at 0.2% of the total volume. This 
is to ensure that DMSO does not result in cytotoxicity of cells. From the results 
obtained (Figure 3.2), the three strongest candidates identified from our earlier SAR  
 
Figure 3.3 Uncompetitive inhibition of 3-1a24 with WNV NS2B-NS3 protease: 
WNV protease assays were performed at various concentrations of 3-1a24 (0, 2.5, 5.0 
and 25μM) and substrate (3.3, 8.3, 16.7, 33.3, 83.3μM). Double reciprocal plots of 
1/V versus 1/[S] for 3-1a24 at each inhibitor concentration were plotted using the 
OriginPro 8. 
 
studies, compounds 3-1a24, 3-1a25 and 3- 1a37 were also shown to be non-cytotoxic 
to BHK21 cells with compound 3-1a24 being the least toxic of the three compounds.  
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To determine the inhibition mode of compound 3-1a24, we followed the kinetics of 
inhibition using Pyr-RTKR-AMC as substrate. Lineweaver-Burk analysis (Figure 3.3) 
of the initial velocities of this substrate concentration-dependent inhibition of the 
NS2B-NS3 protease activity suggested that the inhibition by compound 3-1a24 was 
uncompetitive with respect to the substrate with a Ki value of 2.77±0.13 µM. 
Uncompetitive inhibition by the compound 3-1a24, due to the absence of charge on 
the inhibitor that prefers active site of the protease. 
 
3.3 Docking analysis 
A docking study was performed to rationalize the inhibition and kinetics result as well 
as to identify the possible binding sites of compound on the WNV NS2B-NS3 
protease. The crystal structure of the WNV NS2B-NS3 protease in complex with 
peptide Bz-Nle-Lys-Arg-Arg-H (pdb 2fp7) has been reported earlier.74 To identify the 
potential binding site of compound 3-1a24 on the NS2B-NS3 protease, in silico 
docking studies was performed with Molecular Operating Environment (MOE) using 
these crystal structure coordinates. Since compound 3-1a24 is an uncompetitive 
inhibitor of the WNV NS2B-NS3 protease, we focused our analysis on regions 
beyond the substrate binding sites. Earlier studies have shown that the integration of 
residues 78-87 of NS2B into the protease-cofactor complex affected the formation of 
the catalytic active sites.74,75,105 Deletion or mutagenesis of these residues produced an 
inert enzyme. Therefore, the region on the NS3 protease where key interactions with 
the NS2B cofactor (residue 78-87) occur is important for the NS2B-NS3 protease 
activity and particularly attention was paid to this region during our docking studies. 
The best docked pose for compound 3-1a24 and the WNV NS2B-NS3 protease is 
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shown in Figure 3.4. The docking analysis predicted two strong π-cation type 
interactions between the guanidine group in Arg78 of the NS2B cofactor and the 
phenyl ring directly attached to triazole. Arg78 was also observed to form a hydrogen  
Figure 3.4 Molecular docking of compound 3-1a24 onto WNV NS2B-NS3 protease. 
The WNV protease crystal structure coordinates (pdb 2fp7)74 were used for the 
molecular docking. a) The NS2B-NS3 protease is shown as a wireframe and flat 
ribbon model and the inhibitor is shown as a stick model; b) surface representation of 
NS2B-NS3 protease shows the electrostatic potential where blue represents positive, 
white represents neutral and red represents negative electrostatic potential. Docked 
inhibitor is shown in stick model. All views were generated using Discovery Studio 
3.1 client. 
bonding with the triazole nitrogen. Since the interaction of Arg78 with a ligand 
interferes with the productive interaction of the NS2B cofactor with the catalytic 
active site in the NS3 protease, these bonding interactions between compound 3-1a24 
and Arg78 are important factors contributing to the compound’s inhibitory potency. 
Other interactions present involve the phenyl ring containing R4 and R5 which is 
attracted to Lys88 and Ile123 of NS3 via strong π-cation and π-π type bonding 
respectively and the strong π-π bonding between the triazole ring in compound 3-1a24 
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with Lys73 from NS3 protease. At the same time, the nitrogen atom on triazole and 
the oxygen atom on the amide group directly linked to benzothiazole of 3-1a24 were 
observed to interact with Lys73 of NS3 via hydrogen bonding. Amino acid residues 
that are in close proximity (less than 5 Å) to atoms of compound 3-1a24 include 
Arg78, Leu79, Asp80, Asp81 and Phe85 of NS2B and Lys73, Glu74, Arg76, Lys88, 
Trp89, Gly91, Val115, Pro119, Glu120, Glu122, Ile123, Gly124 and Ile147 of NS3. 
These results support our experimental inhibition assay data that compound 3-1a24 is 
an allosteric inhibitor of the WNV NS2B-NS3 protease. 
 
3.4 Conclusion 
In this study, we have identified a lead compound 3-1a1 with moderate inhibitory 
activity against the WNV NS2B-NS3 protease. Refinement of this initial “hit” by 
synthesizing a focused library of 3-1a1 derivatives for SAR studies provided 
compound 3-1a24 which inhibited the interaction of the NS2B cofactor and the NS3 
protease in low micromolar concentration (IC50 = 3.35±0.15 µM) and in an 
uncompetitive manner. Compound 3-1a24 is stable under physiological condition and 
is non-cytotoxic to baby hamster kidney fibroblast cells. Further studies are presently 
ongoing to further develop compound 3-1a24 as a potential antiviral therapeutic.     
 
3.5 Experimental section 
3.5.1 Chemistry 
All chemical reagents and anhydrous solvent were obtained from Aldrich, Merck, 
Lancaster or Fluka and used without further purification. Flash chromatography was 
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performed with silica (Merck, 70-230 mesh) whilst TLC was carried out on pre-
coated plates (Merck silica gel 60, F254) and visualized with UV light. Final 
compounds were purified on a Gilson preparative HPLC system with a Waters C18 
column (250 x 10.0 mm, 5 μm). Purity of the compound was determined by analytical 
HPLC using a Shimadzu LCMS-IT-TOF system with a Phenomenex C18 column (50 
mm x 3.0 mm, 5 μm). Purity of the compound was checked at 254 nm and integration 
was obtained with Shimadzu LCMS solution software. 1H and 13C NMR spectra were 
recorded using CDCl3, acetone-d6, or DMSO-d6 as solvents and tetramethylsilane 
(TMS) as an internal reference on a Bruker AMX500 or a Bruker ACF300 Fourier 
transform spectrometer. The following abbreviations were used to explain the 
multiplicities: s (singlet), d (doublet), t (triplet), dd (doublet of doublet), q (quartet), 
and m (multiplet). The number of protons (n) for a given resonance was indicated as 
nH. Mass spectrometry was performed on a Finnigan/MAT LCQ mass spectrometer 
using electron spray ionization (ESI) or electron impact (EI) 
General procedure for the synthesis of 3-6a (L=OMe) 
To a solution of the corresponding benzoic acid 3-5 (3.9 mmol) in methanol (15 mL) 
was added concentrated H2SO4 (0.39 mmol). The reaction mixture was microwave 
irradiated at 130 °C (with the heating program starting at 150 W) for 15 min. 
Thereafter, the reaction mixture was concentrated and saturated NaHCO3 was added 
slowly at room temperature until no more bubbling occurred. The reaction mixture 
was then extracted with EtOAc (20x3 mL) and the combined organic layer was dried 
over Na2SO4, concentrated and purified via a short column chromatography using 
EtOAc/hexane (2:3 or 1:49)  as the eluent. The product obtained was dried overnight 
in a vacuum oven at 50 °C to provide compound 3-6a in 86-95% yield. 
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General procedure for the synthesis of 3-6b (L=Cl) 
To a solution of the corresponding benzoic acid 3-5 (9.0 mmol) in CH2Cl2 (30 mL) 
was added oxalyl chloride (27.5 mmol) and DMF (2 drops) at 0 °C. The mixture was 
allowed to stir at room temperature for 2.5 h. After which, the reaction mixture was 
concentrated and the crude product obtained was used directly for the next reaction. 
 
General procedure for the synthesis of 3-7 
To the corresponding methyl benzoate 3-6a (3 mmol) was added hydrazine hydrate (5 
mL, 100 mmol). The reaction mixture was stirred and heated under reflux for 20 min. 
Thereafter, the reaction mixture was cooled to room temperature and then to -15 °C 
for 10 min. The precipitate that formed was filtered and washed with ice-cold water (3 
mL). After which, the crude product 3-7 was dried overnight in a vacuum oven at 50 
°C and used for the next reaction. The crude yield of 3-7 was 82-90%. 
General procedure for the synthesis of 3-8 (R2=Me or Et) 
The corresponding benzohydrazide 3-7 (3.6 mmol) was added to a solution of alkyl 
isothiocyanate (3.96 mmol) in THF (12 mL). The mixture was irradiated under 
microwave at 130 °C (with the heating program starting at 150 W) for 8 min. 
Thereafter the reaction mixture was concentrated and extracted with EtOAc/H2O. The 
combined organic layer was dried over Na2SO4, concentrated and purified by column 
chromatography using EtOAc/hexane (starting from 3:7 to 3:2) as the eluent. The 
product obtained was dried overnight in a vacuum oven at 50 °C to provide compound 
3-8 in 76-86% yield. 
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General procedure for the synthesis of 3-8 (R2=H) 
Commercially available acid chloride (9.0 mmol) or crude product 3-6b (L = Cl, 9.0 
mmol) was added slowly to a mixture of thiosemicarbazide (19.6 mmol) in THF (20 
mL) at 0 oC. The reaction mixture was stirred at room temperature for 1.5 h. 
Thereafter, the reaction mixture was concentrated and the residue was triturated with 
water. The product which precipitated from the reaction mixture was filtered, washed 
with water and dried overnight under vacuum at 50 °C to yield product 3-8 in 60-87% 
yield. This product was directly used for the next reaction. 
General procedure for the synthesis of 3-2a 
To compound 3-8 (3.4 mmol) was added NaOH (2 M, 15 mL) and the reaction 
mixture was irradiated under microwave at 150 °C (with the heating program starting 
at 150 W) for 3 min. Thereafter, the solution was neutralized with acetic acid, and 
extracted with EtOAc (3x15 mL). The combined organic layer was dried over 
Na2SO4, concentrated, and purified by flash column chromatography using 
EtOAc/hexane (starting with EtOAc/hexane = 1:5 and then changing to 
EtOAc/hexane = 1:2) as the eluent. The product was dried overnight under vacuum at 
50 °C to provide compound 3-2a in 71-94% yield. 
Synthesis of 3-(4-aminophenyl)-1H-1,2,4-triazole-5(4H)-thione 3-2a12 
To a mixture of iron powder (10 mmol) in 80% aqueous ethanol (5 mL) was added 
concentrated HCl (1 mmol) and the reaction mixture was stirred in a warm (40 °C) 
water bath. Thereafter 3-(4-nitrophenyl)-1H-1,2,4-triazole-5(4H)-thione 3-2a6 (R1 = 
NO2, 2 mmol ) was added portionwise and the resulting reaction mixture was stirred 
and heated under reflux for 45 min. After which ethanol was removed on a rotavapor 
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and the residual reaction mixture was adjusted to ~pH 13 with NaOH. The reaction 
mixture was then filtered by suction filtration and the filtrate was adjusted to pH 5 
with glacial acetic acid. The precipitate which formed was filtered and purified by 
flash column chromatography using EtOAc/hexane (starting with EtOAc/hexane = 
1:1 and then changing to EtOAc/hexane = 2:1) as eluent. The product obtained was 
dried overnight under vacuum at 50 °C to yield compound 3-2a12 in 61% yield. 
General procedure for the synthesis of 3-10 
To a mixture of KOH (5.5 mmol) in 80% aqueous ethanol (7.5 mL) was added carbon 
disulfide (5.5 mmol) and the reaction mixture was stirred at room temperature for 15 
min. Thereafter, the corresponding phenylamine 3-9 (5 mmol) was added and the 
reaction mixture was irradiated under microwave at 130 °C (with the heating program 
starting at 150 W) for 15 min and then cooled to room temperature. After which, the 
reaction mixture was diluted with water (10 mL), adjusted to pH 5 with glacial acetic 
acid and cooled to 0 °C for 1h to complete the crystallization. The shiny precipitate 
that formed was filtered and dried overnight under vacuum at 50 °C to yield 
compound 3-10 in 85-94 % yield. 
General procedure for the synthesis of 3-11 
The corresponding azole derivative 3-10 (3.0 mmol) was slowly dissolved in 
concentrated H2SO4 (1.4 mL, 25.7 mmol) with cooling at 0 oC to -5 oC. Thereafter, a 
mixture of fuming HNO3 (0.4 mL, 9.6 mmol) and concentrated H2SO4 (0.3 mL, 5.6 
mmol) was added dropwise  and the reaction mixture was stirred for 1 h at 0 oC to -5 
oC then poured into ice. The precipitate that formed was filtered and dissolved in a 
minimum volume of 25% aqueous ammonia solution. The resultant solution was 
heated at 50 oC and filtered under suction. The filtrate was cooled to 0 oC and adjusted 
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to pH 2 with 6M HCl. The precipitate that formed was filtered and purified by flash 
column chromatography using EtOAc/hexane (starting with EtOAc/hexane = 1:2 and 
then changing to EtOAc/hexane = 1:1) as eluent. The product was dried overnight 
under vacuum at 50 °C and compound 3-11 was obtained in 48-65% yield. 
General procedure for the synthesis of 3-3 
The procedure is similar to that used for the synthesis of 3-2b12. However the 
precipitate which formed was purified by flash column chromatography using 
EtOAc/hexane (starting with EtOAc/hexane = 2:3 and then changing to 
EtOAc/hexane = 2:1) as eluent. The product was dried overnight under vacuum at 50 
°C and compound 3-3 was obtained in 67-74% yield. 
General procedure for the synthesis of 3-12 
To a mixture of bromoacetyl bromide (5.3 mmol) in acetonitrile (50 mL) at 0 oC was 
added dropwise the corresponding amine or aniline 3-4 (4.4 mmol). After addition, 
the mixture was stirred at room temperature for 1 h. Acetonitrile was removed by 
rotary evaporation and the residue was extracted with an EtOAc/H2O solvent system. 
The combined organic layer was concentrated and purified by flash column 
chromatography using EtOAc/hexane (starting with EtOAc/hexane = 1:10 and then 
changing to EtOAc/hexane = 3:10) as eluent. The product was dried overnight under 
vacuum at 50 °C and compound 3-12 was obtained in 68-87% yield. 
General procedure for the synthesis of 3-13 
Compound 3-3 (0.3 mmol) was dissolved in a mixture of KOH (0.6 mmol) in 60% 
aqueous ethanol (20 mL). Thereafter, the corresponding intermediate 3-12 (0.3 mmol) 
was added and the reaction mixture was stirred for 1h at room temperature. When the 
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reaction had completed (monitored by TLC), ethanol was removed by rotary 
evaporation and the residual mixture was neutralized with dilute acetic acid followed 
by extraction with EtOAc (3x15 mL). The combined organic layer was concentrated 
and purified using a short silica column with EtOAc/hexane (starting with 
EtOAc/hexane = 3:10 and then changing to EtOAc/hexane = 1:4) as eluent. The semi-
pure product obtained was dried under high vacuum at room temperature and used for 
next step of the reaction. 
General procedure for the synthesis of 3-14  
To the corresponding intermediate 3-13 (4.4 mmol) in CH2Cl2 (30 mL) at 0 oC was 
added bromoacetyl bromide (5.3 mmol) dropwise. After addition, the reaction mixture 
was stirred at room temperature for 1 h. The product which precipitated from the 
reaction mixture was filtered, washed with CH2Cl2  (3x15 mL) and dried overnight 
under vacuum at 50 °C to provide compound 3-14 in 73-86 % yield.   
General procedure for the synthesis of 3-1a 
The corresponding triazole compound 3-2a (0.22 mmol) was dissolved in a mixture of 
KOH (0.66 mmol) in 60% aqueous ethanol (16 mL).  The corresponding intermediate 
3-14 (0.22 mmol) was added and the reaction mixture was stirred for 2 h at room 
temperature. Thereafter, ethanol was removed by rotary evaporation and the residual 
mixture was neutralized with dilute acetic acid followed by extraction with 
EtOAc/H2O. The combined organic layer was concentrated and purified by reverse 
phase HPLC using solvent A with 0.1% TFA in water, and solvent B was 0.1% TFA 
in acetonitrile as the mobile phase. Detection was conducted at 254nm, the mobile 
phase was a gradient with solvent B increasing from 15% to 95% over 30 min and a 
flow rate of 8.0ml/min. Fractions containing the pure product were combined, 
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concentrated and dried overnight under vacuum at 50 °C to give compound 3-1a in 
56-83 % yield. 
3.5.2 Biology 
All the compounds used in the biological testing were at least 95% pure. Compounds 
were tested against the WNV NS2B-NS3 protease using the SensoLite® 440 WNV 
protease assay kit (Catalog # 72079) and the active recombinant WNV protease 
(Calalog # 72081) which were purchased from Anaspec (USA). This protease assay 
kit uses a fluorogenic peptide Pyr-RTKR-AMC as substrate. Eight different substrate 
concentrations ranging from 1 μM to 80 μM were incubated in 96-well plates with 0.3 
μg/mL recombinant WNV protease at 37 °C in the assay buffer provided. The 
increase in fluorescence intensity was monitored using an Infinite F200 microplate 
reader (Tecan, Switzerland) at an excitation wavelength of 354 nm (±10 nm) and 
emission wavelength of 442 nm (±15 nm). The initial velocity was determined from 
the linear portion of the progress curve, and the value of Km was determined using the 
Michaelis-Menten equation, i.e. v = Vmax [S] / ([S] + Km) to be 3.45±0.41 µM. 
Triplicate measurements were taken at each data point and the data were reported as 
mean±SE. In the preliminary WNV NS2B-NS3 protease inhibition assay, analogues 
of 3-1a were screened at a fixed concentration of 50 μM to filter out potential 
inhibitors. Compounds which showed more than 50% inhibition were further 
investigated for their IC50 determination. 
Determination of IC50 
For the IC50 calculations, recombinant WNV protease concentration of 0.3 µg/mL and 
seven different concentrations of the inhibitor ranging from 10 nM to 50 μM were 
used. For each experiment, the protease was pre-incubated with the inhibitor at 37 oC 
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for 15 min in separate wells and the enzyme kinetics was initiated by adding substrate 
Pyr-RTKR-AMC to a final concentration 16.7 µM. The increase in fluorescence 
intensity was monitored continuously using an Infinite F200 microplate reader at an 
excitation wavelength of 354 nm and emission wavelength at 442 nm. Fluorescence 
values obtained from the positive control (no inhibitor) were considered as 100% 
     
                       
    
Figure 3.5 Un-inhibition curve of compounds 3-1a22, 3-1a23, 3-1a24, 3-1a25 and 3-
1a37  
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complex formation and those values obtained in the presence of inhibitors were 
calculated as the percentage of inhibition of the control. Triplicate measurements were 
obtained at each data point. The IC50 values were calculated using a sigmoidal dose-
response using the Graphpad prism 3.0 software (San Diego, USA). Triplicate 
measurements were recorded as the mean ± SE.                                                                                                      
Determination of inhibition mechanism 
Three different inhibitor (3-1a24) concentrations and a no-inhibitor control (0 to 25 
μM) were each assayed at five substrate concentrations ranging from 3.3 μM to 83.3 
μM. In each assay, the enzyme and inhibitor were incubated at 37 °C for 15 min, 
followed by the addition of the substrate to start the kinetic measurement. The rate of 
substrate cleavage (v) was monitored using the F200 microplate reader. To illustrate 
the inhibition mechanism, 1/V versus 1/[S] was plotted for at each inhibitor 
concentration using OriginPro8. 
 
MTS Assay 
The baby hamster kidney fibroblast (BHK21) cells  were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS). 
The 1500 cells were placed in each well of three 96-well plates with a cell density of 
1.66x104 cells/mL and incubated for 24 h at 37 °C with 5% CO2. Thereafter, the 
compound of interest or DMSO was added into each well at 25 µM. Wells containing 
plain DMSO served as a vehicular control. The plate was then placed in the incubator 
for 24, 48 and 72 h of incubation at 37 °C with 5% CO2. At the end of each individual 
incubation time point, MTS reagent solution (20 µL) was added into each sample 
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well. The plate was then incubated again in the dark for 2 h, gently shaken using a 
vortemp machine for 5 min to ensure equal mixing and absorbance at 492 nm was 
taken using a spectrometer. 
3.5.3 Docking 
All docking studies were performed using the Molecular Operating Environment 
(MOE 2009.10) software system designed by the Chemical Computing Group. The 
program operated under the ‘Windows Vista’ operating system installed on an Intel 
Core™2 Duo PC with a 2.4 MHz processor and 4.0 GB RAM. Docked compound 
was built using the MOE builder and subjected to energy minimization with the 
MMFF94x force field. The active site of the WNV protease was prepared using the 
crystal structure of the WNV NS2B-NS3 protease in complex with peptide Bz-Nle-
Lys-Arg-Arg-H (pdb 2fp7). The structure was stripped of all water molecules and 
bound ligand followed by the addition of valance hydrogen atoms to the protein. By 
keeping in mind the amino acid residues in NS2B which are responsible for the 
activation of the catalytic triad, the active site in NS2B-NS3 was identified using the 
Alpha site finder tool. Docking simulations were performed at default settings with 
placement at triangle matcher, rescoring at London DG, refinement at force field and 
the geometry of resulting complex was studied using the Discovery Studio 3.1 client.                                                                                 
 
3.6 1H and 13C NMR data of all compounds synthesized  
1H and 13C NMR data of compound 3-6a 
Methyl 4-aminobenzoate (3-6a1) light brown solid (Yield: 86%): 1H NMR (300 
MHz, DMSO-d6) δ 7.63 (dt, J = 8.7 Hz, 2.5 Hz, 2H), 6.56 (dt, J = 8.7 Hz, 2.5 Hz, 
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2H), 5.95 (s, 2H), 3.72 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 166.4, 153.5, 131.0, 
115.7, 112.7, 51.1. HRMS (ESI) [M + H]+: calcd for C8H10NO2: 152.0706; found 
152.0706. 
Methyl benzoate (3-6a2) colorless liquid (Yield: 95%). 1H NMR (300 MHz, CDCl3) 
δ 8.10 – 7.98 (m, 2H), 7.62 – 7.49 (m, 1H), 7.49 – 7.37 (m, 2H), 3.91 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 167.36, 133.14, 130.44, 129.82, 128.60, 52.31. HRMS (EI) 
[M]: calcd for C8H8NO2: 136.0524; found 136.0525.  
 
1H and 13C NMR data of compound 3-8 
2-(4-Aminobenzoyl)-N-methylhydrazinecarbothioamide (3-8a) white solid (Yield: 
76%): 1H NMR (500 MHz, CDCl3) δ 9.84 (s, 1H), 9.11 (s, 1H), 7.89 (d, J = 3.6 Hz, 
1H), 7.63 (d, J = 8.4 Hz, 2H), 6.56 (d, J = 8.6 Hz, 2H), 5.70 (s, 2H), 2.87 (d, J = 4.2 
Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 182.90, 166.57, 152.71, 129.95, 119.32, 
112.92, 31.39. HRMS (ESI) [M + H]+: calcd for C9H11N4OS: 223.0659; found 
223.0653.  
2-(4-Aminobenzoyl)-N-ethylhydrazinecarbothioamide (3-8b) as a white solid 
(Yield: 81%): 1H NMR (300 MHz, DMSO-d6) δ 9.81 (s, 1H), 9.04 (s, 1H), 7.93 (d, J 
= 4.9 Hz, 1H), 7.63 (d, J = 8.6 Hz, 2H), 6.56 (d, J = 8.6 Hz, 2H), 5.70 (s, 2H), 3.46 
(dt, J = 13.5, 6.8 Hz, 2H), 1.05 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 
181.79, 166.50, 152.72, 129.96, 119.35, 112.89, 38.91, 15.00. HRMS (ESI) [M + H]+: 
HRMS (ESI) [M - H]-: calcd for 10H13N4OS: 237.0816; found 237.0808. 
2-benzoyl-N-methylhydrazinecarbothioamide (3-8c) white solid (Yield: 80%): 1H 
NMR (500 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.32 (s, 1H), 8.05 (d, J = 3.1 Hz, 1H), 
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7.93 (d, J = 7.7 Hz, 2H), 7.59 (t, J = 7.2 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 2.89 (s, 
3H); 13C NMR (125 MHz, DMSO-d6) δ 182.32, 165.93, 132.46, 131.80, 128.20, 
127.79, 30.92. HRMS (ESI) [M + H]+: calcd for C9H10N3OS: 208.0550; found 
208.0543. 
2-benzoyl-N-ethylhydrazinecarbothioamide (3-8d) white solid (Yield: 86%): 1H 
NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.24 (s, 1H), 8.10 (s, 1H), 7.92 (d, J = 
7.5 Hz, 2H), 7.57 (t, J = 7.3 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 3.49 – 3.45 (m, 2H), 
1.06 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 181.34, 166.05, 132.52, 
131.92, 128.32, 127.89, 38.60, 14.56. HRMS (ESI) [M - H]-: calcd for C10H12N3OS: 
222.0707; found 222.0702.    
 
1H and 13C NMR data of compound 3-2a 
3-(4-Aminophenyl)-4-methyl-1H-1,2,4-triazole-5(4H)-thione (3-2a1) white solid 
(Yield: 94%): 1H NMR (500 MHz, DMSO-d6) δ 13.65 (s, 1H), 7.36 (d, J = 7.3 Hz, 
2H), 6.66 (d, J = 7.4 Hz, 2H), 5.67 (s, 2H), 3.50 (s, 3H).13C NMR (125 MHz, DMSO-
d6) δ 166.86, 152.14, 150.96, 129.41, 113.36, 112.35, 31.62. HRMS (ESI) [M - H]-: 
calcd for C9H10N4S: 205.0553; found 205.0544. 
3-(4-Aminophenyl)-4-ethyl-1H-1,2,4-triazole-5(4H)-thione (3-2a2) white solid 
(Yield: 90%). 1H NMR (500 MHz, DMSO-d6) δ 13.65 (s, 1H), 7.29 (d, J = 8.2 Hz, 
2H), 6.66 (d, J = 8.2 Hz, 2H), 5.67 (s, 2H), 4.01 (q, J = 6.9 Hz, 2H), 1.16 (t, J = 6.9 
Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 166.3, 151.9, 151.0, 129.4, 113.6, 112.4, 
39.0, 13.4. HRMS (ESI) [M + H]+: calcd for C10H13N4S: 221.0855; found 221.0848. 
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4-Methyl-3-phenyl-1H-1,2,4-triazole-5(4H)-thione (3-2a3) white solid (Yield: 
90%): 1H NMR (500 MHz, DMSO-d6) δ 12.53 (s, 1H), 7.64 – 7.58 (m, 2H), 7.57 – 
7.49 (m, 3H), 3.65 (s, 3H);13C NMR (125 MHz, DMSO-d6) δ 168.20, 152.44, 131.33, 
129.41, 128.76, 125.88, 32.50. HRMS (ESI) [M – H]–: calcd for C9H8N3S: 190.0444; 
found 190.0437. 
4-Ethyl-3-phenyl-1H-1,2,4-triazole-5(4H)-thione (3-2a4) white solid (Yield: 90%). 
1H NMR (500 MHz, DMSO-d6) δ 12.55 (s, 1H), 7.58 – 7.50 (m, 5H), 4.15 (q, J = 7.0 
Hz, 2H), 1.33 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 167.2, 151.9, 
131.0, 129.1, 128.5, 125.8, 40.0, 13.8. HRMS (ESI) [M – H]–: calcd for C10H10N3S: 
204.0601; found 204.0592. 
3-Phenyl-1H-1,2,4-triazole-5(4H)-thione (3-2a5) white solid (Yield: 82%). 1H NMR 
(500 MHz, DMSO-d6) δ 13.67 (br, 2H), 7.91 – 7.89 (m, 2H), 7.52 – 7.49 (m, 3H); 13C 
NMR (125 MHz, DMSO-d6) δ 167.1, 150.2, 130.1, 129.1, 125.7, 125.5. HRMS (ESI) 
[M – H]–: calcd for C8H6N3S: 176.0288; found 176.0286. 
3-(4-Nitrophenyl)-1H-1,2,4-triazole-5(4H)-thione (3-2a6) yellow solid (Yield: 
78%). 1H NMR: (300 MHz, DMSO-d6) δ 13.94 (br, 2H), 8.34 (d, J = 8.7 Hz, 2H), 
8.13 (d, J = 8.7 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 167.7, 148.6, 148.2, 131.2, 
126.8, 124.4. HRMS (ESI) [M – H]–: calcd for C8H5N4O2S: 221.0139; found 
221.0130. 
3-(4-Hydroxyphenyl)-1H-1,2,4-triazole-5(4H)-thione (3-2a7) as a white solid 
(Yield: 80%). 1H NMR (300 MHz, DMSO-d6) δ 13.46 (s, 1H), 10.07 (s, 1H), 7.73 (d, 
J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 166.5, 
159.6, 150.5, 127.5, 116.4, 115.9. HRMS (ESI) [M – H]–: calcd for C8H6N3OS: 
192.0237; found 192.0245. 
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3-o-Tolyl-1H-1,2,4-triazole-5(4H)-thione (3-2a8) white solid (Yield: 85%): 1H 
NMR (300 MHz, DMSO-d6) δ 7.70 (d, J = 7.6 Hz, 1H), 7.54 – 7.22 (m, 3H), 2.55 (s, 
3H). 13C NMR (75 MHz, DMSO-d6) δ 168.05, 150.57, 137.25, 131.28, 130.23, 
128.67, 126.00, 125.00, 20.18.HRMS (ESI) [M – H]–: calcd for C9H8N3S, 190.0444; 
found 190.0441. 
3-Propyl-1H-1,2,4-triazole-5(4H)-thione (3-2a9) white solid (Yield: 71%): 1H NMR 
(500 MHz, DMSO-d6) δ 13.13 (d, J = 57.3 Hz, 1H), 2.49 (d, J = 6.6 Hz, 1H), 1.62 (d, 
J = 6.5 Hz, 2H), 0.88 (s, 3H).13C NMR (75 MHz, DMSO-d6) δ 165.92, 152.34, 26.90, 
19.80, 13.28. HRMS (ESI) [M – H]–: calcd for C5H8N3S: 142.0444; found 142.0438. 
3-Cyclohexyl-1H-1,2,4-triazole-5(4H)-thione (3-2a10) white solid (Yield: 83%): 1H 
NMR (500 MHz, DMSO-d6) δ 13.12 (d, J = 56.9 Hz, 2H), 2.57 (s, 1H), 2.02 – 1.54 
(m, 5H), 1.53 – 1.08 (m, 5H).13C NMR (75 MHz, DMSO-d6) δ 165.87, 156.12, 34.60, 
29.86, 25.21, 25.04. HRMS (ESI) [M – H]–: calcd for C8H12N3S: 182.0757; found 
182.0755. 
3-(Pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione (3-2a11) white solid (Yield: 76%): 
1H NMR (500 MHz, DMSO-d6) δ 8.60 (d, J = 5.2 Hz, 1H), 7.81 (d, J = 5.2 Hz, 
1H).13C NMR (125 MHz, DMSO-d6) δ 169.01, 154.45, 150.05, 137.69, 119.58. 
HRMS (ESI) [M – H]–: calcd for C7H5N4S: 177.0240; found 177.0235. 
3-(4-Aminophenyl)-1H-1,2,4-triazole-5(4H)-thione (3-2a12) light gray solid (Yield: 
61%). 1H NMR: (300 MHz, DMSO-d6) δ 13.36 (br, 1H), 13.32 (br, 1H), 7.56 (d, J = 
8.6 Hz, 2H), 6.60 (d, J = 8.6 Hz, 2H), 5.64 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 
166.0, 151.0 (2C), 127.0, 113.5, 112.3. HRMS (ESI) [M – H]–: calcd for C8H7N4S: 
191.0397; found 191.0392. 
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1H and 13C NMR data of compound 3-10 
Benzo[d]thiazole-2(3H)-thione (3-10a) white solid (Yield: 94%). 1H NMR (500 
MHz, DMSO-d6) δ 13.75 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.40 – 7.26 (m, 3H).13C 
NMR (125 MHz, DMSO-d6) δ 189.90, 141.28, 129.40, 127.23, 124.30, 121.83, 
112.50. HRMS (ESI) [M-H]-: calcd for C7H4NS2: 165.9791; found 165.9785. 
1H-Benzo[d]imidazole-2(3H)-thione (3-10b) light brown solid (Yield: 85%): 1H 
NMR (300 MHz, CDCl3) δ 11.35 (s, 1H), 7.29 – 7.20 (m, 2H), 7.20 – 7.11 (m, 2H); 
13C NMR (75 MHz, CDCl3) δ 169.78, 132.45, 122.42, 109.33; HRMS (ESI) [M-H]-: 
calcd for C7H5N2S: 149.0179; found 149.0179. 
 
1H and 13C NMR data of compound 3-11 
6-Nitrobenzo[d]thiazole-2(3H)-thione (3-11a) yellow solid (Yield: 48%): 1H NMR 
(500 MHz, DMSO-d6) δ 8.35 (d, J = 2.5 Hz, 1H), 8.08 (dd, J = 9.2, 2.5 Hz, 1H), 7.38 
(s, 2H), 6.90 (d, J = 9.2 Hz, 1H).13C NMR (125 MHz, DMSO-d6) δ 154.47, 135.13, 
132.10, 127.31, 113.80, 109.92, 102.38. HRMS (ESI) [M-H]-: calcd for C7H3N2O2S: 
210.9641; found 210.9633. 
5-Nitro-1H-benzo[d]imidazole-2(3H)-thione (3-11b) yellow solid (Yield: 65%): 1H 
NMR (300 MHz, Acetone-d6) δ 11.87 (s, 2H), 8.41 – 7.78 (m, 2H), 7.38 (d, J = 8.7 
Hz, 1H). 13C NMR (75 MHz, Acetone-d6) δ 172.90, 143.36, 137.29, 132.39, 118.84, 




1H and 13C NMR data of compound 3-3 
6-Aminobenzo[d]thiazole-2(3H)-thione (3-3a) brown solid (Yield: 74%). 1H NMR 
(500 MHz, DMSO-d6) δ 13.37 (s, 1H), 7.01 (d, J = 8.2 Hz, 1H), , 6.76 (s, 1H), 6.63 
(d, J = 8.2 Hz, 1H), 5.27 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ 184.8, 145.4, 
130.9, 129.8, 113.0, 112.0, 103.7. HRMS (ESI) [M + H]+: calcd for C7H7N2S2: 
183.0045; found 183.0041. 
5-Amino-1H-benzo[d]imidazole-2(3H)-thione (3-3b) brown solid (Yield: 67%). 1H 
NMR (500 MHz, DMSO-d6) δ 12.02 (s, 1H), 11.99 (s, 1H), 6.80 (d, J = 9.5 Hz, 1H), 
6.39 (t, J = 4.7 Hz, 2H), 4.92 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ 165.2, 
144.2, 132.6, 122.9, 109.0 (2C), 93.6. HRMS (ESI) [M – H]–: calcd for C7H6N3S: 
164.0288; found 164.0281. 
 
1H and 13C NMR data of compound 3-12 
N-Benzyl-2-bromoacetamide (3-12a) white solid (Yield: 72%). 1H NMR (500 MHz, 
CDCl3) δ 7.39 – 7.28 (m, 5H), 4.49 (d, J = 5.7 Hz, 2H), 3.93 (s, 2H); 13C NMR (125 
MHz, CDCl3) δ 165.4, 137.3, 128.9, 127.8, 127.7 44.2, 29.1. [1H and 13C NMR 
matching with reported values]110 
2-Bromo-N-(4-fluorobenzyl)acetamide (3-12b) white solid (Yield: 77%). 1H NMR 
(500 MHz, Acetone-d6): δ 7.98 (s, 1H), 7.38 – 7.34 (m, 2H), 7.10 – 7.05 (m, 2H), 4.42 
(d, J = 6.3 Hz, 1H), 3.93 (s, 2H); 13C NMR (125 MHz, Acetone-d6) δ 167.5, 163.5 (d, 
J = 242.9 Hz, 1C), 136.7 (d, J = 2.7 Hz, 1C), 131.0 (d, J = 8.3 Hz, 1C), 116.5 (d, J = 
22.0 Hz, 1C), 43.9, 30.2. HRMS (ESI) [M – H]–: calcd for C9H8BrFNO: 243.9779; 
found 243.9773. 
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2-Bromo-N-(4-methoxybenzyl)acetamide (3-12c) white solid (Yield: 76%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.22 (s, 1H), 7.49 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 
Hz, 2H), 4.38 (d, J = 5.7 Hz, 2H), 4.00 (s, 2H), 3.72 (s, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 164.2, 155.6, 131.7, 120.7, 113.9, 55.1,42.2, 30.4. [1H and 13C NMR 
matching with reported values]111  
2-Bromo-N-(4-methylbenzyl)acetamide (3-12d) white solid (Yield: 72%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.71 (s, 1H), 7.16 – 7.14 (m, 4H), 4.25 (d, J = 5.7 Hz, 2H), 
3.90 (s, 2H), 2.28 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.4, 136.5, 136.2, 
129.3, 127.8, 42.8, 29.9, 21.1. HRMS (ESI) [M – H]–: calcd for C10H11BrNO: 
240.0030; found 240.0024 
N-Benzyl-2-bromo-N-methylacetamide (3-12e) white solid ( Yield: 72%). 1H NMR 
(500 MHz, DMSO-d6) δ 8.71 (s, 1H), 7.16 – 7.14 (m, 4H), 4.25 (d, J = 5.7 Hz, 2H), 
3.90 (s, 2H), 2.28 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.4, 136.5, 136.2, 
129.3, 127.8, 42.8, 29.9, 21.1.  HRMS (ESI) [M – H]–: calcd for C10H11BrNO: 
240.0030; found 240.0021. 
2-Bromo-N-phenylacetamide (3-12f) white solid (Yield: 80%). 1H NMR (500 MHz, 
CDCl3) δ 8.18 (s, 1H), 7.52 (d, J = 7.6 Hz, 2H), 7.35 (t, J = 8.2 Hz, 2H), 7.17 (t, J = 
7.6 Hz, 1H), 4.01 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 163.4, 136.9, 129.1, 125.2, 
120.0, 29.4.  HRMS (ESI) [M – H]–: calcd for C8H7BrNO: 211.9717; found 211.9713 
2-Bromo-N-(4-chlorophenyl)acetamide (3-12g) white solid (Yield: 84%). 1H NMR 
(300 MHz, DMSO-d6) δ 10.51 (s, 1H), 7.61 (d, J = 8.9 Hz, 2H), 7.38 (t, J = 8.9 Hz, 
2H), 4.03 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 164.9, 137.5, 128.8, 127.4, 120.8, 
30.3.  HRMS (ESI) [M – H]–: calcd for C8H6BrClNO: 245.9327; found 245.9317. 
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2-Bromo-N-(4-fluorophenyl)acetamide (3-12h) white solid (Yield: 76%). 1H NMR 
(300 MHz, DMSO-d6) δ 10.43 (s, 1H), 7.60 (dd, J = 5.1 Hz, 8.8 Hz, 2H), 7.16 (t, J = 
8.8 Hz, 2H), 4.02 (s, 2H); 13C NMR (125 MHz, DMSO-d6) δ 164.7, 158.3 (d, J = 
240.1 Hz,1C), 134.9 (d, J = 1.8 Hz, 1C), 121.1 (d, J = 7.3 Hz, 1C), 115.4 (d, J = 22.0 
Hz, 1C), 30.2. HRMS (ESI) [M – H]–: calcd for C8H6BrFNO: 229.9622; found 
229.9628. 
2-Bromo-N-(4-methoxyphenyl)acetamide (3-12i) white solid (Yield: 68%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.22 (s, 1H), 7.49 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.8 
Hz, 2H), 4.00 (s, 2H), 3.72 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 164.2, 155.6, 
131.7, 120.7, 113.9, 55.1, 30.4. HRMS (ESI) [M – H]–: calcd for C9H9BrNO2: 
241.9822; found 241.9812. 
2-Bromo-N-p-tolylacetamide (3-12j) white solid (Yield: 83%): 1H NMR (500 MHz, 
DMSO-d6) δ 10.26 (s, 1H), 7.47 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 4.02 (s, 
2H), 2.25 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 167.42, 163.44, 135.05, 131.77, 
128.16, 118.19, 29.38, 19.40. HRMS (ESI) [M – H]–: calcd for C9H9BrNO: 225.9873; 
found 225.9866.  
2-Bromo-N-(4-ethylphenyl)acetamide (3-12k) brown solid (Yield: 77%). 1H NMR 
(500 MHz, DMSO-d6) δ 10.28 (s, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.2 Hz, 
2H), 4.02 (s, 2H), 2.55 (q, J = 7.6 Hz, 2H), 1.15 (t, J = 7.6 Hz, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 164.5, 139.2, 136.2, 128.0, 119.3, 30.4, 27.6, 15.6. HRMS (ESI) 
[M – H]–: calcd for C10H11BrNO: 240.0030; found 240.0020. 
2-Bromo-N-(4-propylphenyl)acetamide (3-12l) white solid (Yield: 87%): 1H NMR 
(500 MHz, CDCl3) δ 8.15 (s, 1H), 7.45 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 
4.03 (s, 2H), 2.69 – 2.47 (m, 2H), 1.76 – 1.47 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H).13C 
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NMR (125 MHz, CDCl3) δ 163.30, 139.84, 134.56, 129.05, 120.15, 77.29, 77.03, 
76.78, 37.46, 29.52, 24.51, 13.72. HRMS (ESI) [M – H]–: calcd for C11H13BrNO: 
254.0186; found 254.0184. 
2-Bromo-N-cyclohexylacetamide (3-12m) white solid (Yield: 82%). 1H NMR (300 
MHz, DMSO-d6) δ 8.15 (s, 1H), 3.79 (s, 2H), 3.51 – 3.48 (m, 1H), 1.74 – 1.64 (m, 
4H), 1.56 – 1.53 (m, 1H), 1.28 – 1.13 (m, 5H); 13C NMR (75 MHz, DMSO-d6): δ 
164.9, 48.0, 32.0, 29.8, 25.1, and 24.4. HRMS (ESI) [M + H]+: calcd for C8H15BrNO: 
220.0332; found 220.0333. 
2-Bromo-N-(3-chlorophenyl)acetamide (3-12n) white solid (Yield: 85%): 1H NMR 
(500 MHz, DMSO-d6) δ 9.67 (s, 1H), 7.87 (t, J = 1.8 Hz, 1H), 7.32 (t, J = 8.1 Hz, 
1H), 7.12 (dd, J = 8.3, 1.4 Hz, 1H), 4.04 (s, 2H).13C NMR (125 MHz, DMSO-d6) δ 
164.17, 139.25, 133.08, 129.40, 123.00, 118.40, 116.87, 29.37. HRMS (ESI) [M + 
H]+: calcd for C8H6ClBrNO: 245.9327; found 245.9320. 
2-Bromo-N-(3-fluorophenyl)acetamide (3-12o) white solid (Yield: 78%). 1H NMR 
(300 MHz, DMSO-d6) δ 10.60 (s, 1H), 7.58 (d, J = 11.4 Hz, 1H), 7.40 – 7.28 (m, 2H), 
6.91 (dt, J = 1.8 Hz, 8.0 Hz, 1H), 4.05 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ 
165.1, 162.1 (d, J = 241.9 Hz, 1C), 140.3 (d, J = 10.8 Hz, 1C), 130.5 (d, J = 9.2 Hz, 
1C), 115.0, 110.3 (d, J = 21.1 Hz, 1C), 106.0 (d, J = 26.5 Hz, 1C), 30.2. HRMS (ESI) 
[M – H]–: calcd for C8H6BrFNO: 229.9622; found 229.9612. 
2-Bromo-N-(3-ethylphenyl)acetamide (3-12p) golden brown gel (Yield: 79%): 1H 
NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.29 (dd, J = 8.7, 
6.7 Hz, 1H), 7.04 (d, J = 7.5 Hz, 1H), 4.05 (s, 2H), 2.68 (q, J = 7.6 Hz, 2H), 1.26 (t, J 
= 7.6 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 163.75, 135.37, 134.48, 129.08, 
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127.10, 126.4, 123.22, 30.14, 24.6, 14.27. HRMS (ESI) [M – H]–: calcd for 
C10H11BrNO: 240.0030; found 240.0019.  
2-Bromo-N-(3-methoxyphenyl)acetamide (3-12q) white solid (Yield: 76%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.34 (s, 1H), 7.27 (t, J = 2.2 Hz, 1H), 7.23 (t, J = 8.2 
Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 6.67 (dd, J = 2.6 Hz, 8.2 Hz, 1H), 4.02 (s, 2H), 3.73 
(s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 164.7, 159.5, 139.7, 129.6, 111.5, 109.2, 
105.0, 55.0, 30.4. HRMS (ESI) [M – H]–: calcd for C9H9BrNO2: 241.9822; found 
241.9817.  
 
1H and 13C NMR data of compound 3-14: 
N-Benzyl-2-(6-(2-bromoacetamido)benzo[d]thiazol-2-ylthio)acetamide (3-14a) 
white solid (Yield: 81%). 1H NMR (500 MHz, DMSO-d6) δ 10.67 (s, 1H), 8.81 (t, J = 
5.5 Hz, 1H), 8.37 (d, J = 0.8 Hz, 1H), 7.78 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 8.8 Hz, 
1H), 7.34 – 7.15 (m, 5H), 4.32 (d, J = 5.9 Hz, 2H), 4.19 (s, 2H), 4.09 (s, 2H).13C 
NMR (125 MHz, DMSO-d6) δ 166.40, 164.94, 164.85, 149.00, 138.97, 135.48, 
135.41, 128.20, 127.11, 126.78, 121.13, 118.61, 111.62, 42.52, 36.54, 30.33. HRMS 
(ESI) [M – H]–: calcd for C18H15 BrN3O2S2: 447.9795; found 447.9789. 
2-Bromo-N-(2-(2-(4-fluorobenzylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14b) white solid (Yield: 76%): 1H NMR (500 MHz, DMSO-d6) δ 
10.73 (s, 1H), 8.85 (t, J = 5.5 Hz, 1H), 8.38 (s, 1H), 7.76 (d, J = 8.8 Hz, 1H), 7.58 (d, 
J = 8.7 Hz, 1H), 7.28 (dd, J = 7.7, 5.9 Hz, 2H), 7.07 (t, J = 8.7 Hz, 2H), 4.29 (d, J = 
5.7 Hz, 2H), 4.18 (s, 2H), 4.12 (d, J = 14.1 Hz, 2H).13C NMR (125 MHz, DMSO-d6) 
δ 166.51, 165.01, 164.84, 162.14, 160.21, 149.02, 135.51, 135.25, 135.23, 129.17, 
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129.11, 121.17, 118.67, 115.04, 114.87, 111.64, 41.88, 36.59, 30.39. HRMS (ESI) [M 
– H]–: calcd for C18H14 BrFN3O2S2: 465.9700; found 465.9701.  
2-Bromo-N-(2-(2-(4-methoxybenzylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14c) white solid (Yield: 86%): 1H NMR (500 MHz, DMSO-d6) δ 
10.71 (s, 1H), 9.18 (s, 1H), 8.75 (t, J = 5.6 Hz, 1H), 8.39 (d, J = 0.9 Hz, 1H), 7.76 (d, 
J = 8.8 Hz, 1H), 7.57 (dd, J = 8.8, 1.4 Hz, 1H), 7.15 (d, J = 8.3 Hz, 2H), 6.80 (d, J = 
8.5 Hz, 2H), 4.23 (d, J = 5.7 Hz, 2H), 4.16 (s, 2H), 4.10 (s, 2H), 3.69 (s, 3H).13C 
NMR (125 MHz, DMSO-d6) δ 166.25, 164.97, 164.85, 158.21, 149.01, 135.51, 
135.46, 130.89, 128.51, 121.18, 118.60, 113.62, 111.59, 55.05, 42.02, 36.62, 30.37. 
HRMS (ESI) [M – H]–: calcd for C19H17 BrN3O3S2: 477.9900; found 477.9907. 
N-Benzyl-2-(6-(2-bromoacetamido)-1H-benzo[d]imidazol-2-ylthio)acetamide (3-
14d) white solid (Yield: 75%): 1H NMR (500 MHz, DMSO-d6) δ 10.71 (s, 1H), 8.84 
(s, 1H), 8.38 (s, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.58 (d, J = 8.6 Hz, 1H), 7.43 – 7.12 
(m, 5H), 4.32 (d, J = 5.6 Hz, 2H), 4.19 (s, 2H), 4.11 (s, 2H). 13C NMR (125 MHz, 
DMSO-d6) δ 166.45, 164.99, 149.03, 139.00, 135.51, 135.46, 128.24, 127.14, 126.82, 
121.16, 118.63, 111.63, 42.56, 36.58, 30.38. HRMS (ESI) [M – H]–: calcd for C18H16 
BrN4O2S: 431.0183; found 431.0186.  
2-Bromo-N-(2-(2-(4-fluorobenzylamino)-2-oxoethylthio)-1H-benzo[d]imidazol-6-
yl)acetamide (3-14e) white solid (Yield: 74%): 1H NMR (300 MHz, DMSO-d6) δ 
10.83 (s, 1H), 8.94 (d, J = 5.8 Hz, 1H), 8.21 (s, 1H), 7.90 – 7.43 (m, 2H), 7.14 (dd, J 
= 33.9, 25.7 Hz, 5H), 4.21 (m, 6H).13C NMR (75 MHz, DMSO-d6) δ 166.20, 165.16, 
162.82, 159.61, 149.86, 136.10, 134.92, 134.88, 133.16, 129.35, 129.24, 117.26, 
115.16, 114.87, 113.79, 102.86, 42.01, 35.86, 30.34. HRMS (ESI) [M – H]–: calcd for 
C18H15BrFN4O2S: 449.0089; found 449.0089.  
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N-Benzyl-2-(6-(2-bromoacetamido)benzo[d]thiazol-2-ylthio)-N-methylacetamide 
(3-14f) white solid (Yield: 73%). 1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 
10.33 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.54 – 7.48 (m, 3H), 
7.14 (d, J = 8.2 Hz, 2H), 4.36 (s, 2H), 4.07 (s, 2H), 2.54 (q, J = 7.6 Hz, 2H), 1.14 (t, J 
= 7.6 Hz, 3H); 13C NMR (125 MHz DMSO-d6) δ 164.9 (2C), 164.8, 149.0, 139.0, 
136.4, 135.5, 135.4, 127.9, 121.1, 119.2, 118.6, 111.6, 37.7, 30.3, 27.5, 15.6. HRMS 
(ESI) [M – H]–: calcd for C19H17BrN3O2S2: 461.9951; found 461.9956.  
2-Bromo-N-(2-(2-(4-methylbenzylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14g) white solid (Yield: 80%). 1H NMR (500 MHz, DMSO-d6) δ 
10.68 (s, 1H), 8.86 – 8.66 (m, 1H), 8.47 – 8.26 (m, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.56 
(d, J = 8.7 Hz, 1H), 7.09 (dd, J = 32.6, 7.6 Hz, 4H), 4.26 (d, J = 5.6 Hz, 2H), 4.17 (s, 
2H), 4.10 (s, 2H), 2.24 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.29, 164.93, 
164.84, 149.00, 135.90, 135.83, 135.48, 135.41, 128.75, 127.14, 121.13, 118.60, 
111.59, 42.30, 36.58, 30.33, 20.64. HRMS (ESI) [M – H]–: calcd for 
C19H17BrN3O2S2: 461.9951; found 461.9953.  
2-Bromo-N-(2-(2-(4-methoxybenzylamino)-2-oxoethylthio)-1H-benzo[d]imidazol-
6-yl)acetamide (3-14h) white solid (Yield: 83%). 1H NMR (500 MHz, DMSO) δ 
10.74 (s, 1H), 8.81 (t, J = 5.6 Hz, 1H), 8.19 (s, 1H), 7.64 (d, J = 8.8 Hz, 1H), 7.48 (dd, 
J = 8.7, 1.0 Hz, 1H), 7.14 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.5 Hz, 2H), 4.22 (d, J = 
5.4 Hz, 4H), 4.11 (s, 2H) 3.71 (s, 3H).13C NMR (126 MHz, DMSO) δ 166.61, 165.53, 
158.79, 150.30, 136.27, 131.06, 129.09, 117.41, 114.35, 114.16, 103.49, 55.56, 42.65, 
36.27, 30.82. 
2-Bromo-N-(2-(2-oxo-2-(phenylamino)ethylthio)benzo[d]thiazol-6-yl)acetamide 
(3-14i) white solid (Yield: 84%). 1H NMR (300 MHz, DMSO-d6) δ 10.78 (s, 1H), 
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10.52 (s, 1H), 8.40 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.59 (t, J = 6.9 Hz, 3H), 7.29 (t, J 
= 7.7 Hz, 2H), 7.03 (t, J = 7.2 Hz, 1H), 4.39 (s, 2H), 4.12 (s, 2H).13C NMR (75 MHz, 
DMSO-d6) δ 165.33, 165.06, 164.89, 149.03, 138.86, 135.58, 135.54, 128.89, 123.68, 
121.22, 119.28, 118.73, 111.68, 37.88, 30.47. HRMS (ESI) [M – H]–: calcd for 
C17H13 BrN3O2S2: 433.9638; found 433.9638.   
2-Bromo-N-(2-(2-(4-chlorophenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14j) white solid (Yield: 81%). 1H NMR (500 MHz, DMSO-d6) δ 
11.01 – 10.43 (m, 1H), 8.39 (s, 1H), 8.00 – 7.31 (m, 6H), 4.40 (s, 2H), 4.09 (s, 2H). 
HRMS (ESI) [M – H]–: calcd for C17H12 BrClN3O2S2: 467.9248; found 467.9248.  
2-Bromo-N-(2-(2-(4-fluorophenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14k) white solid (Yield: 75%). 1H NMR: (300 MHz, DMSO-d6): δ 
10.64 (s, 1H), 10.49 (s, 1H), 8.38 (d, J = 3.6 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.63 – 
7.51 (m, 3H), 7.16 (t, J = 8.9 Hz, 2H), 4.36 (s, 2H), 4.07 (s, 2H); 13C NMR (75 MHz, 
DMSO-d6): δ 165.9, 165.8, 165.5, 158.8 (d, J = 239.9 Hz, 1C), 149.5, 135.8 (d, J = 
17.6 Hz, 1C), 135.3, 135.3, 121.8 (d, J = 8.2 Hz, 1C), 121.7, 119.4, 115.9 (d, J = 22.0 
Hz, 1C), 112.3, 37.9, 30.5. HRMS (ESI) [M – H]–: calcd for C17H12BrFN3O2S2: 
451.9544; found 451.9548. 
2-Bromo-N-(2-(2-(4-methoxyphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14l) white solid (Yield: 74%). 1H NMR (500 MHz, DMSO-d6) δ 
10.61 (s, 1H), 10.27 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.54 – 
7.49 (m, 3H), 6.89 (d, J = 8.8 Hz, 2H), 4.34 (s, 2H), 4.07 (s, 2H), 3.71 (s, 3H); 13C 
NMR (125 MHz DMSO-d6) δ 164.9, 164.8, 164.6,155.4, 149.0, 135.5, 135.4, 131.8, 
121.1, 120.7, 118.6, 113.9, 111.6, 55.1, 37.6, 30.3. HRMS (ESI) [M – H]–: calcd for 
C18H15BrN3O3S2: 463.9744; found 463.9746. 
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2-Bromo-N-(2-(2-oxo-2-(p-tolylamino)ethylthio)benzo[d]thiazol-6-yl)acetamide 
(3-14m) white solid (Yield: 74%). 1H NMR (500 MHz, DMSO-d6) δ 10.60 (s, 1H), 
10.32 (s, 1H), 8.38 (s, 1H), 7.78 (d, J = 8.3 Hz, 1H), 7.53 – 7.46 (m, 3H), 7.11 (d, J = 
7.5 Hz, 2H), 4.36 (s, 2H), 4.08 (s, 2H), 2.24 (s, 3H); 13C NMR (125 MHz DMSO-d6) 
δ 164.89, 164.83, 148.96, 136.22, 135.47, 135.38, 132.52, 129.16, 121.13, 119.15, 
118.63, 111.86, 37.7, 30.29, 20.41. HRMS (ESI) [M – H]–: calcd for 
C18H15BrN3O2S2: 447.9781; found 447.9781. 
2-Bromo-N-(2-(2-(4-ethylphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14n) white solid (Yield: 78%). 1H NMR (500 MHz, DMSO-d6) δ 
10.61 (s, 1H), 10.33 (s, 1H), 8.38 (d, J = 1.9 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.54 – 
7.48 (m, 3H), 7.14 (d, J = 8.2 Hz, 2H), 4.36 (s, 2H), 4.07 (s, 2H), 2.54 (q, J = 7.6 Hz, 
2H), 1.14 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz DMSO-d6) δ 164.9, 164.8, 149.0, 
139.0, 136.4, 135.5, 135.4, 127.9, 121.1, 119.2, 118.6, 111.6, 37.7, 30.3, 27.5, 15.6. 
HRMS (ESI) [M-H]-: cald for C19H17BrN3O2S2: 461.9951; found 461.9935. 
2-Bromo-N-(2-(2-oxo-2-(4-propylphenylamino)ethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14o) white solid (Yield: 85%). 1H NMR (500 MHz, DMSO-d6) δ 
10.70 (s, 1H), 10.39 (s, 1H), 8.40 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.56 
(dd, J = 8.8, 2.0 Hz, 1H), 7.50 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 4.37 (s, 
2H), 4.10 (s, 2H), 2.64 – 2.34 (m, 3H), 1.73 – 1.38 (m, 2H), 0.86 (t, J = 7.3 Hz, 
3H).13C NMR (125 MHz, DMSO-d6) δ 163.95, 163.85, 148.00, 136.38, 135.49, 
134.49, 134.47, 127.58, 120.16, 118.21, 117.67, 110.65, 36.75, 35.66, 29.34, 23.08, 
12.56. HRMS (ESI) [M-H]-: cald for C20H19BrN3O2S2: 476.0108; found 476.0099. 
2-Bromo-N-(2-(2-(cyclohexylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14p) white solid (Yield: 86%). 1H NMR (300 MHz, DMSO-d6) δ 
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10.67 (s, 1H), 8.38 (d, J = 1.5 Hz, 1H), 8.20 (d, J = 7.7 Hz, 1H), 7.76 (d, J = 8.7 Hz, 
1H), 7.53 (dd, J = 1.7 Hz, 8.8Hz, 1H), 4.09 (s, 4H), 3.52 (s, 1H), 1.74 – 1.64 (m, 4H), 
1.54 – 1.51 (m, 1H), 1.27 – 1.15 (m, 5H); 13C NMR (75 MHz, DMSO-d6): δ 165.2, 
165.1, 164.9, 149.0, 135.4, 135.4, 121.1, 118.7, 111.6, 48.0, 36.9, 32.2, 30.3, 25.1, 
24.3. HRMS (ESI) [M – H]–: calcd for C17H19BrN3O2S2: 440.0108; found 440.0108. 
2-Bromo-N-(2-(2-(3-chlorophenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14q) white solid (Yield: 80%). 1H NMR (500 MHz, DMSO-d6) δ 
10.60 (s, 2H), 8.38 (s, 1H), 7.89 – 7.74 (m, 2H), 7.53 (dd, J = 8.8, 1.4 Hz, 1H), 7.45 
(d, J = 8.1 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 4.38 (s, 2H), 
4.07 (s, 2H); 13C NMR (125 MHz, DMSO-d6) δ 166.16, 165.40, 165.12, 149.44, 
140.64, 136.01, 135.93, 133.64, 131.02, 123.81, 121.66, 119.16, 119.14, 118.06, 
112.19, 38.19, 30.79. HRMS (ESI) [M – H]–: calcd for C17H13BrClN3O2S2: 467.9248; 
found 467.9257. 
2-Bromo-N-(2-(2-(3-fluorophenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14r) white solid (Yield: 75%). 1H NMR (300 MHz, DMSO-d6) δ 
8.39 (s, 1H), 7.78 (d, J = 8.9 Hz, 1H), 7.59 – 7.51 (m, 2H), 7.40 – 7.30 (m, 2H), 6.90 
(t, J = 7.5 Hz, 1H), 4.39 (s, 2H), 4.07 (s, 2H); 13C NMR (75 MHz, DMSO-d6): δ 
165.6, 164.9, 164.7, 162.1 (d, J = 241.5 Hz, 1C), 148.9, 140.4 (d, J = 11.0 Hz, 1C), 
135.5, 135.4, 130.5 (d, J = 9.3 Hz, 1C), 121.2, 118.7, 114.9, 111.7, 110.1 (d, J = 20.9 
Hz, 1C), 106.0 (d, J = 26.3 Hz, 1C), 37.7, 30.3. HRMS (ESI) [M – H]–: calcd for 
C17H12BrFN3O2S2: 451.9544; found 451.9546. 
2-Bromo-N-(2-(2-(3-ethylphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14s) white solid (Yield: 82%). 1H NMR (300 MHz, DMSO-d6) δ 
10.69 (s, 1H), 10.39 (s, 1H), 8.39 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.58 – 
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7.53 (m, 1H), 7.47 (s, 2H), 7.40 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.8 Hz, 1H), 6.91 (d, 
J = 7.6 Hz, 1H), 4.37 (s, 2H), 4.10 (s, 2H), 2.56 (q, J = 7.7 Hz, 2H), 1.15 (t, J = 7.6 
Hz, 3H).13C NMR (75 MHz, DMSO-d6) δ 165.11, 164.93, 164.83, 148.97, 144.38, 
138.76, 135.47, 135.45, 128.70, 123.10, 121.14, 118.64, 118.51, 116.62, 111.64, 
37.76, 30.33, 28.21, 15.47. HRMS (ESI) [M – H]–: calcd for C19H17BrN3O2S2: 
461.9951; found 461.9956. 
2-Bromo-N-(2-(2-(3-methoxyphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-
yl)acetamide (3-14t) white solid (Yield: 73%). 1H NMR (300 MHz, DMSO-d6) δ 
10.66 (s, 1H), 10.43 (s, 1H), 8.39 (d, J = 2.0 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.54 
(dd, J = 8.9 Hz, 2.1 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.22 (t, J = 8.1 Hz, 1H), 7.12 
(d, J = 8.7 Hz, 1H), 6.65 (dd, J = 7.8 Hz, 1H), 4.37 (s, 2H), 4.08 (s, 2H), 3.72 (s, 3H); 
13C NMR (75 MHz DMSO-d6) δ 171.1, 165.3, 164.3, 159.5, 148.7, 139.9, 135.5, 
135.3, 129.6, 120.9, 119.2, 111.8, 111.4, 109.0, 105.0, 61.9, 55.0, 37.8. HRMS (ESI) 
[M – H]–: calcd for C18H15BrN3O3S2: 463.9744; found 463.9745. 
2-Bromo-N-(2-(2-(4-ethylphenylamino)-2-oxoethylthio)-1H-benzo[d]imidazol-6-
yl)acetamide (3-14u) white solid (Yield: 73%). 1H NMR (500 MHz, DMSO-d6) δ 
10.77 (s, 1H), 10.46 (s, 1H), 8.19 (s, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.49 (dd, J = 15.3, 
5.0 Hz, 3H), 7.14 (d, J = 8.3 Hz, 2H), 4.42 (s, 2H), 4.11 (s, 2H), 2.54 (dd, J = 15.1, 
7.6 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H).13C NMR (125 MHz, DMSO-d6) δ 165.06, 
164.59, 154.22, 149.95, 139.19, 136.19, 135.92, 133.38, 127.98, 119.31, 117.08, 
113.81, 102.85, 36.81, 30.29, 27.53, 15.57. HRMS (ESI) [M – H]–: calcd for 




1H and 13C NMR data of compound 3-1a: 
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(benzylamino)-
2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a1) white solid (Yield: 83%). 
1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.80 (s, 1H), 8.34 (s, 1H), 7.77 (d, J 
= 8.9 Hz, 1H), 7.52 – 7.23 (m, 8H), 6.65 (d, J =  8.2 Hz, 2H), 5.58 (s, 2H),  4.32 (d, J 
= 5.7 Hz, 2H), 4.18 (s, 2H), 4.10 (s, 2H), 3.59 (s, 3H); 13C NMR (125 MHz, DMSO-
d6): δ 166.9, 166.6, 165.1, 156.6, 150.9, 149.5, 149.3, 139.5, 136.1, 136.0, 
129.8,128.7, 127.6, 127.3, 121.6, 119.1, 114.1, 113.9, 112.0, 43.0, 38.3, 37.0, 32.2. 
HRMS (ESI) [M - H]-: cald for C27H24N7O2S3: 574.1159; found 574.1169. 
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-
fluorobenzylamino)-2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a2) white 
solid (Yield: 71%): 1H NMR (500 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.78 (t, J = 5.7 
Hz, 1H), 8.31 (s, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.49 (dd, J = 8.8, 1.3 Hz, 1H), 7.38 (d, 
J = 8.5 Hz, 2H), 7.24 (dd, J = 8.1, 5.7 Hz, 2H), 7.03 (t, J = 8.7 Hz, 2H), 6.73 (d, J = 
8.4 Hz, 2H), 4.26 (d, J = 5.8 Hz, 2H), 4.14 (d, J = 2.3 Hz, 4H), 3.62 (s, 3H). 13C NMR 
(125 MHz, DMSO-d6) δ 166.49, 165.70, 164.64, 162.12, 160.19, 155.23, 150.58, 
150.10, 148.88, 135.57, 135.51, 135.18, 129.77, 129.13, 129.07, 121.15, 118.61, 
115.00, 114.83, 114.31, 111.53, 41.87, 40.00, 37.60, 36.52, 32.26. HRMS (ESI) [M - 
H]-: cald for C27H23FN7O2S3: 592.1065; found 592.1068. 
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-
methoxybenzylamino)-2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a3) 
white solid (Yield: 76%): 1H NMR (500 MHz, DMSO-d6) δ 10.86 (s, 1H), 8.81 (s, 
1H), 8.38 (s, 1H), 8.03 – 7.31 (m, 5H), 6.99 (m, 7H), 4.21 (br, 6H), 3.68 (br, 6H).13C 
NMR (125 MHz, DMSO-d6) δ 166.29, 165.75, 164.60, 158.20, 155.15, 150.49, 
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149.43, 148.85, 135.68, 135.48, 130.89, 129.81, 128.51, 121.13, 118.55, 114.70, 
113.62, 111.43, 55.04, 42.02, 37.62, 36.62, 32.33. HRMS (ESI) [M - H]-: cald for 
C28H26N7O3S3: 604.1265; found 604.1268. 
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(benzylamino)-
2-oxoethylthio)-1H-benzo[d]imidazol-6-yl)acetamide (3-1a4) white solid (Yield: 
63%). 1H NMR (500 MHz, DMSO-d6) δ 10.68 (s, 1H), 8.89 (s, 4H), 8.10 (s, 2H), 7.59 
(d, J = 8.7 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.7 Hz, 1H), 7.24 (tt, J = 
14.3, 7.1 Hz, 5H), 6.87 (d, J = 8.1 Hz, 2H), 4.31 (d, J = 5.7 Hz, 2H), 4.26 (s, 2H), 
4.22 (s, 2H), 3.72 (s, 3H); 13C NMR (500 MHz, DMSO-d6) δ 166.64, 165.40, 158.70, 
158.41, 151.85, 149.87, 138.81, 135.30, 135.06, 131.87, 130.20, 128.30, 127.21, 
126.90, 116.36, 115.14, 114.03, 103.38, 42.70, 37.54, 35.55, 32.68. HRMS (ESI) [M - 
H]-: cald for C27H25N8O3S3: 557.1547; found 557.1543.  
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-
fluorobenzylamino)-2-oxoethylthio)-1H-benzo[d]imidazol-6-yl)acetamide (3-1a5) 
white solid (Yield: 59%): 1H NMR (500 MHz, DMSO-d6) δ 10.74 (s, 1H), 8.96 (d, J 
= 4.8 Hz, 1H), 8.05 (s, 1H), 7.64 – 7.44 (m, 3H), 7.37 (d, J = 8.5 Hz, 1H), 7.33 – 7.21 
(m, 2H), 7.07 (t, J = 8.5 Hz, 2H), 6.83 (d, J = 8.1 Hz, 3H), 4.25 (dd, J = 35.0, 4.2 Hz, 
6H), 3.68 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.94, 165.44, 162.12, 160.20, 
154.97, 150.91, 149.69, 149.35, 136.31, 135.15, 134.63, 133.55, 129.96, 129.14, 
129.08, 115.49, 115.04, 114.93, 114.87, 114.07, 111.93, 103.50, 41.87, 37.66, 35.37, 
32.46. HRMS (ESI) [M - H]-: cald for C27H24FN8O2S2: 575.1453; found 575.1448. 
2-(5-(4-Aminophenyl)-4-ethyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(benzylamino)-2-
oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a6) white solid (Yield: 82%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.79 (s, 1H), 8.35 (s, 1H), 7.78 – 7.23 
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(m, 9H), 6.66 (d, J =  7.6 Hz, 2H), 5.55 (s, 2H), 4.33 (d, J = 5.1 Hz, 2H), 4.18 (s, 4H), 
4.00 (q, J = 7.0 Hz, 2H), 1.23 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ 
166.8, 166.4, 165.0, 156.0, 150.8, 149.2, 148.9, 139.3, 136.0, 135.9, 129.6, 128.6, 
127.5, 127.2, 121.5, 118.9, 114.0 (2C), 111.8, 42.9, 39.8, 38.1, 36.9, 15.5. HRMS 
(ESI) [M + Na]+: cald for C28H27N7NaO2S3: 612.1281; found 612.1282. 
2-(5-(4-Aminophenyl)-4-ethyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-
fluorobenzylamino)-2-oxoethylthio)-1H-benzo[d] thiazol-6-yl)acetamide (3-1a7) 
white solid (Yield: 60%). 1H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.81 (t, J = 
5.9 Hz, 1H), 8.35 (d, J = 1.8 Hz, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.52 (dd, J = 2.1 Hz, 
8.9 Hz, 1H), 7.31 – 7.24 (m, 3H), 7.08 (t, J = 8.9 Hz, 2H), 6.65 (d, J = 8.6 Hz, 2H), 
5.56 (s, 2H), 4.30 (d, J = 5.8 Hz, 2H), 4.17 (s, 2H), 3.99 (q, J = 7.2 Hz, 2H), 1.22 (t, J 
= 7.2, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.42, 165.96, 164.52, 162.08, 
160.16, 155.63, 150.36, 148.79, 148.53, 135.63, 135.46, 135.18, 135.16, 129.18, 
129.11, 129.05, 121.10, 118.54, 114.98, 114.81, 113.63, 113.56, 111.43, 41.82, 37.66, 
36.50, 15.09. HRMS (ESI) [M - H]–: calcd for C28H25FN7O2S3: 606.1221; found 
606.1236.  
N-Benzyl-2-(6-(2-(4-methyl-5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a8) white solid (Yield: 
77%). 1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.80 (s, 1H), 8.36 (s, 1H), 7.91 
– 7.64 (m, 3H), 7.55 (br, 4H), 7.24 (m, 5H), 4.33 (d, J = 4.8 Hz, 2H), 4.18 (m, 4H), 
3.64 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.89, 166.43, 165.11, 155.88, 
150.83, 149.35, 139.46, 136.09, 135.99, 130.45, 129.36, 128.82, 128.69, 127.61, 
127.50, 127.27, 121.61, 119.05, 111.97, 43.03, 38.11, 37.04, 32.30. HRMS (ESI) [M 
– H]–: calcd for C27H23FN6O2S3: 559.1050; found 559.1046. 
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N-(4-Fluorobenzyl)-2-(6-(2-(4-methyl-5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a9) light brown solid 
(Yield: 62%). 1H NMR (300 MHz, DMSO-d6) δ 10.83 (s, 1H), 8.94 (d, J = 5.8 Hz, 
1H), 8.21 (s, 1H), 7.81 – 7.42 (m, 3H), 7.41 – 6.86 (m, 7H), 4.21 (m, 9H).  13C NMR 
(125 MHz, DMSO-d6) δ 166.47, 165.96, 164.61, 162.12, 160.19, 155.41, 150.37, 
148.85, 135.62, 135.51, 135.22, 129.98, 129.14, 129.07, 128.89, 128.35, 127.01, 
121.15, 118.57, 115.01, 114.84, 111.50, 41.86, 37.63, 36.53, 31.82. HRMS (ESI) [M 
– H]–: calcd for C27H22FN6O2S3: 577.0956; found 577.0957. 
N-Benzyl-2-(6-(2-(4-ethyl-5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a10) white solid (Yield: 
64%). 1H NMR (500 MHz, DMSO-d6) δ 10.89 (s, 1H), 8.89 (s, 1H), 8.38 (s, 1H), 7.76 
(d, J = 8.2 Hz, 1H), 7.63 – 7.56 (m, 6H), 7.25 – 7.22 (m, 5H), 4.32 (d, J = 5.7 Hz, 
2H), 4.25 (s, 2H), 4.19 (s, 2H), 4.05 (q, J = 6.9 Hz, 2H), 1.22 (t, J = 6.9 Hz, 3H); 13C 
NMR (125 MHz, DMSO-d6): δ 166.4, 165.9, 164.5, 154.9, 149.7, 148.8, 139.0, 135.7, 
135.4, 130.0, 129.0, 128.3, 128.2, 127.2, 127.1, 126.7, 121.0, 118.5, 111.3, 42.5, 39.6, 
37.6, 36.5, 15.0. HRMS (ESI) [M – H]–: calcd for C28H25N6O2S3: 573.1207; found 
573.1207. 
N-Benzyl-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)benzo[d]thiazol-
2-ylthio)acetamide (3-1a11) light brown solid (Yield: 60%). 1H NMR (300 MHz, 
DMSO-d6) δ 10.60 (s, 1H), 8.80 (t, J = 6.5 Hz, 1H), 8.37 (s, 1H), 7.95 (d, J = 7.4 Hz, 
2H), 7.77 (d, J = 9.1 Hz, 1H), 7.56 – 7.47 (m, 4H), 7.29 – 7.21 (m, 4H), 4.32 (d, J = 
5.6 Hz, 2H), 4.18 (s, 2H), 4.15 (s, 2H); 13C NMR (125 MHz, DMSO-d6) δ 166.11, 
165.18, 149.87, 138.63, 136.23, 132.90, 129.13, 128.30, 127.28, 127.20, 127.11, 
126.95, 117.38, 113.76, 102.78, 42.72, 35.90, 30.33. HRMS (ESI) [M – H]–: calcd for 
C26H21N6O2S3: 545.0894; found 545.0898.  
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N-(4-Fluorobenzyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a12) white solid (Yield: 
64%). 1H NMR (500 MHz, DMSO-d6) δ 14.40 (s, 1H), 10.53 (s, 1H), 8.79 (s, 1H), 
8.38 (s, 1H), 7.95 (d, J = 6.3 Hz, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.56 – 7.48 (m, 4H), 
7.28 (br, 1H), 7.08 (t, J = 8.2 Hz, 1H), 4.30 (d, J = 5.0 Hz, 2H), 4.17 (s, 4H); 13C 
NMR (125 MHz, DMSO-d6): δ 166.4, 164.4, 162.1, 160.1, 148.7, 135.8, 135.4, 135.2, 
135.1, 130.0, 129.1, 129.0, 128.9, 125.9, 121.1, 118.5, 115.0, 114.8, 111.4, 41.8, 36.5, 
36.4. HRMS (ESI) [M – H]–: calcd for C26H20FN6O2S3: 563.0799; found 563.0806. 
N-(4-Methoxybenzyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a13) white solid (Yield: 
58%). 1H NMR (500 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.73 (t, J = 5.7 Hz, 1H), 8.40 
(d, J = 1.7 Hz, 1H), 8.11 – 7.90 (m, 2H), 7.77 (d, J = 8.8 Hz, 1H), 7.66 – 7.40 (m, 
4H), 7.17 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 4.26 (d, J = 5.8 Hz, 2H), 4.17 
(d, J = 3.6 Hz, 4H), 3.70 (s, 3H).13C NMR (125 MHz, DMSO-d6) δ 166.45, 166.25, 
164.46, 158.21, 148.77, 135.81, 135.50, 130.86, 129.93, 128.92, 128.49, 125.92, 
121.11, 118.52, 113.61, 111.39, 54.99, 42.03, 36.59, 36.47. HRMS (ESI) [M – H]–: 
calcd for C27H23N6O3S3: 575.0999; found 575.0996.  
N-(4-Methylbenzyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a14) white solid (Yield: 
63%). 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 8.76 (t, J = 5.7 Hz, 1H), 8.39 
(d, J = 1.3 Hz, 1H), 7.96 (d, J = 6.9 Hz, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.56 (dd, J = 
1.9 Hz, 8.8 Hz, 1H), 7.48 (m, 2H), 7.13 (d, J = 7.6 Hz, 2H), 7.06 (d, J = 8.2 Hz, 2H), 
4.27 (d, J = 5.7 Hz, 2H), 4.17 (s, 4H), 2.24 (s, 3H).13C NMR (125 MHz, DMSO-d6) δ 
166.79, 164.98, 149.25, 136.38, 136.33, 136.27, 135.96, 129.47, 129.44, 129.24, 
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127.63, 126.42, 121.58, 118.99, 111.87, 42.79, 37.05, 21.11. HRMS (ESI) [M – H]–: 
calcd for C27H23N6O2S3: 559.1050; found 559.1058.  
N-Benzyl-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)-1H-
benzo[d]imidazol-2-ylthio)acetamide (3-1a15) white solid (Yield: 59%). 1H NMR 
(500 MHz, DMSO-d6) δ 12.71 (s, 1H), 10.41 (d, J = 1.1 Hz, 1H), 8.83 (s, 1H), 7.98 (s, 
3H), 7.72 – 6.98 (m, 9H), 4.80 – 3.88 (m, 6H); 13C NMR (125 MHz, DMSO-d6) δ 
167.37, 165.92, 157.17, 156.94, 149.66, 139.01, 133.52, 133.49, 129.89, 128.94, 
128.20, 127.00, 126.70, 125.91, 114.04, 42.43, 36.55, 35.03. HRMS (ESI) [M - H]–: 
calcd for C26H23 FN7O2S2: 528.1282; found 528.1289. 
N-(4-Fluorobenzyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)-1H-
benzo[d]imidazol-2-ylthio)acetamide (3-1a16) white solid (Yield: 56%). 1H NMR 
(500 MHz, DMSO-d6) δ 14.42 (s, 1H), 12.55 (s, 1H), 10.31 (s, 1H), 8.78 (s, 1H), 7.97 
(br, 3H), 7.74 – 6.80 (m, 8H), 5.10 – 3.76 (m, 6H); HRMS (ESI) [M - H]–: calcd for 
C27H21 FN7O2S2: 546.1188; found 546.1208. 
N-(4-Methoxybenzyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)-1H-
benzo[d]imidazol-2-ylthio)acetamide (3-1a17) white solid (Yield: 65%). 1H NMR 
(500 MHz, DMSO-d6) δ 10.44 (s, 1H), 8.70 (s, 1H), 7.97 (d, J = 7.6 Hz, 1H), 7.49 – 
7.47 (m, 3H), 7.37 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 7.6 Hz, 1H), 7.14 (d, J = 7.6 Hz, 
2H), 4.23 (d, J = 5.0 Hz, 2H), 4.12 (s, 2H), 4.04 (s, 2H), 3.69 (s, 3H); 13C NMR (125 
MHz, DMSO-d6): 167.2, 165.9, 158.1, 157.4, 156.8, 149.6, 133.5, 130.8, 129.7, 
128.9, 128.3, 125.8, 114.0, 113.6, 55.0, 41.9, 36.5, 35.1. HRMS (ESI) [M - H]–: calcd 
for C27H24N7O3S2: 558.1388; found 558.1393. 
N-Benzyl-N-methyl-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a18) white solid (Yield: 
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65%). 13C NMR (125 MHz, DMSO-d6): δ. 167.8, 167.5, 165.8, 149.9, 138.3, 137.9, 
136.8, 136.5, 131.1, 130.0, 129.8, 129.5, 128.5, 128.1, 127.9, 127.0, 122.1, 119.6, 
112.5, 37.8, 37.5, 36.2, 34.9. HRMS (ESI) [M – H]–: calcd for C27H23N6O2S3: 
559.1052; found 559.1050. 
N-(2-(2-Oxo-2-(phenylamino)ethylthio)benzo[d]thiazol-6-yl)-2-(5-phenyl-4H-
1,2,4-triazol-3-ylthio)acetamide (3-1a19) white solid (Yield: 66%). 1H NMR (500 
MHz, DMSO-d6) δ 10.53 (s, 1H), 10.40 (s, 1H), 8.39 (s, 1H), 7.95 (d, J = 6.9 Hz, 2H), 
7.78 (d, J = 8.8 Hz, 1H), 7.60 – 7.48 (m, 6H), 7.32 (t, J = 7.6 Hz, 2H), 7.07 (t, J = 7.6 
Hz, 1H), 4.37 (s, 2H), 4.15 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ 166.5, 165.2, 
164.4, 148.7, 138.7, 135.8, 135.5, 130.4, 128.9, 128.8, 125.9, 123.6, 121.1, 119.2, 
118.6, 117.6, 111.4, 37.7, 36.3. HRMS (ESI) [M – H]–: calcd for C25H19N6O2S3: 
531.0737; found 531.0724. 
N-(4-Fluorophenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a20) white solid (Yield: 
68%). 1H NMR (300 MHz, DMSO-d6) δ 10.53 (s, 1H), 10.47 (s, 1H), 10.36 (s, 1H), 
8.38 (s, 1H), 7.95 – 7.93 (m, 2H), 7.78 – 7.76 (m, 2H), 7.62 – 7.48 (m, 5H), 7.19 – 
7.13 (m, 2H), 4.35 (s, 2H), 4.15 (s, 2H). HRMS (ESI) [M – H]–: calcd for 
C25H18FN6O2S3, 549.0643; found 549.0667; 13C NMR (75 MHz, DMSO-d6) δ 166.41, 
165.16, 164.37, 159.75, 156.57, 148.72, 135.82, 135.48, 135.13, 129.97, 128.93, 
127.93, 125.92, 121.10, 121.05, 120.94, 118.58, 115.55, 115.25, 111.45, 37.63, 36.45. 
HRMS (ESI) [M – H]–: calcd for C25H18FN6O2S3: 549.0643; found 549.0641. 
N-(4-Chlorophenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a21) white solid (Yield: 
64%). 1H NMR (500 MHz, DMSO-d6) δ 10.56 (s, 1H), 10.53 (s, 1H), 8.39 (s, 1H), 
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7.94 (m, 2H), 7.76 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.53 – 7.37 (m, 6H), 
4.37 (s, 2H), 4.13 (s, 2H). HRMS (ESI) [M – H]–: calcd for C25H18ClN6O2S3: 
565.0347; found 565.0361. 
N-(4-Methoxyphenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a22) white solid (Yield: 
67%). 1H NMR (500 MHz, DMSO-d6) δ 14.46 (s, 1H), 10.53 (s, 1H), 10.34 – 10.20 
(m, 2H), 8.39 (s, 1H), 7.96 (s, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 6.9 Hz, 1H), 
7.49 – 7.39 (m, 5H), 6.95 – 6.88 (m, 2H), 4.33 (s, 2H), 4.16 (s, 2H), 3.71 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6): δ 166.4, 164.4, 162.1, 160.1, 148.7, 135.8, 135.4, 135.2, 
135.1, 130.0, 129.1, 129.0, 128.9, 125.9, 121.1, 118.5, 115.0, 114.8, 111.4, 41.8, 36.5, 
36.4. HRMS (ESI) [M – H]–: calcd for C26H21N6O3S3: 561.0843; found 561.0847. 
N-(2-(2-Oxo-2-(p-tolylamino)ethylthio)benzo[d]thiazol-6-yl)-2-(5-phenyl-4H-
1,2,4-triazol-3-ylthio)acetamide (3-1a23) white solid (Yield: 70%). 1H NMR (500 
MHz, DMSO-d6) δ 14.36 (s, 1H), 10.55 (s, 1H), 10.31 (s, 1H), 8.38 (d, J = 1.7 Hz, 
1H), 8.06 – 7.87 (m, 2H), 7.77 (d, J = 8.8 Hz, 1H), 7.51 (m, 6H), 7.13 (t, J = 8.9 Hz, 
2H), 4.34 (s, 2H), 4.15 (s, 2H), 2.25 (s, 3H).13C NMR (125 MHz, DMSO-d6) δ 
165.38, 163.91, 163.45, 147.72, 135.22, 134.79, 134.45, 131.54, 128.96, 128.32, 
128.16, 127.93, 124.90, 120.08, 118.17, 117.56, 110.43, 36.72, 35.43, 19.40. HRMS 
(ESI) [M – H]–: calcd for C26H21N6O2S3: 545.0894; found 545.0896. 
N-(4-Ethylphenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a24) white solid (Yield: 
62%). 1H NMR (500 MHz, DMSO-d6) δ 14.56 (s, 1H), 10.55 (s, 1H), 10.34 (s, 1H), 
8.37 (s, 1H), 7.94 (d, J = 7.4 Hz, 2H), 7.78 (d, J = 8.7 Hz, 1H), 7.51 (m, 6H), 7.14 (m, 
2H), 4.33 (s, 2H), 4.15 (s, 2H), 2.53 (q, J = 7.5 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H).13C 
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NMR (125 MHz, DMSO-d6): δ 166.4, 164.9, 164.4, 148.7, 139.0, 136.4, 135.8, 135.4, 
130.0, 128.9, 128.0, 125.9, 121.1, 119.2, 118.6, 111.4, 37.7, 36.4, 27.5, 15.6. HRMS 
(ESI) [M – H]–: calcd for C27H23N6O2S3: 559.1050; found 559.1056. 
N-(2-(2-Oxo-2-(4-propylphenylamino)ethylthio)benzo[d]thiazol-6-yl)-2-(5-
phenyl-4H-1,2,4-triazol-3-ylthio)acetamide (3-1a25) white solid (Yield: 75%). 1H 
NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 10.37 (s, 1H), 8.40 (s, 1H), 7.95 (d, J = 
6.9 Hz, 2H), 7.78 (d, J = 8.6 Hz, 1H), 7.52 (m, 5H), 7.13 (d, J = 7.9 Hz, 2H), 4.36 (s, 
2H), 4.17 (s, 2H), 2.50 (br, 2H), 1.55 (m, 2H), 0.87 (t, J = 7.1 Hz, 3H). 13C NMR (125 
MHz, DMSO-d6) δ 165.45, 164.01, 163.53, 156.04, 155.97, 147.79, 136.42, 135.51, 
134.88, 134.52, 129.06, 127.99, 127.61,126.85, 125.00, 120.14, 118.24, 117.61, 
110.46, 36.79, 35.69, 35.50, 23.14, 12.58. HRMS (ESI) [M – H]–: calcd for 
C28H25N6O2S3: 573.1207; found 573.1209. 
N-(3-Fluorophenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a26) white solid (Yield: 
69%). 1H NMR (300 MHz, DMSO-d6) δ 10.81 (s, 1H), 10.64 (s, 1H), 8.38 (d, J = 1.7 
Hz, 1H), 7.95 (s, 1H), 7.93 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.59 – 7.29 (m, 7H), 6.90 
(t, J = 8.1 Hz, 1H), 4.38 (s, 2H), 4.10 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ 
166.4, 165.7, 164.3, 162.1 (d, J = 241.9 Hz, 1C), 157.2, 156.8, 148.7, 140.4 (d, J = 
11.0 Hz, 1C), 135.8, 135.5, 130.5 (d, J = 9.2 Hz, 1C), 121.1, 118.6, 115.0, 111.5, 
110.0 (d, J = 21.1 Hz, 1C), 106.0 (d, J = 26.6 Hz, 1C), 37.7, 36.5. HRMS (ESI) [M – 
H]–: calcd for C25H18FN6O2S3: 549.0643; found 549.0655. 
N-(3-Chlorophenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a27) white solid (Yield: 
73%). 1H NMR (500 MHz, DMSO-d6) δ 10.84 (s, 2H), 8.39 (s, 1H), 7.97 (s, 2H), 7.79 
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(d, J = 27.3 Hz, 2H), 7.46 (m, 6H), 7.12 (s, 2H), 4.39 (s, 2H), 4.14 (s, 2H). 13C NMR 
(125 MHz, DMSO-d6) δ 167.17, 166.24, 164.73, 157.92, 157.16, 149.17, 140.68, 
136.39, 135.94, 133.60, 130.98, 130.20, 129.34, 128.86, 126.38, 123.78, 121.58, 
119.16, 119.09, 118.10, 111.89, 38.13, 36.93. HRMS (ESI) [M – H]–: calcd for 
C25H18ClN6O2S3: 565.0347; found 565.0347.  
N-(3-Methoxyphenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a28) white solid (Yield: 
65%). 1H NMR (300 MHz, DMSO-d6) δ 10.53 (s, 1H), 10.40 (s, 1H), 8.38 (d, J = 1.8 
Hz, 1H), 7.95 – 7.93 (m, 2H), 7.77 (d, J = 8.9 Hz, 1H), 7.56 – 7.47 (m, 4H), 7.28 – 
7.19 (m, 2H), 7.11 (d, J = 7.9 Hz, 1H), 6.65 (dd, J = 2.4 Hz, 8.1 Hz, 1H), 4.36 (s, 2H), 
4.15 (s, 2H), 3.72 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ 165.23, 164.38, 159.53, 
148.73, 139.86, 135.79, 135.47, 129.59, 128.90, 125.92, 121.07, 118.59, 111.45, 
109.04, 105.03, 54.95, 37.79. HRMS (ESI) [M – H]–: calcd for C26H21N6O3S3: 
561.0843; found 561.0863. 
N-(3-Ethylphenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a29) white solid (Yield: 
83%): 1H NMR (500 MHz, DMSO-d6) δ 10.65 (s, 1H), 10.44 (s, 1H), 8.41 (s, 1H), 
8.20 – 7.08 (m, 10H), 6.91 (s, 1H), 4.37 (s, 2H), 4.18 (s, 2H), 2.55 (q, J = 6.2 Hz, 2H), 
1.14 (s, 3H).13C NMR (125 MHz, DMSO-d6) δ 166.48, 165.20, 164.51, 148.78, 
144.43, 138.81, 135.89, 135.50, 130.04, 128.98, 128.74, 126.00, 123.15, 121.14, 
118.61, 118.57, 116.67, 111.46, 37.80, 36.47, 28.27, 15.52. HRMS (ESI) [M – H]–: 
calcd for C27H23N6O2S3: 559.1050; found 559.1064. 
N-(4-Ethylphenyl)-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-ylthio)acetamido)-1H-
benzo[d]imidazol-2-ylthio)acetamide (3-1a30) white solid (Yield: 57%): 1H NMR 
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(500 MHz, DMSO-d6) δ 14.52 (s, 1H), 10.41 (s, 1H), 10.34 (s, 1H), 7.96 (br, 3H), 
7.45 (m, 6H), 7.24 (d, J = 8.3 Hz, 1H), 7.13 (d, J = 8.2 Hz, 2H), 4.25 (s, 2H), 4.15 (s, 
2H), 2.58 – 2.52 (m, 2H), 1.13 (t, J = 7.5 Hz, 3H).13C NMR (125 MHz, DMSO-d6) δ 
165.95, 165.78, 149.73, 138.95, 136.53, 133.86, 128.98, 128.01, 125.95, 119.16, 
114.42, 36.30, 27.59, 15.67. HRMS (ESI) [M – H]–: calcd for C27H24N7O2S2: 
542.1438; found 542.1453. 
N-(4-Ethylphenyl)-2-(6-(2-(4-methyl-5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a31) white solid (Yield: 
80%): 1H NMR (500 MHz, DMSO-d6) δ 10.58 (s, 1H), 10.35 (s, 1H), 8.37 (s, 1H), 
7.96 – 7.32 (m, 8H), 7.15 (s, 2H), 4.35 (s, 2H), 4.17 (s, 2H), 3.63 (s, 3H), 2.54 (br, 
2H), 1.14 (br, 3H).13C NMR (125 MHz, DMSO-d6) δ 165.94, 164.95, 164.64, 155.40, 
150.35, 148.84, 139.03, 136.45, 135.64, 135.50, 129.98, 128.88, 128.34, 128.02, 
127.00, 121.16, 119.27, 118.60, 111.52, 37.74, 37.61, 31.82, 27.59, 15.67. HRMS 
(ESI) [M – H]–: calcd for C28H25N6O2S3: 573.1207; found 573.1209. 
2-(5-(4-Aminophenyl)-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-ethylphenylamino)-2-
oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a32) white solid (Yield: 65%): 1H 
NMR (500 MHz, DMSO-d6) δ 10.70 (s, 1H), 10.46 (s, 1H), 8.39 (s, 1H), 7.90 (d, J = 
7.4 Hz, 2H), 7.77 (d, J = 8.3 Hz, 1H), 7.54 (m, 3H), 7.14 (m, 3H), 4.36 (s, 2H), 4.16 
(s, 2H), 2.53 (m, 2H), 1.14 (t, J = 7.0 Hz, 3H).13C NMR (125 MHz, DMSO-d6) δ 
165.52, 163.95, 163.43, 158.22, 147.71, 138.15, 138.02, 135.42, 134.84, 134.45, 
126.98, 126.70, 120.08, 118.28, 117.56, 114.68, 110.40, 36.73, 35.34, 26.56, 14.62. 
HRMS (ESI) [M - H]–: calcd for C27H24N7O2S3: 574.1159; found 574.1168. 
N-(4-Ethylphenyl)-2-(6-(2-(5-(4-nitrophenyl)-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a33) light brown solid 
126 
(Yield: 69%): 1H NMR (500 MHz, DMSO-d6) δ 14.49 (s, 1H), 10.57 (s, 1H), 10.31 
(s, 1H), 8.47 – 8.28 (m, 2H), 8.20 (d, J = 8.3 Hz, 2H), 7.78 (d, J = 8.8 Hz, 1H), 7.60 – 
7.40 (m, 3H), 7.15 (d, J = 8.4 Hz, 2H), 4.34 (s, 2H), 4.26 (s, 2H), 2.55 (q, J = 7.6 Hz, 
2H), 1.15 (t, J = 7.6 Hz, 3H).13C NMR (75 MHz, DMSO-d6) δ 166.18, 165.07, 
164.68, 148.89, 147.91, 139.19, 136.47, 135.77, 135.57, 128.08, 126.95, 124.34, 
121.22, 119.41, 118.72, 111.61, 37.78, 36.77, 27.66, 15.72.  HRMS (ESI) [M – H]–: 
calcd for C27H22N7O4S3: 604.0901; found 604.0899. 
N-(4-Ethylphenyl)-2-(6-(2-(5-(4-hydroxyphenyl)-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a34) white solid (Yield: 
60%): 1H NMR (500 MHz, DMSO-d6) δ 10.55 (s, 1H), 10.35 (s, 1H), 9.96 (s, 1H), 
8.39 (s, 1H), 7.77 (d, J = 8.2 Hz, 3H), 7.52 (m, 3H), 7.14 (d, J = 7.7 Hz, 2H), 6.86 (d, 
J = 8.0 Hz, 2H), 4.35 (s, 2H), 4.12 (s, 2H), 2.54 (q, J = 7.4 Hz, 2H), 1.14 (t, J = 7.4 
Hz, 3H). 13C NMR (125 MHz, DMSO-d6) δ 166.54, 164.96, 164.45, 159.23, 158.46, 
158.16, 156.66, 148.74, 139.06, 136.42, 135.85, 135.48, 128.00, 127.71, 121.10, 
119.31, 118.59, 115.70, 111.43, 37.73, 36.36, 27.58, 15.63. HRMS (ESI) [M – H]–: 
calcd for C27H23N6O3S3: 575.0999; found 575.0990. 
2-(5-Cyclohexyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-ethylphenylamino)-2-
oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a35) white solid (Yield: 66%): 1H 
NMR (500 MHz, DMSO-d6) δ 10.41 (s, 1H), 10.26 (s, 1H), 8.34 (d, J = 1.2 Hz, 1H), 
7.77 (d, J = 8.8 Hz, 1H), 7.60 – 7.38 (m, 3H), 7.15 (d, J = 8.3 Hz, 2H), 4.33 (s, 3H), 
4.03 (s, 3H), 2.70 (m, 1H), 2.55 (q, J = 7.5 Hz, 2H), 1.98 – 1.82 (m, 2H), 1.77 – 1.68 
(m, 2H), 1.64 (dd, J = 9.2, 3.4 Hz, 1H), 1.45 (m, 2H), 1.32 (m, 2H), 1.19 – 1.11 (m, 
4H). 13C NMR (125 MHz, DMSO-d6) δ 166.54, 164.94, 164.41, 162.18, 156.85, 
148.70, 139.03, 136.42, 135.83, 135.44, 127.98, 121.06, 119.28, 118.54, 111.37, 
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37.71, 36.19, 35.36, 30.78, 27.57, 25.31, 25.14, 15.62. HRMS (ESI) [M – H]–: calcd 
for C27H29N6O2S3: 565.1520; found 565.1536. 
N-(4-Ethylphenyl)-2-(6-(2-(5-propyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a36) white solid (Yield: 
56%): 1H NMR (500 MHz, DMSO-d6) δ 10.42 (s, 1H), 10.26 (s, 1H), 8.35 (s, 1H), 
7.77 (d, J = 8.7 Hz, 1H), 7.69 – 7.37 (m, 3H), 7.15 (d, J = 8.2 Hz, 2H), 4.34 (s, 2H), 
4.03 (s, 2H), 2.62 (t, J = 7.4 Hz, 2H), 2.56 (q, J = 7.5 Hz, 2H), 1.65 (m, 2H), 1.15 (t, J 
= 7.5 Hz, 3H), 0.88 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.55, 
165.00, 164.49, 158.27, 148.74, 139.08, 136.47, 135.85, 135.49, 128.05, 121.12, 
119.31, 118.56, 111.40, 37.75, 36.24, 27.79, 27.62, 20.64, 15.70, 13.48. HRMS (ESI) 
[M – H]–: calcd for C24H25N6O2S3: 525.1207; found 525.1199. 
N-(4-Ethylphenyl)-2-(6-(2-(5-o-tolyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a37) white solid (Yield: 
79%): 1H NMR (500 MHz, DMSO-d6) δ 14.14 (s, 1H), 10.46 (s, 1H), 10.27 (s, 1H), 
8.37 (s, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.65 (d, J = 7.4 Hz, 1H), 7.51 (m, 3H), 7.42 – 
7.23 (m, 3H), 7.15 (d, J = 8.0 Hz, 2H), 4.34 (s, 2H), 4.15 (s, 2H), 2.55 (q, 7.5 Hz, 2H), 
2.46 (s, 3H), 1.15 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, DMSO-d6) δ 166.27, 
164.83, 164.28, 148.65, 138.95, 136.41, 136.31, 135.75, 135.36, 131.02, 128.71, 
127.84, 125.75, 120.97, 119.24, 118.51, 111.33, 37.65, 36.35, 27.45, 20.62, 15.45. 
HRMS (ESI) [M – H]–: calcd for C28H25N6O2S3: 573.1208; found 573.1207. 
N-(4-Ethylphenyl)-2-(6-(2-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a38) white solid (Yield: 
61%): 1H NMR (500 MHz, DMSO-d6) δ 14.57 (s, 1H), 10.56 (s, 1H), 10.35 (s, 1H), 
8.37 (s, 1H), 7.86 (s, 1H), 7.77 (d, J = 8.7 Hz, 1H), 7.50 (dd, J = 17.9, 8.4 Hz, 3H), 
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7.14 (d, J = 8.2 Hz, 2H), 6.99 (d, J = 1.5 Hz, 1H), 6.66 (s, 1H), 4.34 (s, 2H), 4.15 (s, 
2H), 2.54 (dd, J = 15.0, 7.5 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 165.43, 165.01, 149.24, 139.52, 136.91, 136.21, 135.94, 128.49, 121.60, 
119.75, 119.05, 111.94, 38.19, 28.05, 16.14. HRMS (ESI) [M – H]–: calcd for 
C26H23N7O2S3: 560.1003; found 560.1001. 
2-(5-(4-Aminophenyl)-4-methyl-4H-1,2,4-triazol-3-ylthio)-N-(2-(2-(4-
ethylphenylamino)-2-oxoethylthio)benzo[d]thiazol-6-yl)acetamide (3-1a39) white 
solid (Yield: 57%): 1H NMR (500 MHz, DMSO-d6) δ 10.63 (s, 1H), 10.35 (s, 1H), 
8.36 (s, 1H), 7.78 (d, J = 8.6 Hz, 1H), 7.59 – 7.44 (m, 4H), 7.16 (t, J = 9.4 Hz, 2H), 
6.82 (d, J = 8.1 Hz, 1H), 4.35 (s, 3H), 4.22 (s, 2H), 3.69 (s, 3H), 2.55 (dd, J = 15.1, 
7.8 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H). HRMS (ESI) [M – H]–: calcd for C28H26N7O2S3: 
588.1316; found 588.1316. 
N-Cyclohexyl-2-(6-(2-(5-phenyl-4H-1,2,4-triazol-3-
ylthio)acetamido)benzo[d]thiazol-2-ylthio)acetamide (3-1a40) white solid (Yield:  
59%). 1H NMR (300 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.38 (s, 1H), 8.18 (d, J = 7.9 
Hz, 1H), 7.93 (m, 2H), 7.76 (d, J = 8.7 Hz, 1H), 7.53 – 7.51 (m, 4H), 4.13 (br, 2H), 
4.08 (s, 2H), 3.53 (m, 1H), 1.74 – 1.63 (m, 4H), 1.54 – 1.51 (m, 1H), 1.27 – 1.11 (m, 
5H); 13C NMR (125 MHz, DMSO-d6): δ 166.4, 165.2, 164.7, 159.3, 155.2, 148.8, 
135.7, 135.4, 130.3, 129.0, 126.8, 125.9, 121.0, 118.5, 111.4, 48.0, 36.9, 36.3, 32.1, 






Synthesis, In Vitro Evaluation and Docking Studies of (-)-4-Benzoyl-3-hydroxy-1-
(5-mercapto-1,3,4-thiadiazol-2-yl)-5-phenyl-1H-pyrrol-2(5H)-ones as  Potent 
Inhibitor of WNV NS2B-NS3 Protease 
 
4.1 Synthesis of analogues of the lead compound 
The general synthetic strategies of compounds 4-1a1 and 4-7 are shown in Scheme 
4.1. An appropriate methyl aryl ketone 4-3 was reacted with diethyloxalate in the 
presence of sodium ethoxide to produce 2,4-diketo ethyl ester 4-4, which was 
subsequently hydrolyzed to the target 2,4-diketoacids 4-5 with NaOH in a one pot 
reaction.112 Using this one pot reaction, without isolation of the ester 4-4, compound 
4-5 was obtained in higher yield than that with the isolation of the intermediate 4-4. 
On the other hand, compound 4-2 was synthesized from 5-sulfanyl-1,3,4-thiadiazol-2-
ylamine, which was reacted with different alkyl and benzyl bromide in ethanol at 
room temperature and in the presence of KOH.113 With 4-2 and 4-5 in our hands, we 
proceeded to synthesize the amide compound 4-6 which was obtained in a one pot 
procedure by first treating the acid 4-5 in dimethyl acetamide (DMA) with thionyl 
chloride and then reacting the intermediate with stoichiometric amounts of amine 4-2 
to give 4-6. DMA was used as it offers the rate and stability advantages over 
dimethylformamide (DMF).114,115 The cyclization reaction for forming the racemic 
compound 4-1a was performed either by the reaction of compound 4-6 and aryl 
aldehyde115 or by a three components reaction using 2,4-diketo ethyl ester 4-4, amine 
4-2 and the corresponding aldehyde.116 The reaction of 4-6 with aldehyde was 
investigated with various catalysts, solvents and at different temperature. A  
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Scheme 4.1 Synthesis of 4-1a and 4-7   
Reagents: (a) R3X,  KOH, EtOH, rt, 2h; (b) (COOEt)2, NaOEt, ethanol, rt, 14h;  (c) 
NaOH, H2O, rt, 4h; (d) SOCl2, DMA, 0 °C, 15min; (e) Compound 4-2, rt, 4h; (f) 
R2CHO, toluene,  20 mol% piperidine/acetic acid (1:1), 70 °C, 12h; (g)  R2CHO, 4-2, 
toluene, 20 mol% piperidine/acetic acid (1:1), 70 °C, 12h (h) R4NH2,  dioxane, reflux, 
(i) SnCl2.H2O, EtOH, reflux; (j) m-CPBA, DCM, 0-5 °C, 2.5 h; (k) MeOH, PPh3, 
DIAD, 0 °C-rt, 15 h. 
 
combination of piperidine/AcOH (entry 10) was found to give better yield (60%) in 
toluene at 70 °C. Alternatively, the synthesis of compound 4-1a in a three component 
reaction, at 70 °C in 1,4-dioxane gave better yield than in a two component reaction 
(amide 4-6 and aldehyde). Compound 4-1a30 i.e 4-aminophenyl group at R1 was  
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Table 4.1 Optimization of cyclization reaction to prepare compound 4-1a 
Entry  Catalysis  Solvent Time (h) Temperature Yield 
1 NaOEt Ethanol 12  rfa NA 
2 DBU Toluene 12  rf NA 
3 TMSCl DMF 12  rf NA 
4 Pyridine Toluene 12  rf NA 
5 Piperidine Ethanol 12  rf NA 
6 Piperidine/AcOH  Ethanol  12  rf NA 
7b Piperidine/AcOH 
AcOH 
ACN 0.5  110 °C NA 
8 Piperidine/AcOH THF 12  rf Trace 
9 Piperidine/AcOH Toluene 12  rf 25% 
10 Piperidine/AcOH Toluene 12  70 °C 60% 
[a] rf: reflux; [b] Microwave heating 
 
 
synthesized by reduction of the 4-itrophenyl group of compounds 4-1a29 with 
stannous chloride in ethanol under reflux condition (Scheme 4.1B). Since the best  
inhibitor of the WNV NS2B-NS3 protease reported till date are several sulphone 
derivatives, therefore the sulfide group in 4-1a16 was oxidized to the corresponding 
sulphone to yield compound 4-1a33 (Scheme 4.1C). To explore the importance of the 
enolic hydrogen on the compound’s biological activity, we replaced hydrogen in 4-
1a16 with  methyl group by Mitsunobu reaction.117 To increase the diversity of 
compound 4-1a, the enolic hydroxyl was replaced with 2-hydroxyethylamino group 
Scheme 4.2 Synthesis of compounds 4-8 and 4-9  
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by the reaction of 2-aminoethanol and 4-1a in refluxing anhydrous dioxane118 to 
obtain the desired product 4-7 (Scheme 4.1A). To investigate the importance of the 
thiadiazole ring in compound 4-1a on inhibition activity, structural modifications that 
replaced the enol moiety on the thiadiazole ring with different substituted amine 
groups were achieved using the synthetic strategy shown in Scheme 4.2. To obtain 
compound 4-8, a three-component reaction was applied starting from alkyl 
oxalacetate 4-4 with several amines and aldehydes at room temperature and further 
modification was achieved by replacing the enolic hydroxyl group in compound 4-8 
with various amine to obtain compound 4-9. 
 
4.2 Structure-activity relation studies 
A representative set of 39 analogs of compound 4-1a was synthesized and tested in a 
WNV NS2B-NS3 protease assay at 200 µM concentration to identify potential 
inhibitors. Inhibitors exhibiting more than 50% inhibition were further evaluated for 
their effects at different concentrations and the IC50 values of each compound were 
calculated using the Graphpad Prism software (Table 4.1). The fluorogenic peptide 
Pyr-RTKR-AMC was used as a substrate for the WNV NS2B-NS3 protease and the 
Km value was determined, using the protocol from the SensoLyte® 440 West Nile 
Virus Protease Assay Kit, to be 3.45±0.41 µM. 
In our preliminary SAR study, R1, R2 and R3 in compound 4-1a1 were replaced with 
substituted phenyl groups having electron donating and withdrawing characters 
(Table 1. cpds 4-1a2 to 4-1a13). Although, these changes did not provide any 
significant improvement in the biological activity, the presence of p-Cl-phenyl group 
at R1 and R2 positions and a phenyl group at R3 position (Table 1, cpd 4-1a13) 
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showed relatively better activity compared to the other changes. Therefore, we 
proceeded to screen the inhibitory activity of compounds by varying the substituent 
on the R3 position whilst keeping the substituents on R1 and R2 unchanged. This was 
achieved by decorating the R3 position with different sizes of alkyl chains as well as 
alkyl chains with functional groups of ethylester, cyanide and alcohol. The best 
inhibition was observed in compound 4-1a16 which contains an n-Pr group at the R3 
position. Further tuning of compound 4-1a16 by varying with halide through different 
position on phenyl ring (Table 1, cpd 4-1a23 to 4-1a28) did not result in further 
improvement of the inhibitory activity confirming the importance of the p-Cl-phenyl 
group in the compound’s inhibitory activity. In addition, biological screening result of 
compound 4-1a16 with an electron donating or withdrawing functional group 
containing phenyl ring at R1 and R2  
Table 4.2 IC50 values of compounds a 4-1a, 4-7, 4-8 and 4-9  
Cpd  R1 R2 R3 R4 IC50 
4-1a2 4-Cl-Ph 3,4-CPhCl2Ph 4-F-PhCH2 - 118±8.4 
4-1a3 Ph Ph PhCH2 - 151±21.6 
4-1a4 Ph Ph 4-F-PhCH2 - 44.8±5.7 
4-1a5 Ph 4-MeS-Ph 4-F-PhCH2 - 26.8±4.5 
4-1a6 3-MeO-Ph Ph 4-F-PhCH2 - 79.6±6.2 
4-1a7 Ph 4-F-Ph PhCH2 - 24.5±4.0 
4-1a8 Ph 4-F-Ph 4-MeO-PhCH2 - 41.3±3.7 
4-1a9 Ph 4-MeS-Ph 4-MeO-PhCH2 - 31.1±2.5 
4-1a10 4-Cl-Ph Ph PhCH2 - 35.5+4.1 
4-1a11 4-Cl-Ph 2-Furyl PhCH2 - 38.3±5.1 
4-1a12 4-Cl-Ph 4-MeO-Ph PhCH2 - 34.4±3.4 
4-1a13 4-Cl-Ph 4-Cl-Ph PhCH2 - 21.4±3.1 
4-1a14 4-Cl-Ph 4-Cl-Ph CH3 - 124±5.1 
4-1a15 4-Cl-Ph 4-Cl-Ph CH(CH3)2 - 42.5±5.5 
4-1a16 4-Cl-Ph 4-Cl-Ph CH2CH2CH3 - 6.1±1.9 
4-1a17 4-Cl-Ph 4-Cl-Ph (CH2)3CH3 - 11.4±2.6 
4-1a18b 4-Cl-Ph 4-Cl-Ph CH(CH2)4 - 11.9±1.5 
4-1a19 4-Cl-Ph 4-Cl-Ph (CH2)4CH3 - 70.0±7.1 
4-1a20 4-Cl-Ph 4-Cl-Ph CH2CH2OH - >200 
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4-1a21 4-Cl-Ph 4-Cl-Ph CH2COOEt - >200 
4-1a22 4-Cl-Ph 4-Cl-Ph CH2CH2CN - >200 
4-1a23 4-Cl-Ph 4-F-Ph CH2CH2CH3 - 24.5±3.4 
4-1a24 4-Cl-Ph 4-Br-Ph CH2CH2CH3 - 30.6±0.8 
4-1a25 4-Cl-Ph 3-Cl-Ph CH2CH2CH3 - 51.5±2.3 
4-1a26 4-F-Ph 4-Cl-Ph CH2CH2CH3 - 32±2.08 
4-1a27 4-Br-Ph 4-Cl-Ph CH2CH2CH3 - 58.6±7.3 
4-1a28 4-I-Ph 4-Cl-Ph CH2CH2CH3 - NA 
4-1a29 4-NO2-Ph 4-Cl-Ph CH2CH2CH3 - 32.6±11.1 
4-1a30 4-NH2-Ph 4-Cl-Ph CH2CH2CH3 - 38.8±7.5 
4-1a31 4-Cl-Ph 4-NO2-Ph CH2CH2CH3 - 19.7±5.3 
4-1a32 2Benzofuryl 4-Cl-Ph CH2CH2CH3  21.3±0.6 
4-1a33 4-Cl-Ph 4-Cl-Ph SO2CH2CH2C
H3 
 NAc 
4-1a34 4-Cl-Ph  4-Cl-Ph  CH2CH2CH3  CH3 NA 
4-7 4-Cl-Ph 4-F-Ph 4-F-PhCH2 CH2CH2OH NA 
4-8a CH3 Ph CH3 - NA 
4-8b CH3 Ph PhCH2 - NA 
4-9a CH3 Ph PhCH2 H NA 
4-9b CH3 Ph PhCH2 CH3 NA 
4-9c CH3 Ph PhCH2 CH2CH2OH NA 
[a] Data represent the concentrations required to inhibit the WNV NS2B-NS3 
protease activity by 50% and are the mean±SE of triplicate experiments; compounds 
used are ≥95% pure. [b] R3= cyclopentyl. [c] NA = no activity. 
 
positions did not result in further improvement of the biological activity. However, 
replacement of R1 group with benzofuryl showed moderate activity (Table 1, cpd 4-
1a32). To investigate the effect of the enolic hydrogen, we replaced it with methyl 
group and oxidized the bonded to R3 in compound 4-1a16 to a sulphone (Table 1, cpd 
4-1a33). However these compounds did not show any biological activity. Next, we 
examined the importance of the hydroxyl group on inhibition potency against WNV 
NS2B-NS3 protease by replacing the enolic hydroxyl with 2-hydroxyethylamino 
group (Table 1, cpd 4-7). However, this compound completely lost its inhibitory 
activity against WNV protease. Finally, we investigated the importance of the 
thiadiazole ring for inhibiting the protease activity. A series of compounds (4-8 and 4-
9) where the thiadiazole ring was replaced by simple amine groups were synthesized 
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and tested for their inhibition activities. Unfortunately, these compounds also showed 
no inhibitory activity against the WNV NS2B-NS3 protease. The stabilities of 
compounds 4-1a13, 4-1a16 and 2-1a17 in pH 8 buffer were determined by analyzing 
the amount of compound remaining with time using LCMS-IT-TOF detection. 
Quantization of the compounds was determined by Shimadzu's LCsolution software. 
Compounds 4-1a13, 4-1a16 and 4-1a17 showed excellent stability in a pH 8 buffer. 
Considering that the compounds tested thus far were always racemate, we proceeded 
to investigate the influence of stereochemistry on the compounds’ biological 
activities. Compounds 4-1a13, 4-1a16 and 4-1a17 which showed comparatively 
better inhibition results were selected for chiral separation. Table 4.3 showed that the 
inhibition results of the (-) and (+) enantiomers of compound 4-1a13, 4-1a16, 4-1a17.  
Table 4.3, The inhibition results of enantiomers from selected racemic compounds 
Entry cpd Optical rotation IC50(μM) Ki (μM) 
  racemic 21.4±9.1  
1 4-1a13 - 16.6±0.4 13.76±0.33 
  + 62.8±6.1  
  racemic 6.1±1.9  
2 4-1a16 - 2.2±0.7 1.82±0.58 
  + 90.4±28.3  
  racemic 11.4±2.6  
3 4-1a17 - 7.2±0.3 5.97±0.25 
  + 22.3±0.5  
 
The results show that the (-) enantiomer demonstrated much better inhibition potency 
than the corresponding (+) enantiomer. Among these enantiomers, the (-) enantiomer 
of compound 4-1a16 exhibited the best inhibition activity with an IC50 value of 
2.2±0.7 μM.   
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 Figure 4.1 MTS assay results obtained at incubation times of 24 h (     ), 48 h (     ) 
and 72 h (  ) with the BHK21 cell line. Compounds were added at a final 
concentration of 25 µM. 
 
Next we evaluated the cytotoxicities of compounds (-)-4-1a13, (-)-4-1a16 and (-)-4-
1a17 against baby hamster kidney fibroblast (BHK21 cells) at three different 
incubation timings. Vehicular control, dimethyl sulfoxide (DMSO), was also included 
to serve as control as the test compounds were dissolved in DMSO. The amount of 
DMSO used in the assay was controlled at 0.1% of the total volume. This is to ensure 
that DMSO does not result in cytotoxicity of cells. From the results obtained (Figure 
4.1), compounds (-)-4-1a13, (-)-4-1a16 and (-)-4-1a17 were shown to be non-
cytotoxic to BHK21 cells. 
To determine the mode of inhibition of the WNV NS2B-NS3 protease activity by the 
(-) enantiomer of compound 4-1a16, we performed the kinetics of inhibition using  
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Figure 4.2 Uncompetitive inhibition of (-)-4-1a16 with WNV NS2B-NS3 protease. 
WNV protease assays were performed at various concentrations of (-)-4-1a16 (0, 2.5, 
5.0, 10, and 25μM) and substrate concentrations (3.3, 8.3, 16.7, 33.3, 83.3, 166.7μM). 
Double reciprocal plots of 1/V versus 1/[S] for (-)-4-1a16 at each inhibitor 
concentration were plotted using the Microsoft excel 2007. 
 
Pyr-RTKR-AMC as substrate. Four different inhibitor concentrations and a no-
inhibitor control (0 to 25 μM) were each assayed at six or more substrate 
concentrations ranging from 3.3 μM to 166.7 μM. In each assay, the enzyme and 
inhibitor were incubated at 37 °C temperature for 15 min, followed by the addition of 
the substrate to start the kinetic measurement. The rate of substrate cleavage (v) was 
monitored using an Infinite F200 microplate reader. To illustrate the inhibition 
mechanism, double reciprocal plots of 1/V versus 1/[S] at each inhibitor concentration 
were plotted using Microsoft Excel (Figure 4.2). The parallel lines for the control data 
and the plus inhibitor data in the double reciprocal plots of 1/V versus 1/[S] at each 
inhibitor concentration were consistent with an uncompetitive mechanism of 
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inhibition of the WNV NS2B-NS3 protease. Ki values were calculated from the IC50 
values according to the equation, Ki = IC50 / (1+ Km /[S])119 for uncompetitive 
inhibition (Table 4.3). The experiments were repeated three times with similar results. 
Further investigation of the inhibition mechanism of (-) enantiomer of compound 4- 
4-1a17 was found to be uncompetitive inhibitor in absence of charge on the inhibitor 
that prefers active site of the protease. 
 
4.3 Docking analysis  
A docking study was performed to rationalize the inhibition and kinetics result as well 
as to identify possible binding site of compound 4-1a16 on NS2B-NS3 protease. The 
crystal structure of the WNV NS2B-NS3 protease in complex with peptide Bz-Nle-
Lys-Arg-Arg-H (pdb 2fp7) has been reported earlier.74  We performed in silico 
docking study with Molecular Operating Environment (MOE) using this reported 
crystal structure coordinates. Since compound (-)-4-1a16 is an uncompetitive 
inhibitor of the WNV NS2B-NS3 protease, we focussed our analysis on regions 
beyond the substrate binding sites. Earlier studies have shown that the integration of 
residues 78-87 of NS2B into the protease-cofactor complex affected the formation of 
the catalytic active sites.74,75,105  Deletion or mutagenesis of these residues produced 
an inert enzyme. Therefore, the region on the NS3 protease, where key interactions 
with the NS2B cofactor (residues 78-87) occur, is important for the NS2B-NS3 
protease activity and particularly attention was paid to this region during our docking 
studies. 
Since compound 4-1a16 contains a chiral centre, the R- and S-enantiomers were 
separately analyzed for their interactions with the WNV NS2B-NS3 protease. Our 
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docking analysis suggested that both enantiomers bind to NS3 protease with 
 
 Figure 4.3 Molecular docking of compound 4-1a16 onto WNV NS2B-NS3 protease. 
The WNV protease crystal structure coordinates (pdb 2fp7)74 were used for the 
molecular docking. The NS2B-NS3 protease and the enantiomers of compound 4-
1a16 are shown as a wireframe and flat ribbon model generated using Discovery 
Studio 3.1 client. (a) R-enantiomer; (b) S-enantiomer. 
 
good shape and complementarities. The amino acid residues that are in close 
proximity (less than 5 Å) to the atoms of the R-enantiomer include Arg78, Leu79 and 
Phe85 of NS2B; Trp69, Lys73, Glu74, Arg76, Lys88, Thr118, Pro119, Glu120, 
Gly121, Glu122, Ile123, Gln167, Gly168 and Glu169 of the NS3 protease. Amino 
acid residues that are in close proximity (less than 5 Å) to the atoms of the S-
enantiomer are Val77, Arg78, Leu79 and Phe85 of NS2B; Trp69, Lys73, Glu74, 
Arg76, Trp83, Lys88, Thr118, Pro119, Glu120, Ile123, Val166, Gln167, Gly168 and 
Glu169 of the NS3 protease. The guanidine group in Arg76 of the NS3 protease is 
bound to the thiodiazole group of both enantiomers via π-cation type of interaction. In 
addition, the R-enantiomer could potentially form hydrogen bonds with residue 
Glu169 and Glu120 as well as π-cation type of interactions with Lys88 on the NS3 
protease (Figure 4.3a).  On the other hand, a π-cation type of interaction was also 
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observed between acetophenyl group of S-enantiomer and protonated amino group 
from Lys73 on NS3 protease (Figure 4.3b). Bound enantiomers very closely interact 
with amino acid residue Leu-79 of NS2B and that might thus interfere with the 
productive associations of NS2B with NS3protease. However, docking analysis 
predicted that the dock score of the R- enantiomer (-28.56 kJ/mol) is higher than the 
S-enantiomer (-24.04 kJ/mol). This indicates that the R-enantiomer is a preferred 
isomer for the inhibition of the WNV NS2B-NS3 protease which is in agreement with 
the experimental inhibition result obtained for (-)-4-1a16. 
 
4.4 Conclusion 
In this study, a primary screening of 110 compounds has led to the discovery of an 
initial “hit” compound with promising therapeutic indices and activity against WNV 
NS2B-NS3 protease. Based on this initial “hit” compound, we have designed and 
developed a focused chemical library to further evaluate the initial “hit” and gain 
insight into the requirements for activity. In the evaluation, compound (-)-4-1a16 with 
Ki value of 1.82±0.58 μM was identified to be an uncompetitive inhibitor of the WNV 
NS2B-NS3 protease. 
 
4.5 Experimental section 
4.5.1 Chemistry 
All chemical reagents were obtained from Aldrich, Merck, Lancaster or Fluka and 
used without further purification. Analytical TLC was carried out on pre-coated plates 
(Merck silica gel 60, F254) and visualized with UV light or stained with ninhydrin. 
141 
Flash column chromatograph was performed with silica (Merck, 70-230 mesh). Final 
compounds for biological assay were purified on a Gilson preparative HPLC system 
with a Waters C18 column (250 x 10.0 mm, 5 μm). Detection was conducted at 254 
nm, The mobile phase was a gradient with solvent B increasing from 5% to 100% 
over 40 min and a flow rate of 5.0ml/min. Solvent A was 0.1% trifluoroacetic acid in 
water, and solvent B was 0.1% trifluoroacetic acid in acetonitrile. The purities of the 
compounds were determined via analytical HPLC using a Shimadzhu LCMS-IT-TOF 
system with a Phenomenex Luma C18 column (50 x 3.0 mm, 5 μm). Detection was 
conducted at 254 nm, and integration was obtained with a Shimadzhu LCMS solution 
software. The mobile phase was a gradient with solvent B increasing from 0% to 
100% over 7 min and a flow rate of 0.8 ml/min. Compounds used in biological assay 
has purities of at least 95%. Racemic compound separation was performed on a 
Shimadzhu HPLC system with a Chiralpak AD-H column (250 x 4.6 mm, 5 μm), 
eluted with hexanes/iPrOH (80:20) or Chiralpak IC column (250 x 4.6 mm, 5 μm), 
eluted with 100% CHCl3 with 0.1% TFA at 1.0 ml/min, γ =254 nm. 1H NMR and 13C 
NMR spectra were measured at 298 K on a Bruker ACF 300 or AMX 500 Fourier 
Transform spectrometer. Chemical shifts were reported in δ (ppm) relative to the 
residual undeuterated solvent which was used as internal reference. The signals 
observed were described as: s (singlet), d (doublet), t (triplet), m (multiplet). The 
number of protons (n) for a given resonance was indicated as nH. Mass spectra were 
performed on Finnigan MAT 95/XL-T spectrometer under electron impact (EI and 
electrospray ionization (ESI) techniques. Optical rotations were determined with a 
JASCO DCP-1000 digital polarimeter and were the average of at least 10 
measurements with an RSD value of less than -100%.  
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General procedure for the synthesis of 4-2 
5-Amino-1,3,4-thiadiazole-2-thiol (2.664 g, 20 mmol) was dissolved in a mixture of 
KOH (2.64 g, 40 mmol) in absolute ethanol (20 mL). After 10 min, the corresponding 
benzyl or alkyl bromide (20 mmol) was added drop wise with vigorous stirring. The 
reaction progress was monitored by TLC and was completed within 2 hours; the 
reaction mixture was concentrated under rotary evaporator. The organic compound 
was extracted with EtOAc/H2O and the combined organic layer was dried over 
anhydrous Na2SO4, concentrated, purified by column chromatography using 
EtOAc/hexane as an eluent and dried in a vacuum oven (at 50 °C) to afford 4-2 as a 
solid in 69-95% yield. 
General procedure for the synthesis of 4-4 
To a mixture of the corresponding acetophenone 4-3 (10 mmol) and diethyloxalate 
(2.03 mL, 15 mmol) in anhydrous ethanol (40 mL) was added 21% sodium ethoxide 
solution in ethanol (11.33 mL, 30 mmol ). The resulting mixture was stirred at room 
temperature for 12 hours. After that, the reaction mixture was neutralized with 4M 
HCl and solvent was removed under rotary evaporation. The resultant brown solid 
residue obtained was extracted with EtOAc/H2O solvent system and combined 
organic layer was dried over Na2SO4, concentrated and purified by column 
chromatography using ethyl acetate/hexane (starting from 1:20 to 1:9) solvent system 
and dried under vacuum at 50 °C temperature to yield compound 4-4 in 70-85% yield.  
General procedure for the synthesis of 4-5 
To a mixture of the corresponding acetophenone 4-3 (10 mmol) and diethyloxalate 
(2.03 mL, 15 mmol) in anhydrous ethanol (40 mL) was added 21% sodium ethoxide 
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solution in ethanol (11.33 mL, 30 mmol). The resulting mixture was stirred at room 
temperature for 12 hours. After that, the solvent was removed on a rotary evaporator; 
a solution of 1M NaOH (50 mL, 50 mmol) in water was added into the crude mixture. 
The hydrolysis reaction was stirred at room temperature for 4 hours. The basic 
solution was extracted 3 times with ethyl acetate; the water phase was collected and 
then acidified with 4N HCl solution to pH 1-2. The resulting solution was again 
extracted 3 times with ethyl acetate and the combined organic layer was dried over 
anhydrous Na2SO4, filtered, concentrated by evaporation and dried under vacuum at 
50 °C temperature to yield compound 4-5. The crude yield of the reaction is 80-90% 
which was directly coupled with various amines without further purification to obtain 
compound 4-6.   
General procedure for the synthesis of 4-6 
A solution of the respective acid 4-5 (2.21 mmol) in anhydrous dimethylacetamide 
(10 mL) was stirred at 0-5 °C for 10min. Thereafter, thionyl chloride (160 µL, 2.21 
mmol) was added over 10 min. The reaction mixture was stirred for next 20 min and 
the corresponding amine 4-2 (2.21 mmol) was added to the solution very slowly at 
same temperature. Upon completion of addition, the mixture was warmed to room 
temperature and stirred for another 4 hours. After that, 60 mL of water was added into 
the reaction mixture and the resultant precipitate formed 4-6 was recovered by 
filtration and copiously washed with water (3x20 mL) followed by cold ether (2x10 
mL). This product was used without further purification as the impurities present did 




General procedure for the synthesis of 4-1a 
To an amide 4-6 (0.8 mmol) in toluene (10 mL) was added 20 mol% of acetic acid 
(9.2 μL, 0.16 mmol) and piperidine (15.8 μL, 0.16 mmol) followed by the 
corresponding benzaldehyde (81.5 μL, 0.8 mmol). The mixture was stirred at 70°C for 
14 hours then cooled to room temperature for 1 hour. The precipitate that formed was 
filtered by suction then washed with water and cold ether. This crude product was 
purified by preparative HPLC using a Gilson preparative HPLC system with a Waters 
C18 column (250 x 10.0 mm, 5 μm). Detection was set up at 254 nm and the mobile 
phase was a gradient with solvent B increasing from 5% to 100% over 40 min and a 
flow rate of 5.0ml/min. Solvents A and B were prepared with 0.1% trifluoroacetic 
acid in water and acetonitrile respectively. Fractions containing the pure product were 
combined, concentrated and dried overnight under vacuum at 50 °C to give compound 
4-1a in 35-60% yield. 
General procedure for the synthesis of 4-1a and 4-8  
To a suspension of  2,4-diketo ethyl ester 4-4 (1.0 mmol), the corresponding amine (1 
mmol), and the aldehyde (1.0 mmol) in 1,4-dioxane (8 mL) was stirred at 70 °C 
temperature for 18h. After which, the reaction mixture was concentrated under rotary 
evaporator and wash with water and cold diethyl ether. Residual crude product was 
purified either by column chromatography (EtOAc:DCM = 1:1) or by reverse phase 
preparative HPLC using solvent A with 0.1% TFA in water, and solvent B was 0.1% 
TFA in acetonitrile as the mobile phase. Detection was conducted at 254 nm, the 
mobile phase was a gradient with solvent B increasing from 5% to 95% over 30 min 
and a flow rate of 8.0ml/min. Fractions containing the pure product were combined, 
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concentrated and dried overnight under vacuum at 50 °C to give compound 4-1a in 
54-75% yield and compound 4-8 in 45-60% yield. 
Synthesis of 4-(4-aminobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylthio)-
1,3,4-thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a30)  
To a solution of compound 4-1a29 (26 mg, 0.05 mmol) in absolute ethanol (8 mL) 
was added SnCl2.H2O (57 mg, 0.25 mmol). The mixture was stirred under reflux 
condition and checked by TLC for reaction completion. When the reaction has 
completed, the mixture was concentrated and extracted with EtOAc/H2O mixture and 
combined organic layer was concentrated under rotary evaporator, purified by column 
chromatography using ethyl acetate/hexane (3:1) solvent system and dried under 
vacuum at 50 °C temperature to yield compound 4-1a30 in 87% yield.  
Synthesis of 4-(4-chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-
(propylsulfonyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a32) 
A solution of the compound 4-1a16 (150 mg, 0.29 mmol) in DCM (10 mL) at 0 °C 
was treated with m-CPBA (110 mg, 0.64 mmol) and the mixture was stirred at 0-5 °C 
for 2.5 hrs. The reaction mixture was diluted with another 10 ml of DCM and wash 
with saturated Na2CO3 solution three times. The organic layer was dried over Na2SO4 
and concentrated under rotary evaporator to get the crude product 4-1a32. The crude 
product was purified by reverse phase preparative HPLC using solvent A with 0.1% 
TFA in water, and solvent B was 0.1% TFA in acetonitrile as the mobile phase. 
Detection was conducted at 254 nm, the mobile phase was a gradient with solvent B 
increasing from 5% to 95% over 30 min and a flow rate of 8.0ml/min. Fractions 
containing the pure product were combined, concentrated and dried overnight under 
vacuum at 50 °C to give compound 4-1a32 in 76% yield.   
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Synthesis of 4-(4-chlorobenzoyl)-5-(4-chlorophenyl)-3-methoxy-1-(5-(propylthio)-
1,3,4-thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a33)  
To a solution of starting materials 4-1a16 (100 mg, 0.2 mmol) in THF (5 mL) at 0 °C 
was added triphenylphosphine (0.3 mmol) and DIAD (0.3 mmol). The mixture was 
stirred for 15 min at 0 °C then methanol (12 µL, 0.3 mmol)) was added. The resulting 
reaction mixture was stirred at room temperature for the next 15 h and then the 
solvent was removed with a rotary evaporator. The crude mixture was dissolved in 
EtOAc (30 mL), washed with 1M NaOH followed by saturated sodium chloride 
solution. The resultant organic layer was dried over Na2SO4, concentrated under 
vacuum, purified by flash chromatography using ethyl acetate/hexane (starting from 
1:1 to 3:1) as the eluent and dried under vacuum at 50 °C temperature to yield 
compound 4-1a33 in 83% yield.    
Synthesis of 4-(4-chlorobenzoyl)-1-(5-(4-fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-
5-(4-fluorophenyl)-3-(2-hydroxyethylamino)-1H-pyrrol-2(5H)-one (4-7). To a 
solution of 1-(5-(4-fluorobenzylthio)-1,3,4- thiadiazol-2-yl)-3-amino-4-(4-
chlorobenzoyl)-5-(4-fluorophenyl)-1H-pyrrol-2(5H)-one (55.5 mg, 0.1 mmol,) in 
anhydrous 1,4-dioxane (10 mL) was added 2-aminoethanol (12 μL, 0.2 mmol). The 
mixture was stirred under reflux condition and checked by TLC for reaction 
completion. When the reaction has completed, the mixture was concentrated and 
extracted with ethyl acetate/H2O mixture and the combined organic layer was 
concentrated under rotary evaporation and purified by column chromatography using 




General procedure for the synthesis of 4-9 
To a solution of 4-8 (0.3 mmol, 92.2 mg) in dioxane (10 mL) was added the 
corresponding amine (0.3 mmol). The reaction mixture was stirred at reflux condition 
until TLC monitoring showed that the reaction has completed. After which, the 
mixture was concentrated under rotary evaporator and purified by column 
chromatography by (EtOAc:DCM = 1:1) and dried under vacuum at 50 °C 
temperature to yield compound 4-9 in 70-90% yield. For 4-9c, AcOH was used as 
solvent.  
4.5.2 Biology 
All the compounds used in the biological testing were at least 95% pure. Compounds 
were tested against the WNV NS2B-NS3 protease using the SensoLite® 440 WNV 
protease assay kit (Catalog # 72079) and the active recombinant WNV protease 
(Calalog # 72081) which were purchased from Anaspec (USA). This protease assay 
kit uses a fluorogenic peptide Pyr-RTKR-AMC as substrate. Eight different substrate 
concentrations ranging from 1 μM to 80 μM were incubated in 96-well plates with 0.3 
μg/mL recombinant WNV protease at 37 °C in the buffer provided. The increase in 
fluorescence intensity was monitored using an Infinite F200 microplate reader (Tecan, 
Switzerland) at an excitation wavelength of 354 nm (±10 nm) and emission 
wavelength of 442 nm (±15 nm). The initial velocity was determined from the linear 
portion of the progress curve, and the value of Km was determined using the 
Michaelis-Menten equation, i.e. v = Vmax [S] / ([S] + Km) to be 3.45±0.41 µM. 
Triplicate measurements were taken at each data point and the data were reported as 
mean±SE. In the preliminary WNV NS2B-NS3 protease inhibition assay, analogs of 
4-1a were screened at a fixed concentration of 50 μM to filter out potential inhibitors. 
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Compounds which showed more than 50% inhibition were further investigated for 
their IC50 determination. 
Determination of IC50 
For the IC50 calculations, recombinant WNV protease concentration of 0.3 µg/mL and 
seven different concentrations of the inhibitor ranging from 10 nM to 200 μM were 
used. For each experiment, the protease was pre-incubated with the inhibitor at 37 oC 
for 15 min in separate wells and the enzyme kinetics was initiated by adding substrate 
Pyr-RTKR-AMC to a final concentration 16.7 µM. The increase in fluorescence 
intensity was monitored continuously using an Infinite F200 microplate reader at an 
excitation wavelength of 354 nm and emission wavelength at 442 nm. Fluorescence 
values obtained from the positive control (no inhibitor) were considered as 100% 
complex formation and those values obtained in the presence of inhibitors were 
calculated as the percentage of inhibition of the control. Triplicate measurements were 
obtained at each data point. The IC50 values were calculated using a sigmoidal dose-
response using the Graphpad prism 3.0 software (San Diego, USA). Triplicate 
measurements were recorded as the mean±SE. 
Determination of inhibition mechanism 
Three different inhibitor concentrations and a no-inhibitor control (0 to 25 μM) were 
each assayed at five substrate concentrations ranging from 3.3 μM to 83.3 μM. In 
each assay, the enzyme and inhibitor were incubated at 37 °C for 15 min, followed by 
the addition of the substrate to start the kinetic measurement. The rate of substrate 
cleavage (v) was monitored using the F200 microplate reader. To illustrate the 
inhibition mechanism, 1/V versus 1/[S] was plotted for at each inhibitor concentration 
using OriginPro8. 
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 MTS Assay 
The baby hamster kidney fibroblast (BHK21) cells  were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS). 
The 1500 cells were placed in each well of three 96-well plates with a cell density of 
1.66x104 cells/mL and incubated for 24 h at 37 °C with 5% CO2. Thereafter, the 
compound of interest or DMSO was added into each well at 25 µM. Wells containing 
plain DMSO served as a vehicular control. The plate was then placed in the incubator 
for 24, 48 and 72 h of incubation at 37 °C with 5% CO2. At the end of each individual 
incubation time point, MTS reagent solution (20 µL) was added into each sample 
well. The plate was then incubated again in the dark for 2 h, gently shaken using a 
vortemp machine for 5 min to ensure equal mixing and absorbance at 492 nm was 
taken using a spectrometer. 
4.5.3 Docking 
All docking studies were performed using the Molecular Operating Environment 
(MOE 2009.10) software system designed by the Chemical Computing Group. The 
program operated under the ‘Windows Vista’ operating system installed on an Intel 
Core™2 Duo PC with a 2.4 MHz processor and 4.0 GB RAM. Docked compounds 
were built using the MOE builder and subjected to energy minimization with the 
MMFF94x force field. The active site of the WNV protease was prepared using the 
crystal structure of the WNV NS2B-NS3 protease in complex with peptide Bz-Nle-
Lys-Arg-Arg-H (pdb 2fp7). The structure was stripped of all water molecules and 
bound ligand followed by the addition of valance hydrogen atoms to the protein. By 
keeping in mind the amino acid residues in NS2B which are responsible for the 
activation of the catalytic triad, the active site in NS2B (NS2B-NS3) was identified 
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using the Alpha site finder tool. Docking simulations were performed at default 
settings with placement at triangle matcher, rescoring at London DG, refinement at 
force field and the geometry of resulting complex was studied using the Discovery 
Studio 3.1 client. 
 
4.6 1H and 13C NMR data of all compounds synthesized  
1H and 13C NMR data of compound 4-2: 
5-(Benzylthio)-1,3,4-thiadiazol-2-amine (4-2a). (Yield 90%). 1H NMR (500 MHz, 
DMSO-d6) δ 7.36-7.24 (m, 7H), 4.30 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ 
169.8, 149.5, 137.0, 128.9, 128.4, 127.4, and 38.5. HRMS-EI [M] calcd for C9H9N3S2: 
223.0238, found: 223.0245.  
5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-amine (4-2b). (Yield 88%). 1H NMR 
(500 MHz, DMSO-d6): δ 7.40-7.37 (m, 2H), 7.28 (s, 2H), 7.16-7.13 (m, 2H), 4.29 (s, 
2H). 13C NMR (125 MHz, DMSO-d6): δ 169.9, 149.1, 133.4, 131.0, 130.9, 115.3, 
1115.1, 37.5. HRMS-EI [M] calcd for C9H8FN3S2: 241.0144, found: 241.0146. 
5-(4-Methoxybenzylthio)-1,3,4-thiadiazol-2-amine (4-2c). (Yield 89%). 1H NMR 
(500 MHz, DMSO-d6): δ 7.29-6.86 (m, 6H), 4.24 (s, 2H), 3.72 (s, 3H). 13C NMR (125 
MHz, DMSO-d6): δ 169.8, 158.6, 149.6, 130.2, 128.7, 113.8, 55.0, 38.0. HRMS-EI 
[M] calcd for C10H11N3OS2: 253.0344, found: 253.0349. 
5-(Methylthio)-1,3,4-thiadiazol-2-amine (4-2d). (Yield 85%). 1H NMR (500 MHz, 
DMSO-d6): δ 3.34 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ 169.3, 152.4, 17.1. 
HRMS-EI [M] calcd for C3H5N3S2: 146.9925, found: 146.9930. 
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5-(Propylthio)-1,3,4-thiadiazol-2-amine (4-2e). (Yield 83%). 1H NMR (500 MHz, 
CDCl3): δ 5.62 (s, 2H), 3.11-3.08 (t, J = 7.6 Hz, 2H), 1.78-1.73 (m, 2H), 1.03-1.01 (t, 
J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 168.8, 154.8, 36.9, 22.8, 13.2. 
HRMS-EI [M] calcd for C5H9N3S2: 175.0238, found: 175.0238. 
5-(Isopropylthio)-1,3,4-thiadiazol-2-amine (4-2f). (Yield 85%). 1H NMR (500 
MHz, CDCl3): δ 6.05 (s, 2H), 3.64-3.56 (m, 1H), 1.38-1.37 (d, J = 7.0 Hz, 6H). 13C 
NMR (125 MHz, CDCl3): δ 170.1, 152.9, 40.8, 22.2. HRMS-EI [M] calcd for 
C5H9N3S2: 175.0238, found: 175.0248. 
5-(Butylthio)-1,3,4-thiadiazol-2-amine (4-2g). (Yield 80%). 1H NMR (500 MHz, 
CDCl3): δ 6.02 (s, 2H), 3.10-3.08 (t, J = 7.6 Hz, 2H), 1.72-1.66 (m, 2H), 1.46-1.39 
(m, 2H), 0.92-0.89 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 169.3, 154.5, 
34.8, 31.4, 21.7, 13.5. HRMS-EI [M] calcd for C6H11N3S2: 189.0394, found: 
189.0397. 
5-(Pentylthio)-1,3,4-thiadiazol-2-amine (4-2h). (Yield 78%). 1H NMR (500 MHz, 
CDCl3): δ 6.62 (s, 2H), 3.04-3.01 (t, J = 6.9 Hz, 2H), 1.68-1.64 (m, 2H), 157-1.26 (m, 
4H), 0.87-0.83 (t, J = 6.7 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 169.8, 154.1, 35.2, 
30.6, 30.0, 22.1 13.8. HRMS-EI [M] calcd for C7H13N3S2: 203.0551, found: 203.0550. 
5-(Cyclopentylthio)-1,3,4-thiadiazol-2-amine (4-2i). (Yield 95%). 1H NMR (500 
MHz, CDCl3): δ 5.47 (s, 2H), 3.81 (b, 1H), 2.11-1.63 (m, 8H). 13C NMR (125 MHz, 
CDCl3): δ 168.8, 154.9, 48.1, 33.6. 24.7. HRMS-EI [M] calcd for C7H11N3S2: 
201.0394, found: 201.0397. 
2-(5-Amino-1,3,4-thiadiazol-2-ylthio)ethanol (4-2j). (Yield 69%). 1H NMR (500 
MHz, MeOD): δ 4.84 (s, 2H), 3.81-3.78 (t, J = 6.3 Hz, 2H), 3.22-3.20 (t, J = 6.3 Hz, 
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2H), 1.03-1.01 (t, J = 7.3 Hz, 3H). 13C NMR (125 MHz, MeOD): δ 172.1, 154.4, 61.6, 
38.2. HRMS-EI [M] calcd for C4H7N3OS2: 177.0031, found: 177.0030. 
3-(5-Amino-1,3,4-thiadiazol-2-ylthio)propanenitrile (4-2k). (Yield 71%). 1H NMR 
(500 MHz, MeOD): δ 4.83 (s, 2H), 3.37-3.32 (m, 2H), 2.94-2.92 (t, J = 6.9 Hz, 2H). 
13C NMR (125 MHz, MeOD): δ 172.6, 151.9, 119.3, 31.1, 19.1. HRMS-EI [M] calcd 
for C5H6N4S2: 186.0034, found: 186.0027. 
Ethyl 2-(5-amino-1,3,4-thiadiazol-2-ylthio)acetate (4-2l). (Yield 82%). 1H NMR 
(500 MHz, CDCl3): δ 6.02 (s, 2H), 4.21-4.17 (m, 2H), 3.88 (s, 2H), 1.27-1.24 (t, J = 
7.0 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 169.7, 168.4, 152.0, 62.1, 36.3, 14.0. 
HRMS-EI [M] calcd for C6H9N3O2S2: 219.0136, found: 219.0135. 
 
1H and 13C NMR data of compound 4-4: 
Ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate (4-4a). 1H NMR (500 MHz, CDCl3): 
δ 7.85 (d, J = 8.6 Hz, 2H), 7.64 (d, J = 8.5 Hz, 2H), 7.02 (s, 1H), 4.40 (q, J = 7.1 Hz, 
2H), 1.41 (t, J = 7.2 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 189.74, 170.37, 162.29, 
133.97, 132.52, 129.56, 129.29, 97.99, 62.99, 14.35. 
Ethyl 4-(4-iodophenyl)-2,4-dioxobutanoate (4-4b) 
1H NMR (500 MHz, CDCl3): δ 15.25 (s, 1H), 7.87 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 
8.1 Hz, 2H), 7.02 (s, 1H), 4.40 (dd, J = 14.2, 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 13C 
NMR (125 MHz, CDCl3): δ 189.91, 170.54, 162.32, 138.53, 134.52, 129.41, 102.09, 
97.93, 63.00, 14.36. 
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Ethyl 4-(benzofuran-2-yl)-2,4-dioxobutanoate (4-4c) 1H NMR (500 MHz, CDCl3) δ 
7.62 (ddd, J = 52.0, 27.2, 7.8 Hz, 4H), 7.36 (t, J = 7.4 Hz, 1H), 7.14 (s, 1H), 4.44 (dd, 
J = 14.1, 7.0 Hz, 2H), 1.45 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, CDCl3): δ 
181.16, 168.93, 162.11, 156.48, 151.18, 128.94, 127.56, 124.46, 123.53, 114.16, 
112.65, 99.35, 62.96, 14.36. 
 
1H and 13C NMR data of compound 4-6: 
(Z)-N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-hydroxy-4-oxo-4-phenylbut-2-
enamide (4-6a). (Yield 52%). 1H NMR (500 MHz, DMSO-d6): δ 8.10-7.10 (m, 11H), 
4.52 (s, 2H). HRMS-EI [M] calcd for C19H14FN3O3S2: 415.0461, found: 415.0464. 
N-(5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-2,4-dioxo-4-phenylbutanamide 
(4-6b). (Yield 52%). 1H NMR (500 MHz, DMSO-d6): δ 8.10-7.14 (m, 10H), 4.52 (s, 
2H). HRMS-EI [M] calcd for C19H15N3O3S2: 397.0555, found: 397.0558. 
N-(5-(4-Methoxybenzylthio)-1,3,4-thiadiazol-2-yl)-2,4-dioxo-4-phenylbutanamide 
(4-6c). (Yield 54%).1H NMR (500 MHz, DMSO-d6): δ 8.11-6.89 (m, 10H), 4.48 (s, 
2H), 3.73 (s, 3H). HRMS-ESI m/z [M - H] calcd for C20H16N3O4S2: 426.0582, found: 
426.0597. 
N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorophenyl)-2,4-dioxobutanamide 
(4-6d). (Yield 57%). 1H NMR (500 MHz, CDCl3): δ 7.89-7.13 (m, 10H), 4.45 (s, 2H). 
HRMS-ESI m/z [M - H] calcd for C19H13ClN3O3S2: 430.0087, found: 430.0085. 
4-(4-Chlorophenyl)-N-(5-(4-fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-2,4-
dioxobutanamide (4-6e). (Yield 61%). 1H NMR (500 MHz, DMSO-d6): δ 8.07-7.14 
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(m, 9H), 4.52 (s, 2H). HRMS-ESI m/z [M - H] calcd for C19H12ClFN3O3S2: 447.9993, 
found: 447.9998. 
4-(4-Chlorophenyl)-N-(5-(methylthio)-1,3,4-thiadiazol-2-yl)-2,4-dioxobutanamide 
(4-6f). (Yield 54%). 1H NMR (500 MHz, DMSO-d6): δ 8.10-7.61 (m, 4H), 7.08 (s, 
1H), 2.74 (s, 2H). HRMS-ESI m/z [M - H] calcd for C13H9ClN3O3S2: 364.0556, 
found: 364.0566. 
4-(4-Chlorophenyl)-2,4-dioxo-N-(5-(propylthio)-1,3,4-thiadiazol-2-yl)butanamide 
(4-6g). (Yield 48%). 1H NMR (500 MHz, DMSO-d6): δ 8.12-7.62 (m, 4H), 7.08 (s, 
1H), 3.26-3.00 (m, 2H), 1.75-1.62 (m, 2H), 1.01-1.94 (m, 3H). HRMS-ESI m/z [M - 
H] calcd for C15H13ClN3O3S2: 382.0087, found: 382.0089. 
Ethyl 2-(5-(4-(4-chlorophenyl)-2,4-dioxobutanamido)-1,3,4-thiadiazol-2-ylthio) 
acetate (4-6h). (Yield 45%). 1H NMR (500 MHz, DMSO-d6): δ 8.08-7.61 (m, 4H), 
7.08 (s, 1H), 2.57-2.50 (m, 2H), 1.19-1.16 (m, 3H). HRMS-ESI m/z [M - H] calcd for 
C16H13ClN3O5S2: 425.9985, found: 425.9990. 
N-(5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-4-(3-methoxyphenyl)-2,4-
dioxobutanamid (4-6i). (Yield 56%). 1H NMR (500 MHz, DMSO-d6): δ 7.10-7.15 
(m, 10H), 4.53 (s, 2H), 3.86 (s, 3H). HRMS-ESI m/z [M - H] calcd for 
C20H15FN3O4S2: 444.0488, found: 444.0495. 
4-(4-Nitrophenyl)-2,4-dioxo-N-(5-(propylthio)-1,3,4-thiadiazol-2-yl)butanamide 
(4-6j). (Yield 45%). 1H NMR (500 MHz, DMSO-d6): δ 8.37-8.15 (m, 4H), 7.11 (s, 
1H), 3.25-3.00 (m, 2H), 1.76-1.60 (m, 2H), 1.01-0.93 (m, 3H). HRMS-ESI m/z [M - 
H] calcd for C15H13N4O5S2: 393.0327, found: 393.0332. 
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1H and 13C NMR data of compound 4-1a: 
4-(4-Chlorobenzoyl)-5-(3,4-dichlorophenyl)-1-(5-(4-fluorobenzylthio)-1,3,4-
thiadiazol-2-yl)-3-hydroxy-1H-pyrrol-2(5H)-one (4-1a2). (Yield 35%). 1H NMR 
(500 MHz, DMSO-d6) δ 7.76-7.12(m, 12H), 6.15 (s, 1H), 4.52-4.43 (m, 2H). 13C 
NMR (125 MHz, DMSO-d6): δ 187.6, 164.8, 162.5, 160.5, 159.2, 155.8, 149.6, 137.7, 
136.3, 135.0, 132.6, 131.1, 129.8, 128.3, 128.2, 120.8, 115.4, 115.2, 61.5, 36.4. 
HRMS-ESI m/z [M - H] calcd for C26H14Cl3FN3O3S2: 603.9526, found: 603.9531. 
4-Benzoyl-1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-3-hydroxy-5-phenyl-1H-pyrrol-
2(5H)-one (4-1a3). (Yield 50%). 1H NMR (500 MHz, DMSO-d6): δ 7.74-7.19 (m, 
13H), 6.19 (s, 1H), 4.52-4.44 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 189.0, 
164.9, 159.4, 155.8, 148.1, 137.4, 136.4, 135.5, 133.0, 129.0, 128.8, 128.5, 128.2, 
128.1, 127.7, 127.6, 122.2, 62.4, 37.3. HRMS-ESI m/z [M - H] calcd for 
C26H18N3O3S2: 484.0790, found: 484.0801. 
1-(5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-4-benzoyl-3-hydroxy-5-phenyl-
1H-pyrrol-2(5H)-one (4-1a4). (Yield 49%). 1H NMR (500 MHz, DMSO-d6): δ 7.74-
7.11(m, 14H), 6.18 (s, 1H), 4.51-4.42 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 
188.75, 165.4, 160.5, 159.1, 156.0, 137.8, 136.2, 132.8, 136.2, 132.8, 132.7, 131.1, 
131.0, 128.8, 128.1, 128.0, 127.7, 115.4, 115.2, 62.3, 36.4. HRMS-ESI m/z [M - H] 
calcd for C26H17FN3O3S2: 502.0695, found: 502.0700. 
1-(5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-4-benzoyl-3-hydroxy-5-(4-
(methylthio)phenyl)-1H-pyrrol-2(5H)-one (4-1a5). (Yield 47%). 1H NMR (500 
MHz, DMSO-d6): δ 7.74-7.12(m, 13H), 6.13 (s, 1H), 4.52-4.44 (m, 2H), 2.40 (s, 3H). 
156 
13C NMR (125 MHz, DMSO-d6):  HRMS-ESI m/z [M - H] calcd for C27H19FN3O3S3: 
548.0573, found: 548.0551. 
1-(5-(4-Fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-3-hydroxy-4-(3-
methoxybenzoyl)-5-phenyl-1H-pyrrol-2(5H)-one (4-1a6). (Yield 48%).1H NMR 
(500 MHz, CDCl3): δ 7.48-7.12(m, 13H), 6.15 (s, 1H), 4.52-4.43 (m, 2H), 3.77 (s, 
3H). HRMS-ESI m/z [M - H] calcd for C27H19FN3O4S2: 532.0801, found: 532.0791. 
4-Benzoyl-1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-5-(4-fluorophenyl)-3-hydroxy-
1H-pyrrol-2(5H)-one (4-1a7). (Yield 46%). 1H NMR (500 MHz, DMSO-d6): δ 7.77-
7.06 (m, 14H), 6.20 (s, 1H), 4.54-4.43 (m, 2H). 13C NMR (125 MHz, DMSO-d6): δ 
189.1, 164.8, 163.4, 160.2, 159.4, 155.8, 148.4, 137.5, 136.4, 133.0, 131.8, 130.1, 
130.0, 129.0, 128.8, 128.5, 128.2, 127.6, 121.8, 115.2, 114.9, 61.7, 37.2. HRMS-ESI 
m/z [M - H] calcd for C26H17FN3O3S2: 502.0695, found: 502.0708. 
1-(5-(4-Methoxybenzylthio)-1,3,4-thiadiazol-2-yl)-4-benzoyl-5-(4-fluorophenyl)-
3-hydroxy-1H-pyrrol-2(5H)-one (4-1a8). (Yield 35%). 1H NMR (500 MHz, DMSO-
d6): δ 7.74-6.86 (m, 13H), 6.14 (s, 1H), 4.46-4.39 (m, 2H), 3.73 (s, 3H). 13C NMR 
(125 MHz, DMSO-d6): δ 188.3, 162.5, 160.6, 159.3, 158.7, 155.8, 138.1, 132.4, 
130.3, 130.0, 129.9, 128.8, 128.6, 128.1, 128.0, 115.0, 114.8, 114.0, 61.5, 55.0, 36.9. 
HRMS-ESI m/z [M - H] calcd for C27H19FN3O4S2: 532.0801, found: 532.0796. 
1-(5-(4-Methoxybenzylthio)-1,3,4-thiadiazol-2-yl)-4-benzoyl-3-hydroxy-5-(4-
(methylthio)phenyl)-1H-pyrrol-2(5H)-one (4-1a9). (Yield 41%). 1H NMR (500 
MHz, DMSO-d6): δ 7.56-6.59(m, 13H), 5.64 (s, 1H), 4.41-4.30 (m, 2H), 3.76 (s, 3H), 
2.41 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ168.9, 165.8, 163.4, 161.1, 159.2, 
156.3, 138.1, 135.2, 134.0, 131.3, 130.3, 129.9, 129.6, 128.8, 128.4, 128.3, 127.7, 
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125.7, 114.1, 108.2, 61.5, 55.2, 37.7, 23.4, 15.4. HRMS-ESI m/z [M - H] calcd for 
C28H22N3O4S3: 560.0772, found: 560.0769. 
1-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorobenzoyl)-3-hydroxy-5-phenyl-
1H-pyrrol-2(5H)-one (4-1a10). (Yield 60%). 1H NMR (500 MHz, DMSO-d6): δ 
7.76-7.19(m, 14H), 6.17 (s, 1H), 4.53-4.44 (m, 2H). 13C NMR (125 MHz, DMSO-d6): 
δ 187.8, 164.7, 159.4, 155.8, 148.7, 137.9, 136.4, 136.2, 135.5, 130.7, 129.0, 128.5, 
128.4, 128.2, 128.1, 127.8, 127.6, 121.7, 62.3, 37.3. HRMS-ESI m/z [M - H] calcd for 
C26H17ClN3O3S2: 518.0400, found: 518.0387. 
1-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorobenzoyl)-5-(furan-2-yl)-3-
hydroxy-1H-pyrrol-2(5H)-one (4-1a11). (Yield 40%). 1H NMR (500 MHz, CDCl3): 
δ 7.52-5.98(m, 12H), 5.8 (s, 1H), 4.51-4.38 (m, 2H). 13C NMR (125 MHz, DMSO-d6): 
δ 187.8, 164.4, 159.6, 155.8, 149.2, 147.4, 142.9, 137.9, 136.5, 136.2, 130.7, 129.1, 
128.6, 128.5, 127.6, 118.6, 110.8, 110.5, 56.0, 37.3. HRMS-ESI m/z [M - H] calcd for 
C24H15ClN3O4S2: 508.0193, found: 508.0189. 
1-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorobenzoyl)-3-hydroxy-5-(4-
methoxyphenyl)-1H-pyrrol-2(5H)-one (4-1a12). (Yield 45%).1H NMR (500 MHz, 
DMSO-d6): δ 7.77-6.80 (m, 13H), 6.11 (s, 1H), 4.53-4.44 (m, 2H), 3.67 (s, 3H). 
HRMS-ESI m/z [M - H] calcd for C27H19ClN3O4S2: 548.0506, found: 548.0520. 
1-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorobenzoyl)-5-(4-chlorophenyl)-3-
hydroxy-1H-pyrrol-2(5H)-one (4-1a13). (Yield 59%). 1H NMR (500 MHz, DMSO-
d6): δ 7.77-7.25 (m, 13H), 6.16 (s, 1H), 4.52-4.44 (m, 2H). 13C NMR (125 MHz, 
DMSO-d6): δ 187.7, 164.7, 159.5, 155.7, 149.3, 137.8, 136.4, 136.2, 134.8, 132.7, 
130.7, 129.8, 129.0, 128.5, 128.4, 128.2, 127.6, 121.0, 61.6, 37.3. HRMS-ESI m/z [M 
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- H] calcd for C26H16Cl2N3O3S2: 552.0010, found: 552.0001. (-)-4-1a13, [α]25 -48.4° 
degmLg-1dm-1 (c 3.2 x 10-3 g/mL, CH2Cl2); (+)-4-1a13, [α]25 +84.7° (c 3.0 x 10-3 
g/mL, CH2Cl2). 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(methylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a14). (Yield 53%). 1H NMR (500 MHz, 
DMSO-d6): δ 7.75-7.20 (m, 8H), 6.2 (s, 1H), 2.68 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6): δ 189.0, 164.8, 161.5, 155.2, 148.1, 137.4, 135.6, 133.0, 128.8, 127.7, 
122.1, 62.3, 15.9. HRMS-ESI m/z [M - H] calcd for C20H12Cl2N3O3S2: 475.9697, 
found: 475.9701. 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(isopropylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a15). (Yield 55%). 1H NMR (500 MHz, 
DMSO-d6): δ 7.78-7.26 (m, 8H), 6.0 (s, 1H), 3.78-3.72 (m, 1H), 1.35-1.32(t, J =6.0 
Hz, 6H). HRMS-ESI m/z [M - H] calcd for C22H16Cl2N3O3S2: 504.0010, found: 
504.0011. 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a16). (Yield 55%). 1H NMR (500 MHz, 
DMSO-d6): δ 7.77-7.30 (m, 8H), 6.1 (s, 1H), 3.23-3.14 (m, 2H), 1.71-1.64 (m, 2H), 
0.96-0.94 (t, 3H, CH3, J =4.9Hz). 13C NMR (125 MHz, DMSO-d6): δ 186.6, 160.0, 
155.6, 137.2, 137.1, 136.8, 136.4, 136.4, 136.4, 132.2, 130.6, 129.7, 118.6, 61.4, 35.3, 
22.3, 12.9. HRMS-ESI m/z [M - H] calcd for C22H16Cl2N3O3S2: 504.0010, found: 
504.0004. (-)-4-1a16, [α]25 -42.9° (c 11.2 x 10-3 g/mL, CH2Cl2); (+)-4-1a16, [α]25 
+13.1° (c 12.1 x 10-3 g/mL, CH2Cl2).   
1-(5-(Butylthio)-1,3,4-thiadiazol-2-yl)-4-(4-chlorobenzoyl)-5-(4-chlorophenyl)-3-
hydroxy-1H-pyrrol-2(5H)-one (4-1a17). (Yield 49%). 1H NMR (500 MHz, DMSO-
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d6): δ 7.76-7.31 (m, 8H), 6.1 (s, 1H), 3.26-3.15 (m, 2H), 1.67-1.61 (m, 2H), 1.41-1.34 
(m, 2H), 0.88-0.85(t, J =4.8 Hz, 3H). 13C NMR (125 MHz, DMSO-d6): δ. 210.6, 
187.3, 165.1, 160.1, 155.5, 137.4, 136.6, 135.5, 132.5, 130.6, 129.8, 128.2, 128.1, 
120.1, 61.5, 33.1, 30.9, 21.1, 13.3. HRMS-ESI m/z [M - H] calcd for 
C23H18Cl2N3O3S2: 518.0167, found: 518.0167. (-)-4-1a17, [α]25 -9.2° (c 11.0 x 10-3 
g/mL, CH2Cl2); (+)-4-1a13, [α]25 +41.9° (c 2.6 x 10-3 g/mL, CH2Cl2).   
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-1-(5-(cyclopentylthio)-1,3,4-thiadiazol-2-
yl)-3-hydroxy-1H-pyrrol-2(5H)-one (4-1a18). (Yield 45%). 1H NMR (500 MHz, 
DMSO-d6): δ 7.79-7.25 (m, 8H), 5.96 (s, 1H), 3.90-3.87 (t, J =6.3 Hz, 2H), 3.01-3.00 
(m, 2H), 2.11-2.08 (m, 2H), 1.68-1.54 (t, J =6.27 Hz, 4H). 13C NMR (125 MHz, 
DMSO-d6): δ 183.7, 169.2, 162.9, 158.9, 156.1, 140.1, 139.4, 134.3, 131.1, 130.5, 
129.3, 127.4, 126.9, 112.4, 60.9, 46.7, 43.7, 33.3, 24.2, 24.1. HRMS-ESI m/z [M - H] 
calcd for C24H18Cl2N3O3S2: 530.0167, found: 530.0177. 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(2-hydroxyethylthio)-
1,3,4-thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a20), (Yield 48%). 1H NMR (500 
MHz, DMSO-d6): δ 7.77-7.31 (m, 8H), 6.14 (s, 1H), 3.67-3.64 (t, J =6.3 Hz, 2H), 
3.35-3.25 (m, 2H). HRMS-ESI m/z [M - H] calcd for C21H14Cl2N3O4S2: 505.9803, 
found: 505.9805. 
5-(4-Chlorophenyl)-4-(4-fluorobenzoyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a23). (Yield 54%).  1H NMR (300 MHz, 
DMSO) δ 7.84 (dd, J = 8.6, 5.6 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 7.39 – 7.17 (m, 
4H), 6.16 (s, 1H), 3.31 – 3.05 (m, 2H), 1.80 – 1.53 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 
13C NMR (75 MHz, DMSO) δ 186.50, 165.61, 163.75, 162.28, 159.19, 154.48, 
147.84, 133.88, 133.12, 133.09, 131.74, 130.93, 130.80, 128.90, 127.27, 120.29, 
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114.54, 114.25, 60.68, 34.30, 21.29, 11.90. HRMS-ESI m/z [M - H] calcd for 
C22H17ClFN3O3S2-H: 488.0306, found: 488.0306.  
5-(4-Bromophenyl)-4-(4-chlorobenzoyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a24). (Yield 64%). 1H NMR (500 MHz, 
DMSO) δ 7.75 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.5 Hz, 2H), 7.49 – 7.39 (m, 4H), 6.12 
(s, 1H), 3.24 – 3.14 (m, 4H), 1.81 – 1.58 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR 
(125 MHz, DMSO) δ 187.69, 164.76, 160.19, 155.44, 149.55, 137.79, 136.26, 135.42, 
131.13, 130.67, 130.17, 128.38, 121.30, 120.82, 61.64, 35.31, 22.26, 12.86. HRMS-
ESI m/z [M - H] calcd for C22H16ClBrN3O3S2: 547.9510, found: 547.9509; HRMS-
ESI m/z [M - H] calcd for C22H16Cl81BrN3O3S2: 549.9490, found: 549.9491. 
3-(4-Chlorobenzoyl)-4-(3-chlorophenyl)-2-hydroxy-5-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)cyclopent-2-enone (4-1a25). (Yield 57%). 1H NMR (500 MHz, 
DMSO) δ 7.76 (dd, J = 6.3, 4.6 Hz, 2H), 7.59 (s, 1H), 7.53 (dd, J = 8.6, 1.9 Hz, 2H), 
7.44 (dt, J = 7.0, 1.8 Hz, 1H), 7.35 – 7.23 (m, 2H), 6.14 (s, 1H), 3.29 – 3.10 (m, 2H), 
1.76 – 1.61 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 13C NMR (125 MHz, DMSO) δ 187.73, 
164.76, 160.27, 155.51, 149.68, 138.48, 137.86, 136.25, 132.75, 130.71, 130.08, 
128.39, 128.22, 128.06, 126.46, 120.72, 61.71, 35.34, 22.28, 12.87. HRMS-ESI m/z 
[M - H] calcd for C22H16Cl2N3O3S2: 504.0016, found: 504.0024. 
4-(4-Bromobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a27). (Yield 61%). 1H NMR (500 MHz, 
DMSO) δ 7.69 (s, 4H), 7.52 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 6.16 (s, 
1H), 3.27 – 3.15 (m, 2H), 1.75 – 1.62 (m, 2H), 0.97 (t, J = 7.3 Hz, 3H); 13C NMR 
(125 MHz, DMSO) δ 187.84, 164.77, 160.17, 155.44, 149.63, 136.62, 134.99, 132.67, 
131.30, 130.74, 129.83, 128.20, 126.88, 120.80, 61.54, 35.31, 22.25, 12.85. HRMS-
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ESI m/z [M - H] calcd for C22H16ClBrN3O3S2: 547.9510, found: 547.9511; HRMS-
ESI m/z [M - H] calcd for C22H16Cl81BrN3O3S2: 549.9490, found: 549.9496. 
5-(4-Chlorophenyl)-3-hydroxy-4-(4-iodobenzoyl)-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a28). (Yield 59%). 1H NMR (500 MHz, 
DMSO) δ 7.85 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 7.9 Hz, 4H), 7.32 (d, J = 8.3 Hz, 2H), 
6.13 (s, 1H), 3.21 (m, 3H), 1.68 (dd, J = 14.4, 7.2 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H). 
HRMS-ESI m/z [M - H] calcd for C22H16ClIN3O3S2: 595.9372, found: 595.9394.  
5-(4-Chlorophenyl)-3-hydroxy-4-(4-nitrobenzoyl)-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a29). (Yield 54%). 1H NMR (500 MHz, 
DMSO) δ 8.27 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.1 Hz, 2H), 
7.34 (d, J = 8.1 Hz, 2H), 6.17 (s, 1H), 3.31 – 3.04 (m, 2H), 1.66 (dt, J = 14.0, 7.0 Hz, 
2H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, DMSO) δ 187.57, 164.64, 160.43, 
155.41, 151.32, 149.55, 142.96, 135.06, 132.79, 130.00, 129.94, 128.27, 123.41, 
120.13, 61.48, 35.32, 22.30, 12.92. HRMS-ESI m/z [M - H] calcd for 
C22H17ClN4O5S2: 515.0256, found: 515.0265.  
4-(4-Aminobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a30). (Yield 87%). 1H NMR (500 MHz, 
DMSO) δ 7.53 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 7.9 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 
6.51 (d, J = 8.2 Hz, 2H), 6.13 (s, 1H), 3.30 – 3.07 (m, 2H), 1.67 (dd, J = 14.3, 7.1 Hz, 
2H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, DMSO) δ 185.73, 165.02, 159.85, 
155.59, 154.38, 144.85, 134.70, 132.67, 132.05, 129.64, 128.31, 124.47, 124.24, 
112.31, 62.06, 35.31, 22.32, 12.92. HRMS-ESI m/z [M - H] calcd for 
C22H18ClN4O3S2: 485.0514, found: 485.0531.  
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4-(Benzofuran-2-carbonyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a32). (Yield 75%). 1H NMR (500 MHz, 
DMSO) δ 8.11 (s, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.53 (t, J = 
9.0 Hz, 3H), 7.34 (dd, J = 20.1, 7.6 Hz, 3H), 6.27 (s, 1H), 3.37 – 3.09 (m, 2H), 1.68 
(dd, J = 14.2, 7.1 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (125 MHz, DMSO) δ 
176.60, 165.06, 160.78, 155.90, 155.46, 152.19, 149.89, 135.28, 133.31, 130.45, 
129.26, 128.73, 127.16, 124.55, 124.37, 121.38, 116.82, 112.61, 61.96, 35.84, 22.78, 
13.37. HRMS-ESI m/z [M - H] calcd for C24H17ClN3O4S2: 510.0354, found: 
510.0370. 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-hydroxy-1-(5-(propylsulfonyl)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a33). (Yield 76%) 1H NMR (500 MHz, 
DMSO) δ 7.78 (d, J = 8.5 Hz, 2H), 7.56 (dd, J = 23.5, 8.4 Hz, 4H), 7.34 (d, J = 8.5 
Hz, 2H), 6.22 (s, 1H), 3.77 – 3.61 (m, 2H), 1.85 – 1.59 (m, 2H), 0.95 (t, J = 7.4 Hz, 
3H). HRMS-ESI m/z [M - H] calcd for C22H16Cl2N3O5S2: 535.9914, found: 535.9917. 
4-(4-Chlorobenzoyl)-5-(4-chlorophenyl)-3-methoxy-1-(5-(propylthio)-1,3,4-
thiadiazol-2-yl)-1H-pyrrol-2(5H)-one (4-1a34). (Yield 83%). 1H NMR (500 MHz, 
DMSO) δ 7.92 – 7.82 (m, 2H), 7.60 (dd, J = 6.2, 4.5 Hz, 2H), 7.56 – 7.44 (m, 2H), 
7.34 (dd, J = 6.2, 4.5 Hz, 2H), 6.18 (s, 1H), 4.02 (s, 3H), 3.21 (ddd, J = 19.4, 11.1, 4.5 
Hz, 2H), 1.69 (dd, J = 14.5, 7.3 Hz, 2H), 0.97 (t, J = 7.4 Hz, 3H).  
4-(4-Chlorobenzoyl)-1-(5-(4-fluorobenzylthio)-1,3,4-thiadiazol-2-yl)-5-(4-
fluorophenyl)-3-(2-hydroxyethoxy)-1H-pyrrol-2(5H)-one (4-7a). (Yield 40%). 1H 
NMR (500 MHz, DMSO-d6): δ 7.56-6.36 (m, 12H), 5.75 (s, 1H), 4.45-4.33 (m, 2H), 
3.79-3.77 (t, J = 6.5 Hz, 2H), 3.36-3.35 (b, 2H). 13C NMR (125 MHz, DMSO-d6): δ 
173.9, 166.5, 163.3, 162.9, 161.2, 161.0, 155.9, 136.8, 132.9, 131.5, 130.9, 130.8, 
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129.5, 129.4, 128.4, 115.7, 115.5, 115.1, 115.0, 108.9, 61.0, 60.0, 47.6, 37.4, 29.8. 
HRMS-ESI m/z [M - H] calcd for C28H20ClF2N4O3S2: 597.0633, found: 597.0633. 
4-Acetyl-3-hydroxy-1-methyl-5-phenyl-1H-pyrrol-2(5H)-one (4-8a). (Yield 45%). 
1H NMR (500 MHz, DMSO-d6): δ 7.34-7.16 (m, 5H), 5.12 (s, 1H), 2.63(s, 3H), 2.27 
(s, 3H). 13C NMR (125 MHz, DMSO-d6): δ 191.3, 165.1, 154.8, 136.8, 128.5, 128.0, 
127.5, 120.0, 61.8, 29.7, 27.2. HRMS-ESI m/z [M - H] calcd for C13H12NO3: 
230.0817, found: 230.0814. 
4-Acetyl-1-benzyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one (4-8b). (Yield 60%). 
1H NMR (500 MHz, DMSO-d6): δ 7.33-7.06 (m, 10H), 4.94 (s, 1H) 4.86-4.82 (d, J = 
15.8 Hz, 1H), 3.61-3.58 (d, J = 15.2 Hz, 1H), 2.27 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6): δ 191.3, 165.3, 154.7, 136.4, 136.3, 128.7, 128.6, 128.1, 127.7, 127.6, 
127.4, 120.2, 59.9, 43.6, 40.3, 29.7. HRMS-ESI m/z [M - H] calcd for C19H16NO3: 
306.1130, found: 306.1124. 
4-Acetyl-3-amino-1-benzyl-5-phenyl-1H-pyrrol-2(5H)-one (4-9a). (Yield 85%). 1H 
NMR (500 MHz, CDCl3): δ 7.37-7.11 (m, 10H), 5.21-5.18 (d, J = 15.1 Hz 1H), 4.86 
(s, H), 3.47-3.44 (d, J = 15.1 Hz, 1H), 1.69 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 
191.3, 165.3, 154.7, 136.4, 136.3, 128.7, 128.6, 128.1, 127.7, 127.6, 127.4, 120.2, 
59.9, 43.6, 40.3, 29.7. HRMS-ESI m/z [M - H] calcd for C19H17N2O2:  305.1290, 
found: 305.1290. 
4-Acetyl-1-benzyl-3-(methylamino)-5-phenyl-1H-pyrrol-2(5H)-one (4-9b). (Yield 
70%). 1H NMR (500 MHz, CDCl3): δ 11.05 (b, H), 7.28-7.04 (m, 10H), 5.17-5.14 (d, 
J = 14.5 Hz, 1H), 4.78 (s, H), 3.37-3.34 (d, J = 15.1 Hz 1H), 2.92-2.91 (d, J = 5.7 Hz, 
1H), 1.58 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 177.7, 165.1, 164.3, 138.1, 136.5, 
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129.0, 128.6, 128.5, 128.1, 127.6, 108.9, 58.8, 43.9, 29.9, 14.9. HRMS-ESI m/z [M - 
H] calcd for C19H19N2O2: 319.1447, found: 319.1447. 
4-Acetyl-1-benzyl-3-(2-hydroxyethylamino)-5-phenyl-1H-pyrrol-2(3H)-one (4-
9c). (Yield 90%). 1H NMR (500 MHz, CDCl3): δ 11.31 (b, H), 7.28-7.03 (m, 10), 
5.04-5.01 (d,  J = 15.2 Hz, 1H), 4.76 (s, 1H), 4.50 (b, 1H), 3.81-3.79 (t, J = 5.7 Hz, 
2H), 3.50-3.42 (b, 2H), 3.39-3.36 (d, J = 15.2 Hz, 1H), 1.62 (s, 3H). 13C NMR (125 
MHz, CDCl3): δ 176.4, 165.5, 164.5, 137.7, 136.3, 128.9, 128.6, 128.3, 128.1, 127.5, 
106.9, 66.9, 60.6, 59.1, 45.9, 43.9, 15.4. HRMS-ESI m/z [M - Na] calcd for 













4.7 Chiral Chromatogram of compounds 4-1a13, 4-1a16 and 4-1a17 
a) Chiral chromatogram of compound 4-1a13 using AD-H column 















b) Chiral chromatogram of compound 4-1a16 using IC column 
















c) Chiral chromatogram of compound 4-1a17 using AD-H column 
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*** Acquisition  Parameters ***
AQ_mod : dqd
AUNM : au_zg
BF1 :   300.1300000 MHz
BF2 :   300.1300000 MHz
BF3 :   300.1300000 MHz
DATE_t : 21:07:42
DATE_d :Aug 17 2009
INSTRUM : spect
NS :              8
O1 :        1250.00 Hz
O2 :        1853.43 Hz
PARMODE: 1D
SFO1 :   300.1312500 MHz
SOLVENT : DMSO
SW :        15.9573 ppm
TE :          299.2 K
*** Processing Parameters ***
AZFW :          0.100 ppm
LB :           0.10 Hz
MAXI :      10000.00 cm
MI :           0.20 cm
PC :           4.00
WDW : EM
*** 1D NMR Plot Parameters ***
Start :          10.46 ppm
Stop :          -0.22 ppm












































































































*** Acquisition  Parameters ***
INSTRUM: av500
LOCNUC : 2H
NS :            114
NUCLEUS: off
O1 :      13204.57 Hz
PULPROG: zgpg30
SFO1 :   125.7709936 MHz
SOLVENT: DMSO
SW :      238.7675 ppm
TD :          65536
TE :          300.0 K
*** Processing Parameters ***
LB :           1.00 Hz
















































































































*** Acquisition  Parameters ***
BF1 :   500.1300000 MHz
BF2 :   500.1300000 MHz
BF3 :   500.1300000 MHz
DATE_t : 00:35:19
DATE_d :Oct 08 2009
NS :              8
SOLVENT: DMSO
*** Processing Parameters ***
INTSCL :       1.00000


















































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :            132
O1 :      13204.57 Hz
PULPROG: zgpg30
SFO1 :   125.7709936 MHz
SOLVENT: DMSO
SW :      238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :       237.050 degree






















































































































































































































































































































*** Acquisition  Parameters ***
BF1 :   125.7577890 MHz
LOCNUC : 2H
NS :            332
O1 :      13204.57 Hz
PULPROG: zgpg30
SFO1 :   125.7709936 MHz
SOLVENT: DMSO
SW :      238.7675 ppm
*** Processing Parameters ***
LB :           1.00 Hz
PHC0 :         75.874 degree






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10) 1H and 13C NMR spectra of 4-1a17 
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